

AD _____

Award Number: DAMD17-98-1-8022

TITLE: Assessing the Efficacy of a CDSS for Breast Cancer

PRINCIPAL INVESTIGATOR: Maria Jibaja-Weiss, Ed.D.

CONTRACTING ORGANIZATION: Baylor College of Medicine
Houston, Texas 77030

REPORT DATE: May 2003

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030904 028

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE May 2003	3. REPORT TYPE AND DATES COVERED Final (13 Apr 98 - 12 Apr 03)	
4. TITLE AND SUBTITLE Assessing the Efficacy of a CDSS for Breast Cancer			5. FUNDING NUMBERS DAMD17-98-1-8022	
6. AUTHOR(S) Maria Jibaja-Weiss, Ed.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Baylor College of Medicine Houston, Texas 77030 E-Mail: mariaj@bcm.tmc.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Original contains color plates: All DTIC reproductions will be in black and white.				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) The five-year project developed and tested a computer-based decision support system (CDSS) on breast cancer for low-income women who speak English or Spanish. The populations included in the study are predominantly African American and Hispanic women. Hispanic women included a high proportion who speak only Spanish and have only limited English proficiency. Delivery of the educational message involves use of computer-based instruction to provide for an interactive learning experience. A unique feature of the project is the use of decision analysis techniques to assess the effectiveness of the CDSS program in facilitating treatment choices that are most likely to lead to outcomes preferred by patients. The application of decision analysis methods involves generation of patient-specific utilities that can be plugged into the analytical model for the purpose of comparing descriptive choices--those actually made by women with early stage breast cancer--against prescriptive choices--those that are determined to result in preferred outcomes for an individual patient as determined from application of the modeling program. We have completed recruitment into the clinical and follow-up assessments are still ongoing. A preliminary evaluation of the project has been conducted.				
14. SUBJECT TERMS breast cancer, computer-based decision support, decision-making, breast conserving surgery				15. NUMBER OF PAGES 66
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

TABLE OF CONTENTS

	PAGE
Front Cover	1
Standard Form (SF) 298, Report Documentation Page	2
Table of Contents	3
Introduction.....	4
Body.....	5
Key Research Accomplishments	19
Reportable Outcomes.....	20
Conclusions.....	20
References.....	21
List of Personnel	22
Appendices.....	23
<u>Appendix A:</u>	
Breast Cancer Treatment Questionnaire (English & Spanish versions)	24
<u>Appendix B:</u>	
CDSS Program Flowchart.....	30
<u>Appendix C:</u>	
Sample Screens—Utility Assessment Program	31
Utility Program Flowchart	32
<u>Appendix D:</u>	
Sample Screens—CDSS for Breast Cancer Program	33
<u>Appendix E:</u>	
Listing of CDSS Movies, Casts, Members, and Cue Points	35
<u>Appendix F:</u>	
CDSS Clinical Procedures During Trials	54
<u>Appendix G:</u>	
Satisfaction with Decision Questionnaire (English & Spanish versions)	57
CDSS Program Rating Form.....	59
<u>Appendix H:</u>	
CDSS Data Form.....	61
CDSS Summary Log.....	64

INTRODUCTION

Title Research Study: Assessing the Efficacy of a CDSS for Breast Cancer

The purpose of this project is to develop a computer-based decision support system for breast cancer treatment. This program will enhance understanding among low-income women who are diagnosed with breast cancer about the nature of the disease, the treatment options available to them, and the outcomes that are likely to result from selection of a specific treatment option. The CDSS will be developed in a manner that facilitates understanding by women from a range of educational backgrounds, including women with low literacy levels who may have difficulty with information presented in standard print formats. This will be accomplished by: (1) providing information in a variety of formats, including video clips, photo novellas, and voice-over narration of material included in the program; and (2) engaging women in culturally and linguistically appropriate interactive learning activities. The information will be provided in either English or Spanish formats using everyday, non-technical language. A unique feature of the project will involve generation of patient-specific preferences (utilities), which can be used in a decision-analytic model to determine the optimal treatment strategy based on a patient's personal preferences for the outcomes. This project was designed to inform and educate women with Stage I, IIA, IIB, and IIIA breast cancer using a culturally sensitive CDSS and to determine whether they (1) make breast cancer treatment decisions more consistent with their personal preferences, (2) are more knowledgeable about treatment options, and (3) are more satisfied about treatment decision prior and post treatment, compared with women who get standard care and education at two public hospitals.

BODY

This section describes the research accomplishments associated with each Task as outlined in the approved Statement of Work.

FINAL REPORT: SUMMARY OF PRIOR REPORTING PERIODS (YEARS 1, 2, 3 , and 4) AND PRELIMINARY FINDINGS

As described in the sections below, during the four previous reporting periods Tasks 1 through 7 were fully completed, while Task 8 was still in process, and Task 9 was abandoned. This final report provides a description of additional activities conducted to accomplish Task 8, although this task is still in process since we are still conducting follow-up assessments of patients already recruited into the study. Task 10 is being accomplished by the submission of this final report (**Deliverable 9**), which includes preliminary research findings, and Task 11 is in process.

Task 1. Develop Markov decision analytic model

An initial step in this study was to develop the decision analytic model for early breast cancer. To accomplish this we reviewed and adapted breast cancer decision analysis trees previously published. With that information, we convened our Expert Advisory Panel and developed breast cancer treatment decision trees by early breast cancer stage (Stage I, IIA, IIB and IIIA). These decision trees were used to develop the final decision analytic model and to aid in structuring the presentation of the CDSS program. All baseline values for the decision-analytic model were obtained from published literature: randomized trials, cohort studies and meta-analyses. We performed a MEDLINE search to include the years 1989 - 1999 with key words “early breast cancer”, “breast conservative surgery (BCS)”, “mastectomy”, “tamoxifen”, “risk”, and “outcome” and carefully selected relevant literature.

A Markov model has been developed to compare five strategies: Breast Conservative Surgery with radiotherapy (BCS), BCS with tamoxifen (TMX), Modified Radical Mastectomy (MRM), MRM with TMX, and TMX only. All probabilities and relative risks were integrated across studies and estimated mean and standard error using inverse variance weighted meta-analysis. All transition probabilities were calculated from the cohort rate according to the DEALE (declining exponential approximation of life expectancy) method. Thus, the decision model (**Deliverable 3**) was finalized and it was used to pilot test utility assessment data that was collected. The model will be used to compare each patient’s prescriptive, utility-driven decision with her “descriptive” decision, which was made based on the information presented in the CDSS.

Task 2: Identify and develop the outcome states for the utility assessment program

We had proposed to assess breast cancer treatment utilities using two methods: linear scaling and time trade-off. After meeting with our Expert Advisory Panel, it was decided that we would assess utilities using only the linear scaling method. The decision was based on consideration of our target population (i.e. women with a newly diagnosed breast cancer) and the objectives of the study. Six outcome states were identified for assessment based on the decision analytic model described above (Task 1): modified radical mastectomy, lumpectomy, no treatment, radiation, chemotherapy, and Tamoxifen. With guidance of our breast cancer content experts, we developed descriptions of the outcome states written at a third-grade reading level. Once developed, the outcome state descriptions were translated from English into Spanish. Once both English and Spanish versions of the outcome states were completed, we pilot tested them with 20 patients (English and Spanish-speaking). All of the testing sessions were tape recorded to aid us in summarizing the information.

Based on the pilot test results the descriptions were revised and the final outcome states scripts were completed (**Deliverable 1**).

Task 3: Produce and test the computer program for utility assessment

Once Task 2 above had been completed, the outcome state descriptions were used to develop portions of the program script. For the purpose of measuring utilities using linear scaling, the concept of using a “Health Ruler” was developed by the research team. The health ruler “looks” like a measuring tape with measurement marks that range from 0 to 20 (zero indicates poor health or death; and 20 indicates perfect health). This approach to utility measurement was chosen in order to provide our target population with a concept with which they were familiar. The patient uses this ruler to rank each of the health states using this ruler. The rank values from the health ruler will then be transformed to utility values (range 0 to 1) for use in the decision-analytic model.

At the start of the assessment program, the patient is asked to respond to some initial patient information (entry parameters). This information is used to tailor the program to the individual patient (e.g. language of preference—English or Spanish; ethnicity). This program utilizes a novel approach for utility assessment by using dramatized scenes (i.e. video segments) to introduce the patient to the topic and provide her with a familiar environment for responding. From the video segments, the patient is introduced to a training section and to the actual measurement of the outcome states. The training section provides the patient an opportunity to practice using the “Health Ruler.” In the next section, the patient ranks the outcome states using the ruler. For presentation purposes, the six outcome states were divided into two sets: 1) Initial surgery decision (mastectomy, lumpectomy, no treatment); and 2) Adjuvant Therapies (radiation, chemotherapy, and tamoxifen). After each set is presented, the patient has the opportunity to change the ranking of her responses using the health ruler.

For producing the computer-based utility assessment program, we developed a frame-by-frame script, designed skeleton screen layouts, developed storyboards for a prototype, and began gathering media assets to conform to the script. With the exception of the some voice over audio files and some video segments, most of the media pieces were already produced for the CDSS program. Then, we developed, tested and refined the prototype in-house. Once the prototype was refined, we integrated other segments of the program and developed the program for beta testing (**Deliverable 4**).

Task 4: Pilot test (beta test) the utility assessment and knowledge test

We pilot tested the utility assessment program, developed in Task 3 above, and the knowledge test at the Breast Pathology Clinic at Ben Taub General Hospital. In preparation for this pilot, and with the assistance from our Expert Advisory Panel, we revised the knowledge test that was originally proposed (Chapman, Elstein, Kostbade, 1995). This revision was necessary since some of the items on breast cancer information were not applicable to the educational intervention we are developing. The revised knowledge test contained 30 items including questions about mastectomy, lumpectomy/breast conserving surgery, no treatment, radiation therapy, chemotherapy, Tamoxifen, and life after treatment. Once the English version of the test was developed, it was translated into Spanish, and both copies were readied for pilot testing.

The procedures for pilot testing the utility program and knowledge test were established and were followed carefully by the Case Manager who enrolled and assisted patients for this pilot test at the clinic. Once a patient was identified as a possible participant, she was provided information about the project, given informed consent forms to sign, and asked to complete the knowledge test. After the patient had completed the knowledge test, she was asked to test the utility assessment program. The pilot test included 60 patients (30 English-and 30

Spanish-speaking patients). No major problems were observed while testing the utility assessment program. Using the pilot test results, we made refinements and finalized both, the knowledge test and the utility assessment program (**Deliverable 5**). We will also use the results to norm both the utility assessment program and the knowledge test.

Measure of Breast Cancer Knowledge

We developed a 28-item, fixed response questionnaire to assess patients' knowledge of breast cancer treatment. Items were identified for each of the following treatment modalities: modified radical mastectomy, lumpectomy, no treatment, radiation therapy, chemotherapy, and tamoxifen. Items were also developed to measure knowledge about quality of life after treatment. Response options were "yes," "no," and "not sure." Two additional questions assessed the patient's breast cancer history.

Table 1 presents item analyses of the 28-item measure, from a pilot sample of 90 patients—59 from the Breast Pathology Clinic and 31 from the General Medicine Clinic from Ben Taub General Hospital. In general, the measure performed well and should provide a sensitive measure of change in knowledge after the CDSS intervention. The internal consistency reliability of the entire instrument was very good, with a coefficient of .85. The four tamoxifen items were the most difficult, with fewer than 20% of the subjects answering a question correctly. In contrast, the no treatment questions had the lowest item difficulty and item discrimination. These items have been reworded and we have added an additional item to offer better discrimination. (See [Appendix A](#) – Breast Cancer Treatment Questionnaire [English and Spanish versions])

Utility Assessment Program

A unique aspect of this study is the comparison of women's choices for breast cancer treatment ("descriptive decisions") with the optimal treatment strategy suggested by a clinical decision-analytic model ("prescriptive decisions"). The use of decision analysis in this study requires that we have some measure of the patient's preferences for the possible treatment and outcome states.

Category scaling is a technique whereby a subject's preferences for a given health state are evaluated relative to perfect health or death. We used the metaphor of a "health ruler," represented as a cloth ruler used in sewing, to depict the range of evaluations someone might use when considering a treatment state. Descriptions of six treatment states were developed as part of the CDSS program. A sample of 59 women then completed the utility assessment program and provided their preferences for the health states, including the option of no treatment. Table 2 provides descriptive statistics for the category scaling scores, where 0 is "death" and 20 is "perfect health."

As the table shows, subjects rated the No Treatment state as worst, followed by Modified Radical Mastectomy and Chemotherapy. These rankings suggest that the category scaling approach is providing valid preferences, and that there is some variability in subjects' preferences for these health states.

Based on the pilot test results we also made some program design refinements, primarily to the program interface design, in order to make the program easier to use and navigate. (See [Appendix C](#) – Sample Screens—Utility Assessment Program and Utility Program Flowchart)

Table 1: Item-Analyses of Breast Cancer Treatment Knowledge Questionnaire: 90 Subjects from Pilot Study

Question Number and Name	Item Difficulty* (%)	Item Discrimination**	Item-Total Correlation	Percent "Not Sure"	Percent Missing
1. MAST1	33.3	.53	.36	43.3	0
2. MAST2	31.3	.53	.39	65.6	0
3. MAST3	36.7	.66	.48	53.3	0
4. MAST4	44.4	.88	.60	50.0	0
5. LUMP1	14.4	.37	.38	46.7	0
6. LUMP2	28.9	.45	.39	52.2	0
7. LUMP3	41.1	.58	.34	48.9	0
8. LUMP4	12.4	.26	.20	72.2	1.1
9. LUMP5	31.1	.75	.52	63.3	0
10. NOTR1	81.8	.18	.20	10.0	2.2
11. NOTR2	71.3	.16	.11	18.9	3.3
12. NOTR3	86.4	.17	.16	8.9	2.2
13. RAD11	14.8	.46	.46	20.0	2.2
14. RAD12	45.5	.76	.50	46.7	2.2
15. RAD13	22.7	.63	.47	63.3	2.2
16. RAD14	13.6	.38	.38	72.2	2.2
17. RAD15	12.5	.38	.38	77.8	2.2
18. CHEM1	35.2	.50	.38	56.7	2.2
19. CHEM2	45.5	.70	.52	46.7	2.2
20. CHEM3	59.1	.63	.39	31.1	2.2

Question Number and Name	Item Difficulty* (%)	Item Discrimination**	Item-Total Correlation	Percent "Not Sure"	Percent Missing
21. CHEM4	39.8	.75	.51	45.6	2.2
22. TAMO1	17.8	.33	.39	76.7	0
23. TAMO2	13.3	.38	.45	82.2	0
24. TAMO3	11.1	.25	.45	74.4	0
25. TAMO4	17.8	.50	.42	78.9	0
26. AFTX1	77.8	.40	.30	17.8	0
27. AFTX2	48.9	.44	.19	37.8	0
28. AFTT3	25.8	.52	.46	62.2	1.1

Note. Internal consistency reliability = .85

* Item Difficulty is percent of subjects answering question correctly.

** Item Discrimination is difference between proportion of correct responses to item for subjects in the upper quartile of total scale score, and the same proportion in subjects from lower quartile of scale score.

Table 2: Ranked Preferences for Treatment States (n=59 pilot subjects)			
Treatment State	Percentile		
	25th	50th	75th
1. No Treatment	0.0	0.0	1.0
2. Modified Radical Mastectomy	3.0	6.0	10.0
3. Chemotherapy	5.0	10.0	13.0
4. Tamoxifen	5.0	10.0	15.0
5. Radiation Therapy	9.0	10.0	15.0
6. Lumpectomy	10.0	10.0	15.0
7. All treatments	10.0	15.0	18.0
Scores range from 0 “death” to 20 “perfect health.”			

Task 5: Interview patients to identify pertinent content for the CDSS

In order to identify pertinent content for the CDSS from the patient’s perspective, we interviewed a total of 50 English- and Spanish-speaking patients from the General Medicine Clinic at Ben Taub General Hospital. This task was conducted early in the project year in order to include the findings into the content of the CDSS program. The interviewer asked the patients questions about the breast cancer treatment options, which were to be covered in the CDSS program: modified radical mastectomy, lumpectomy, radiation therapy, chemotherapy, Tamoxifen, and receiving no treatment. A Patient Interview Script Form was developed for use during the interview. The interviews were all audio taped to aid in summarizing the patient’s responses. A visual aid with a matrix describing the treatment options was used by the Case Manager to aid her presentation of the material to the patient.

Results from the patient interviews were summarized into areas of concern within each of the treatment options tested (**Deliverable 2**). We then selected the concerns that occurred most often in each of the treatment options and included them into the descriptions used in the CDSS program. We found some similarities and some differences in concerns according to the age of the woman (younger than 50 years of age, or older than 50). For example, conserving the breast in a lumpectomy was mentioned more frequently by younger women than older women. We observed similar concerns between the English- and Spanish-speaking women.

Task 6: Produce the CDSS for clinical trials

Production of the CDSS for the clinical trials began from the first month of this project. Some of the activities for production included:

- 1) Structuring the CDSS program using the CDSS decision trees for early stage breast cancer (Stage I, IIA, IIB, and IIIA) developed in Task 1 above, to organize the information, and drawing on cancer related literature and content experts to develop descriptions in the CDSS (See [Appendix B](#) - CDSS Program Flowchart).
- 2) Convening with the Expert Content Panel several times during production to present program structure descriptions, to review program scripts at various stages of development, and to define information parameters for entry into the program.

- 3) Designing the interactive and skeleton design of the program.
- 4) Developing the complete frame-by-frame script and storyboards for a prototype.
- 5) Producing and gathering multimedia assets to incorporate into the program (i.e. video, stills, graphics, audio, music)
- 6) Developing an in-house prototype.
- 7) Pilot testing the prototype with 10 patients (English and Spanish speakers)
- 8) Used the refined prototype to create one complete path of the program, integrating multimedia assets.
- 9) Pilot testing a completed program path with 10 patients (English and Spanish speakers)
- 10) Using the pilot tested results to refine the program and complete the other program paths in the following reporting year.

We finalized production of the CDSS program at the end of Project Year 2 (**Deliverable 6**). The CDSS English version of the program was entitled "*A Patchwork of Life: One Woman's Story—For Women Making Breast Cancer Treatment Decisions.*" The Spanish version of the program was entitled "*Bordando con Hilos de Seda...—Decisiones Para el Tratamiento del Cáncer del Seno.*" We beta tested the complete version of the program with 10 patients (English and Spanish speakers) and made final revisions. Then, the program was readied for the clinical trials. Development of this program turned out to be a more complex task that we had anticipated, taking all of project year two to complete the program. The tailoring of the program by race/ethnicity (i.e., video segments) and by language of preference (English and Spanish), in addition to personalization by stage of breast cancer diagnosis (i.e. Stages I, IIA, IIB, or IIIA) introduced great complexity to the design, production of the media assets, and programming.

The CDSS is a very comprehensive decision support and educational tool guiding the user through learning paths that give her thorough and important information for making a breast cancer treatment decision. The program guides the user through a series of learning modules (Interactive Learning Modules - ILMs) which eventually lead her to a decision-aid module (Module #5) to help her make an initial treatment decision. Each of the ILMs are linked to soap opera scenes which provide appropriate contexts for the material presented in each of the ILMs. (See Appendix B – CDSS Program Flowchart; and Appendix D – Sample Screens – CDSS Program)

The complexity and very large size of the CDSS is highlighted by components of the program containing 174 movies and 294 casts, and by its size consuming over four gigabytes of hard drive space. We utilized four CD-ROM disks for installing the program into the computer systems that house the CDSS for clinical trials. (See Appendix E – Listing of CDSS Movies, Casts, Members, and Cue Points).

Task 7: Prepare study components to be used in clinical trials

In preparation for the start of the clinical trials, we:

- 1) formalized the protocol to be followed during the trial at the Breast Pathology Clinic at Ben Taub Hospital (see [Appendix F](#) – CDSS Clinical Procedures During Trials). We also developed the following instrumentation schedule to aid us in following the protocol.

CDSS Clinical Trials Instrumentation Schedule						
Instrument	Assessment					
	Pre-decision visit (T1)		Pre-op visit (T2)		Follow-ups	
	Pre-I	Post-I	Pre-U	Post-U	6 M (T3)	1 Yr (T4)
Breast Cancer Knowledge Questionnaire	X		X		X	X
Satisfaction with Decision Scale			X		X	X
Evaluation of CDSS (Intervention group only)		X				

- 2) ascertained that the computer which contains the CDSS and Utility Assessment programs at the Breast Pathology Clinic at Ben Taub Hospital, and other computer peripherals (i.e. printer) are in working order;
- 3) supplied the computer kiosk, which houses the CDSS, with additional supplies (i.e. additional ink cartridges and print paper)
- 4) prepared the informed consent forms, questionnaires and tests to be used in the trial (see [Appendix A](#) – Breast Cancer Treatment Questionnaire [English and Spanish versions]). With the assistance of our Expert Content Panel, we revised the Satisfaction with Decision Questionnaire that was originally proposed (Holmes-Rovner M, Kroll J, Schmitt N, Rovner DR, Breer L, Rother ML, Faan GP, Talarczyk G, 1996) (See [Appendix G](#) – Satisfaction with Decision Questionnaire [English and Spanish versions]) and developed an evaluation form for rating the CDSS (See [Appendix G](#) – CDSS Rating Form);
- 5) developed data forms which will be used by the Case Manager to recruit and track the patients during the clinical trials; (See [Appendix H](#) – CDSS Data Form and CDSS Summary Log)
- 6) informed the staff at the Breast Pathology Clinic about the activities that will take place during the trial.

Task 8: Conduct clinical trials of the CDSS (months 25-57—revised) and assemble database of results (month 58—revised)

Because we requested a one-year project schedule extension from the DoD in order to complete participant recruitment, we revised due dates for the remaining Tasks by writing ‘revised’ after the relevant month.

We began conducting the randomized prospective clinical trial October 2000 and that activity is presently ongoing since, although we have completed the recruitment phase of the trial, follow-up assessments are still being conducted for patients already recruited into the study. In the original proposal we indicated that we were going to recruit 130 subjects (65 intervention and 65 control groups) into the study; however, actual recruitment has been lower than anticipated. We reported this concern in the Year 3 Technical Report. As recommended by the Reviewer of this report, we revised the study methodology to address this problem by: (1) extending the project schedule by one year thus requesting a one-year, no-cost extension from the DoD; and, (2) identifying another source for recruitment of study participants—the Lyndon B. Johnson (LBJ) Hospital. As the Ben Taub General Hospital, the LBJ Hospital is an urban, public hospital, serving primarily minority, underserved

populations in the Houston area. LBJ and Ben Taub Hospitals are both administered by the Harris County Hospital District (HCHD). The only difference is that medical personnel from the University of Texas (UT) staff LBJ while Baylor College of Medicine medical personnel staff Ben Taub. The BPC at LBJ generally has equal or larger number of visits per year as Ben Taub's BPC. In addition, the BPC at Ben Taub General Hospital increased its hours of operation from a half-day to a full day. Thus, we were fairly confident that with these changes we would be able to recruit the necessary number of participants.

Due to a lower volume of eligible patients than originally expected, we have recruited 95 women to the study. While not reaching our target of 65 women in each group, the sample is sufficient to test the main hypotheses of the project with sufficient power to detect meaningful between group differences. The findings reported later in the report show important group differences in breast cancer knowledge and preferences for treatment options. We are therefore confident that the aims of the study will be fully addressed.

In order to add LBJ Hospital as a recruiting site the following activities were accomplished:

- 1) Convened a meeting with Dr. Emily Robinson, Director of the BPC of the LBJ Hospital to discuss collaborating in this study as an additional recruitment site.
- 2) After receiving notice from Dr. Robinson of LBJ Hospital's willingness to collaborate with us in this study, we proceeded to conduct the appropriate procedures to make this collaboration possible. To this end, with the assistance of Dr. Robinson, we accomplished the following:
 - Submitted documentation to obtain approval from the Institutional Review Board for Human Subject Research (IRB) from the UT.
 - Received IRB approval from the UT on March 25, 2002.
 - After receiving IRB approval from UT, we submitted an amended protocol to the Baylor IRB for approval.
 - Received approval from the Baylor IRB office on April 9, 2002.
- 3) The case manager in charge of recruiting subjects into the study visited LBJ's BPC clinic several times during this period in order to familiarize herself with clinic procedures and to make appropriate contacts with the clinic staff. During these visits, the case manager confirmed that the required CDSS clinical procedures could be followed during the trials. Because both hospitals use the same appointment and medical record systems, the addition of this recruitment site was relatively easy to implement.
- 4) Contacted Baylor College of Medicine's Office of Research about notifying the DoD of the addition of LBJ Hospital as a recruitment site. The DoD should have been notified by our office of research of the addition of LBJ Hospital into the study.

Recruitment at the LBJ Hospital site did not begin until April 15, 2002. The following research activities have been conducted during the clinical trial period at both recruitment sites:

- 1) Ascertain and monitor that procedures and elements for conducting the trial are in place (computer kiosk, questionnaires, informed consent forms)
- 2) Assign women to control or intervention groups using random process
- 3) Follow trial protocol with each of the identified patients that includes:
 - Patient Encounter #1—after scheduled appointment at Breast Pathology Clinic (BPC)
 - Patient Encounter #2—screening clinic prior to surgery, and
 - Six-month and one year follow-ups
- 4) Monitor that trial protocol is strictly followed without deviation throughout the period (See Appendix F)

– Clinical Procedures During Trials)

5) Assemble database of clinical trial results (**Deliverable 8, month 44**)

Two half-time case managers are in charge of accomplishing the research tasks at the breast pathology clinics of the Ben Taub and LBJ hospitals.

Task 9: Develop, produce (months 16-24) and pilot test (months 39-42) additional educational paths for Stages 0, IIIB, and IV.

We had originally proposed to produce additional educational paths for Stages 0, IIIB and IV; however, due to the complexities in developing and producing the CDSS program for the clinical trials, which we presented above (Task 6), we dedicated all our efforts and funding resources to the completion of the CDSS program. Not completing this task does not have any adverse effects on accomplishing the specific aims originally proposed for the project. These additional educational paths were going to merely provide a learning tool for women diagnosed at those stages. Our Expert Content Panel recommended that we concentrate on the development of the CDSS since tailoring information for Stages 0, IIIB, and IV is a very complex issue, much too complex for a computer-base decision support system since there are too many variables to consider when counseling the patient. This modification was communicated to the DoD in the Year 2 Technical Report.

Task 10: Analyze and evaluate results from clinical trials (months 57-60—revised)

This document is our final report (**Deliverable 9**) and it includes preliminary findings for data collected up to April 12, 2003. Although we have completed recruitment into the study, we are still conducting follow-up assessments; therefore, we will continue to assemble the database as we collect data from the pre-operative visits (T2), six-month (T3), and one-year (T4) follow-up assessments. We expect to conduct the final analyses and evaluation when we finish assembling the database sometime in April or May of 2004.

PRELIMINARY RESEARCH FINDINGS

As proposed in the original application, we evaluated the project in order to test the study's hypotheses. If the program is effective, the results of clinical trials should indicate that women who viewed the CDSS make treatment decisions that are more consistent with their utilities (preferences). In testing the second of the two hypotheses stated for this project, it is expected that women who are assigned to the intervention group, as compared with women in the control group, will demonstrate higher levels of knowledge concerning treatment options for breast cancer and its side effects, and are more satisfied with their treatment decision prior to and after their treatment. This final report provides preliminary findings for testing of the second hypothesis; however, findings for the first hypothesis are not included in this report since those analyses are not completed. After data collection is complete, and we have utility information for each subject, we will consider the first hypothesis related to "prescriptive decisions" suggested by the decision analytic model and actual treatment choices. This will be accomplished by taking the utility data for each subject, and using it as adjustment weights for the life expectancy outcomes to determine the optimal treatment strategy for each subject. Then, the optimal "prescriptive decision" from the decision analytic model will be compared with the actual treatment received by each women, and concordance among the CDSS group and control group examined.

Subject Characteristics

Patient recruitment into the study took place at the Breast Pathology Clinics of Ben Taub and LBJ Hospitals. Since we began recruitment at both sites (Ben Taub, October 2000; LBJ, April 2002) a total of 4,258 patients came for diagnosis/evaluation for breast cancer—3,118 and 1,140 to Ben Taub and LBJ, respectively. Of the

3,118 patients who came to Ben Taub, 244 (7.83%) had positive results. Of the patients with positive results, 159 of them did not meet eligibility requirements for a variety of reasons (e.g., clinical breast cancer stage 0, IIIB, or IV; did not speak English or Spanish) while 85 of the patients met the eligibility requirements. Sixty-four patients were enrolled into the study, 10 patients did not show for their clinic appointment, and eleven subjects refused to participate. The reasons for not participating were that the women decided to have treatment in another hospital, were too upset emotionally to deal with the project activities during the visit, or that they simply they did not want to participate. Of the 1,140 patients who came to LBJ for diagnosis, 106 (9.29%) had positive results. Of the patients with positive results, 60 did not meet the eligibility criteria, while 46 did meet the eligibility requirements. Thirty-one patients were enrolled in the study, 10 did not show up for their appointment, and five refused to participate. The reasons expressed for refusing to participate were similar to those stated above for the patients at Ben Taub Hospital. Thus, in total we recruited 95 subjects into the study, 64 from Ben Taub and 31 from LBJ hospitals.

To date we have recruited 95 women into the randomized controlled trial; 48 women into the intervention group and 47 into the control group. The mean age of patients participating in the study was 48.9 years of age in the intervention group, and 53.0 years in the control group. The age range for all subjects was 28 to 81 years. Hispanic was the primary ethnicity represented in both study groups—54.2% and 42.6% in the intervention and control groups, respectively. African-American women represented 29.2% of the sample in the intervention group, and 42.6% in the control group. The language of preference was English in 58.3% of the intervention group women and 65.2% of the control group women. Women who participated in the study had the following preliminary breast cancer stage at diagnosis: Intervention group—Stage I 19.1%, Stage IIA 29.8%, Stage IIB 21.3%, Stage IIIA 29.8%; and Control group—Stage I 28.9%, Stage IIA 22.2%, Stage IIB 17.8%, and Stage IIIA 31.1%.

Treatment Preferences

Preliminary findings from data collected at the pre-operative data collection point (T2, including 64 women) suggest that women assigned to the intervention group—CDSS program viewers—were more likely to prefer mastectomies (57.1%), and less likely to prefer lumpectomies (40.0%), to treat their breast cancer that were women assigned to the control group (31.0% and 55.2% for mastectomy and lumpectomy, respectively). The surgical option selected confirmed these initial preferences, with 79.4% of the intervention women receiving modified radical mastectomies compared to 53.1% of control group women ($P=.024$).

Breast Cancer Treatment Knowledge

The following table displays subjects' performance on the Breast Cancer Treatment Knowledge Questionnaire for women assigned to the Intervention and Control Groups. Because follow-up data collection is ongoing, we report responses for each time period noting that the sample size decreases for each subsequent data collection period. Sixteen items from the Questionnaire were considered core indicators on breast cancer treatment knowledge. The means given in the following table represent the number of questions answered correctly out of the 16 core items.

As the table shows, women's knowledge at the pre-intervention T1 assessment did not differ between the groups. At the T2 post-intervention assessment, women assigned to the Intervention Group showed greater knowledge than women assigned to the Control Group. At T3 and T4, the two groups did not differ on the knowledge scores for those who completed follow-up assessments. It is noteworthy that women in the Control Group showed an increase in knowledge at T3 which appears to be maintained at T4.

Changes in Scores on Breast Cancer Treatment Knowledge Questionnaire across Duration of the Study								
	Time 1 Pre-Intervention		Time 2 Post-Intervention		Time 3 6-month Follow-up		Time 4 1-year Follow-up	
	n	Mean (95%CL)	n	Mean (95%CL)	n	Mean (95%CL)	n	Mean (95%CL)
Intervention Group	48	5.7 (4.7, 6.8)	35	9.7 (8.5, 10.9)	27	10.1 (8.8, 11.4)	16	10.4 (8.5, 12.2)
Control Group	46	5.7 (4.7, 6.7)	30	6.0 (4.4, 7.7)	23	9.4 (8.0, 10.7)	17	10.5 (8.6, 12.3)
P-value	0.96		0.00		0.43		0.94	

*P-value represents significance of F-ratio for comparison of Intervention and Control Group patients within each time period.

Satisfaction with the Treatment Decision

The Satisfaction with Decision Scale developed by Holmes-Rovner was modified for this study to address breast cancer treatment decision making. Higher scores on this scale indicate greater satisfaction with the decision made. As the following table indicates, there were no differences between the two groups on the scale scores.

Changes in Scores on Satisfaction with Decision Scale.						
	Time 2 Post-Intervention		Time 3 6-month Follow-up		Time 4 1-year Follow-up	
	n	Mean (95%CL)	n	Mean (95%CL)	n	Mean (95%CL)
Intervention Group	35	4.6 (4.3, 4.9)	27	4.5 (4.1, 5.0)	16	4.5 (4.1, 4.9)
Control Group	30	4.3 (3.8, 4.8)	23	4.7 (4.4, 4.9)	17	4.5 (3.9, 5.2)
P-value	0.34		0.45		0.94	

*P-value represents significance of F-ratio for comparison of Intervention and Control Group patients within each time period.

Rating the CDSS

Ratings of the CDSS are available for 46 women. The following table gives their responses to the program ratings. Overall, the ratings are favorable and the women appear to have benefited from viewing the program.

Subject Ratings of the CDSS Program (46 participants assigned to CDSS intervention).			
	Yes	No	Unsure
Was the program easy to understand?	44	0	2
Was the amount of information given in the program less than you needed?	6	39	1
Was the program too long?	14	32	0
Did the amount of information given in the program make it hard to remember it?	14	32	0

Was the sound good?	45	1	0
Were the pictures and videos clear?	45	1	0
Did you enjoy using the program?	45	0	1
Did the program make you think about your health?	44	1	1
Did the program teach you things about the health of your breasts?	45	0	1
Would you use the program again?	43	3	0
Would you recommend that other women watch this program?	46	0	0
	Increase	Decrease	Same
Did viewing the CDSS program increase or decrease your worries about treatment?	7	23	16

TASKS TO BE ACCOMPLISHED BEYOND PROJECT PERIOD

Because of lower than anticipated patient recruitment into the study, we were not able to complete all of the tasks proposed in the original application; however, we are committed to continue the study until all of the remaining tasks are accomplished. Specifically, we are planning to:

(Task 8: Conduct clinic trials of the CDSS and assemble database of results)

- Continue to assemble the database as we move forward in collecting data from the pre-operative visits (T2) and follow-up assessments (T3 – six-month follow-up; and, T4 – one-year follow-up). Because we have just finished recruiting patients into the study in April 2003, the one-year follow-up assessments are not expected to be completed until April of 2004. Therefore, we expect to assemble the entire database by May of 2004 and get it ready for final analysis.

(Task 10: Analyze and evaluate results from clinical trials)

- Fully analyze and evaluate the results of the clinical trial since this final report only included preliminary findings of the data to date. More specifically, as proposed in the original application, we will evaluate the project in order to test the study's hypotheses. This will include using the utility data and our decision-analytic model to determine the option strategy for each subject, and comparing this to the actual treatment choice made.

(Task 11: Package the refined CDSS for distribution to audiences nationally and disseminate information about its availability)

- Now that we have finalized the testing of the CDSS in the clinical trial, we are proceeding to make final refinements to the program. Then, we will package the refined CDSS for distribution to audiences nationally and we will disseminate information about its availability. Specific activities to accomplish this task will be to:
 - 1) Prepare the tested and refined CDSS program in a packaged format (i.e. DVD) that includes appropriate documentation to facilitate use.
 - 2) Announce the availability of the packaged CDSS program through newsletters, journals, presentations at meetings, and posting in appropriate newsgroups on the Internet.
 - 3) Prepare at least one major paper on the results of the project for submission to an appropriate journal. Other manuscripts will also be prepared and submitted reporting on completion of formative tasks.

- 4) Monitor interest in the program and follow-up with users to determine the value of the CDSS as a tool for facilitating treatment selection by women from diverse backgrounds.

KEY RESEARCH ACCOMPLISHMENTS

- Developed a Markov decision analytic model for early breast cancer.
- Identified and developed the outcome health states for the utility assessment program.
- Produced and pilot tested the computer program for utility assessment. (See [Appendix C](#) – Sample Screens—Utility Assessment Program and Utility Program Flowchart)
- Pilot tested the breast cancer knowledge questionnaire. (See [Appendix A](#) – Breast Cancer Treatment Questionnaire [English and Spanish versions])
- Identified content for CDSS from the patient’s perspective.
- Finalized production of the CDSS for clinical trials. (See [Appendix B](#) – CDSS Program Flowchart; and [Appendix D](#) – Sample Screens – CDSS Program)
- Prepared study components for clinical trials. (See [Appendix A](#) – Breast Cancer Treatment Questionnaire [English and Spanish versions]; [Appendix F](#) – CDSS Clinical Procedures During Trials; [Appendix G](#) – Satisfaction with Decision Questionnaire and CDSS Rating Form; and [Appendix H](#) – CDSS Data Form and CDSS Summary Log)
- Began conducting the clinical trials at Ben Taub General Hospital, Houston, Texas.
- Added an additional participant recruitment site—the LBJ Hospital, Houston, Texas.
- Conducted preliminary evaluation of the project.

REPORTABLE OUTCOMES

- Jibaja ML, with NE Neff, T Granchi, RJ Volk, SJ Spann, JR Beck, N Aoki, and D Georgiou. *Assessing the Efficacy of a Computer-based Decision-Support System for Breast Cancer*. Poster presented at the U.S. Department of Defense Era of Hope Breast Cancer Research Program Meeting, Atlanta, Georgia, June 11, 2000.
- Jibaja ML, with NE Neff, T Granchi, RJ Volk, SJ Spann, JR Beck, N Aoki, and D Georgiou. *Efficacy of a Computerized Decision-Support System for Breast Cancer: A Progress Report*. Poster presentation and demonstration made at the Annual Meeting of the Society of Medical Decision Making, Cincinnati, Ohio, September 25, 2000.
- Jibaja ML, with NE Neff, T Granchi, RJ Volk, SJ Spann, JR Beck, N Aoki, and D Georgiou. *Efficacy of a Computerized Decision-Support System for Breast Cancer: A Progress Report*. Poster presented at the Houston Area Health and Outcomes Services Research Conference, Houston, Texas, November 3, 2000.
- Jibaja ML, with NE Neff, T Granchi, RJ Volk, SJ Spann, JR Beck, N Aoki, and D Georgiou. *Development of a Computerized Decision-Support System to Aid Lower Literacy Women in Making Breast Cancer Treatment Decisions*. Theater/demonstration-style presentation made at the American Medical Informatics Association Annual Symposium, Washington, D.C., November 5, 2001.
- Maria L. Jibaja-Weiss received a recognition award for contributions to health disparities research (development of the computer-based decision support system for breast cancer treatment), from the Center for Research on Minority Health, The University of Texas, MD Anderson Cancer Center, April 25, 2002.
- Jibaja-Weiss ML, with NE Neff, T Granchi, RJ Volk, SJ Spann, JR Beck, N Aoki, and D Georgiou. *A Computer-based Breast Cancer Decision Support System to Aid Lower Literacy Women in Making Treatment Decisions*. Demonstration presentation made at Slice of Life 2002—for Medical Multimedia Developers and Educators, Toronto, Canada, June 21, 2002.
- Jibaja-Weiss ML, with NE Neff, T Granchi, RJ Volk, SJ Spann, JR Beck, and N Aoki. *Making Breast Cancer Treatment Decisions: A Computerized Decision-Support System to Aid Lower Literacy Women*. Poster presented at the U.S. Department of Defense Era of Hope Breast Cancer Research Program Meeting, Orlando, Florida, September 27, 2002.

CONCLUSIONS

The purpose of this study was to develop and evaluate a computerized decision support system (CDSS) on breast cancer to aid low-literate, multi-ethnic women who speak English or Spanish in making a treatment decision. As part of this project we: developed a decision analytic model for early breast cancer; produced, tested, and validated the utility assessment program; tested and finalized the Breast Cancer Treatment Questionnaire; completed the CDSS program to be tested during the clinical trials; prepared the study materials for use during the trials; started and finished recruitment into the clinical trials; and are currently conducting follow-up assessments with patients enrolled in the study. The utility assessment program utilizes a novel approach for the measurement of utilities using the liner scaling method—it uses a “Health Ruler” to rank the patients’ responses to the program. In producing the CDSS program, we have learned that developing computer-based decision support systems that tailor the information to patients, providing and interactive and

friendly environment for a lower literacy user, are complex and lengthy to produce—beginning with development of the decision analytic models and defining the content structure, through actually producing the multimedia paths. Projects of similar complexity should allow for longer developmental time of the content and of production of the various CDSS components. In addition, based on this project's experience, it is important that researchers include a subject recruitment contingency plan during the planning process of clinical trials in case actual recruitment turns out to be slower than anticipated.

We have been conducting a randomized controlled trial of the CDSS, with one intervention group (CDSS plus usual care) and one control group (usual care plus informational printed materials). Primary outcomes include breast cancer treatment decision consistent with preferences, knowledge about treatment, and satisfaction with the treatment decision. The setting is two urban community hospitals located in a large urban area, which serves primarily indigent, low-literacy and multiethnic populations. Preliminary findings of the 95 participants recruited into the study indicate that women who viewed the CDSS were more likely to prefer mastectomies, and had greater knowledge of breast cancer treatment options at their pre-operative visit than women assigned to the control group. Interestingly, knowledge about treatment options increased for subjects in the control group to similar levels of subjects in the intervention group at the six-month and one-year follow-up assessments. Women in both study groups seemed to be equally satisfied with their treatment decisions. Overall, the ratings of using the CDSS are favorable and the women appear to have benefited from viewing the program.

Although breast-conserving surgery (BCS) is the treatment of choice for treating early-stage breast cancer (Winchester et al. 1997; Veronesi et al. 2002; Fisher et al. 2002), available data suggest that many women with this condition select more invasive forms of surgery (e.g., radical mastectomy) (Lazovich et al. 1999; Lantz et al. 2002). For the medically indigent populations targeted for this study, available data indicate that they had lower use of BCS—approximately 21% of women eligible for BCS selected that treatment option (Dolan et al. 1999). To date, emerging technologies (e.g., CD/DVD-ROM technology, computer-assisted instruction) have not been used to their fullest in helping women with breast cancer, particularly those with lower literacy, understand the range of treatment options available to them that are likely to result in preferred outcomes. The intent of this project was to improve the utilization of BCS in the targeted populations; however, our preliminary findings indicate that although women assigned to the intervention group chose the more invasive surgery option, their decisions were more informed, and they appeared to be equally satisfied with their treatment decision as women assigned to the control group. Thus, the CDSS program may be beneficial to the women who viewed it—those assigned to the intervention group—by making them more informed health care consumers.

REFERENCES

-
- Chapman GB, Elstein AS, Kostbade Hugues K (1995). Effects of Patient Education on Decisions about Breast Cancer Treatments: A Preliminary Report. *Medical Decision Making* 15: 231-239.
- Dolan, J.T., , Granchi, T.S., Miller III, C.C., Brunicardi, F.C. (1999). Low use of breast conservation surgery in medically indigent populations. *The American Journal of Surgery*, 178, 470-473.
- Fisher, B., Anderson, S., Bryant, J., Margolese, R.G., Deutsch, M., Fisher, E.R., Jeong, J.H., & Wolmark, N. (2002). Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. *The New England Journal of Medicine*, 347 (16), 1233-1241.
-

- Holmes-Rovner M, Kroll J, Schmitt N, Rovner DR, Breer L, Rother ML, Faan GP, Talarczyk G (1996). Patient satisfaction with health care decisions: The Satisfaction with Decision Scale. Medical Decision Making 16: 58-64.
- Lantz, P.V., Zemencuk, J.K., & Katz, S.J. (2002). Is mastectomy overused? A call for an expanded research agenda. Health Services Research, 37 (2), 417-431.
- Lazovich, D., Solomon, C.C., Thomas, D.B., Moe, R.E., & White, E. (1999). Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma. Cancer, 86, 628-637.
- Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., Aguilar, M., & Marubini, E. (2002). Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. The New England Journal of Medicine, 347 (16), 1227-1232.
- Winchester, D.J., Menck, H.R., & Winchester, D.P. (1997). The national cancer data base report on the results of a large nonrandomized comparison of breast preservation and moodified radical mastectomy. Cancer, 80, 162-167.

LIST OF PERSONNEL

The following list includes personnel receiving pay from this research effort:

Glori Chauca (Case manager)
Brenda Congdon, B.A. (Write Eye Productions)
Jessica Couderc (Project Coordinator/Case manager)
Lois Friedman, Ph.D.
Armandina Garza (Case manager)
Doris Georgiou, Ph.D.
Thomas S. Granchi, M.D.
Maria L. Jibaja-Weiss, Ed.D.
Paul Long (Loga Interactive Multimedia)
Nancy E. Neff, M.D.
Valory Pavlik, Ph.D.
Robert J. Volk, Ph.D.
Brian White (Schumann & Company)

APPENDICES

Appendix A:

Breast Cancer Treatment Questionnaire [English & Spanish versions] .. 24

Appendix B:

CDSS Program Flowchart 30

Appendix C:

Sample Screens—Utility Assessment Program 31

Utility Program Flowchart..... 32

Appendix D:

Sample Screens – CDSS for Breast Cancer Program 33

Appendix E:

Listing of CDSS Movies, Casts, Members and Cue Points 35

Appendix F:

CDSS Clinical Procedures During Trials 54

Appendix G:

Satisfaction with Decision Questionnaire (English & Spanish versions) 57

CDSS Rating Form (English & Spanish versions) 59

Appendix H:

CDSS Data Forms..... 61

CDSS Summary Log 64

Date _____

Patient's MR# _____

Breast Cancer Treatment Questionnaire

MASTECTOMY	Is mastectomy the removal of only the cancerous part of the breast?	? Yes No Unsure
	After mastectomy, do some women have numbness and tingling of their chest or arm on the operated side?	Yes No Unsure
	Is the recovery period for mastectomy about 1 week?	Yes No Unsure
	Is chemotherapy a treatment your doctor may recommend after you have a mastectomy?	Yes No Unsure
LUMPECTOMY OR BREAST- SPARING SURGERY	After lumpectomy, also called breast-sparing surgery, is there a high chance that cancer will recur in the treated breast?	Yes No Unsure
	Is breast reconstruction strongly recommended after lumpectomy/breast-sparing surgery?	Yes No Unsure
	Is radiation therapy usually necessary after lumpectomy/breast-sparing surgery?	Yes No Unsure
	After a lumpectomy, is the treated breast going to feel firm or hard?	Yes No Unsure
	Are some of the lymph nodes in the armpit removed, regardless of which type of surgery a woman chooses (mastectomy or lumpectomy/breast-sparing surgery)?	Yes No Unsure

NO TREATMENT	If a woman doesn't get treatment for breast cancer, will the cancer stay only in the breast?	? Yes No Unsure
	Does not getting treatment for breast cancer lead to pain and breakdown of the breast?	Yes No Unsure
	After receiving treatment for breast cancer, are women less likely to be alive after 5 years compared to those that got no treatment?	Yes No Unsure
	Does not getting treatment for breast cancer eventually lead to death?	Yes No Unsure
RADIATION THERAPY (X-RAY OF THE BREAST)	During radiation therapy, a woman gets high energy x-rays on the breast that has the cancer. Is hair loss a frequent side effect of radiation therapy?	Yes No Unsure
	During radiation therapy, will the treated area frequently look and feel like it has been sunburned (i.e. red, itchy)?	Yes No Unsure
	Does the entire course of radiation treatment last between 1 to 2 weeks?	Yes No Unsure
	Is radiation treatment given 5 times per week during the treatment period?	Yes No Unsure
	Does the actual radiation treatment last 2 to 3 minutes?	Yes No Unsure
CHEMOTHERAPY	Is chemotherapy taken in cycles for 4 to 6 months?	Yes No Unsure
	Is chemotherapy generally given in pill form?	Yes No Unsure
	Is nausea the most common side effect of chemotherapy?	Yes No Unsure
	Are the side effects from chemotherapy treated generally with medication?	Yes No Unsure

TAMOXIFEN	Is hormone treatment with Tamoxifen used before menopause only?	? Yes No Unsure
	Is Tamoxifen generally taken for at least 5 years?	Yes No Unsure
	Is vomiting a common side effect after taking Tamoxifen?	Yes No Unsure
	Does Tamoxifen block the supply of estrogen to cancer cells?	Yes No Unsure
AFTER TREATMENT	When all the treatment for breast cancer is finished, is it normal for a woman to feel fearful about cancer?	Yes No Unsure
	After a woman recovers from breast cancer surgery, does she need to take special care of her hands and arms?	Yes No Unsure
	Do most women feel weak and sick for months or years after their treatment is all over?	Yes No Unsure
YOUR MEDICAL HISTORY	Have you had breast cancer before?	Yes No Unsure
	Has any close relative (i.e. mother, sister) had cancer in your family?	Yes No Unsure
[Adapted questionnaire items from: Chapman GB, Elstein AS, Kostbade Hughes K (1995). Effects of Patient Education on Decisions about Breast Cancer Treatments: A Preliminary Report. <i>Medical Decision Making</i>, 15: 231-239]		

Date _____

Patient's MR # _____


Cuestionario Sobre el Tratamiento del Cáncer del Seno

MASTECTOMÍA	En la mastectomía, ¿Se quita solamente la parte cancerosa del seno?	? Sí No No sé
	Después de una mastectomía, ¿Sienten algunas mujeres la sensación de entumecimiento o picazón en el pecho o en el brazo operado?	Sí No No sé
	¿Toma la recuperación de una mastectomía casi una semana?	Sí No No sé
	¿Puede recomendar su doctor la quimioterapia después de su mastectomía?	Sí No No sé
LUMPECTOMÍA O CIRUGÍA PARA CONSERVAR EL SENO	Después de una lumpectomía, también llamada cirugía para conservar el seno, ¿Existen posibilidades altas de que el cáncer regrese al seno operado?	Sí No No sé
	¿Es la reconstrucción del seno muy recomendada después de una lumpectomía o cirugía para conservar el seno?	Sí No No sé
	¿Es necesaria la terapia de radiación después de una lumpectomía o cirugía para conservar el seno?	Sí No No sé
	Después de una lumpectomía, ¿Se sentirá el seno operado firme o duro?	Sí No No sé
	¿Se quitan algunos de los nódulos linfáticos de la axila (debajo del brazo), en cualquier tipo de cirugía que la mujer escoja (mastectomía o cirugía para conservar el seno)?	Sí No No sé


A NO TRATAMIENTO	Si una mujer no obtiene tratamiento para el cáncer del seno, ¿Se quedará el cáncer solo en su seno? Si uno no obtiene tratamiento para el cáncer del seno, ¿Podrá esto causar dolor y deterioro en el seno? ¿Después de tener tratamiento para el cáncer del seno, tienen las mujeres menos posibilidades de estar vivas después de 5 años a comparación a mujeres que no tuvieron tratamiento? Si uno no obtiene tratamiento para el cáncer del seno, ¿Podrá esto llegar a la muerte?	? Sí No No sé Sí No No sé Sí No No sé Sí No No sé
TERAPIA DE RADIACIÓN (RAYOS-X DEL SENO)	Durante la terapia de radiación, se reciben rayos-x de alta intensidad sobre el seno que tiene cáncer. ¿Es la pérdida del cabello un efecto secundario frecuente de la terapia de radiación? Durante la terapia de radiación, ¿Se sentirá y verá el área tratada frecuentemente, como si estuviese quemada por el sol (rojiza y con picazón)? ¿Durará el tratamiento completo de radiación entre 1 y 2 semanas? Durante el período de tratamiento, ¿Se da la terapia de radiación 5 veces por semana? ¿Dura el momento de la radiación misma de 2 a 3 minutos?	Sí No No sé Sí No No sé Sí No No sé Sí No No sé Sí No No sé
QUIMIOTERAPIA	¿Se toma la quimioterapia en ciclos por 4 a 6 meses? ¿Se toma la quimioterapia generalmente en una pastilla? ¿Es la náusea el efecto secundario más común de la quimioterapia? ¿Son generalmente tratados con medicamentos los efectos secundarios de la quimioterapia ?	Sí No No sé Sí No No sé Sí No No sé Sí No No sé

TAMOXIFEN	¿Se usa el tratamiento hormonal con Tamoxifen solo antes de la menopausia? ¿Se toma Tamoxifen generalmente por lo menos por 5 años? ¿Es el vómito un efecto secundario común después de tomar Tamoxifen? ¿Es el Tamoxifen el que no deja que el estrógeno llegue a las células cancerosas?	? Sí No No sé Sí No No sé Sí No No sé Sí No No sé
DESPUÉS DEL TRATAMIENTO	Cuando se ha terminado el tratamiento para el cáncer del seno, ¿Es normal que una mujer se sienta con miedo del cáncer? Después que una mujer se recupera de la cirugía para el cáncer del seno, ¿Debe de mantener un cuidado especial de sus manos y brazos? Cuando ya han terminado todo su tratamiento, ¿Se sienten la mayoría de las mujeres débiles y enfermas por meses y años después?	Sí No No sé Sí No No sé Sí No No sé
SU HISTORIA MÉDICA	¿Ha tenido usted cáncer del seno? ¿Ha tenido cáncer del seno algún familiar cercano (madre, hermana)?	Sí No No sé Sí No No sé
[Adapted questionnaire items from: Chapman GB, Elstein AS, Kostbade Hughes K (1995). Effects of Patient Education on Decisions about Breast Cancer Treatments: A Preliminary Report. <u>Medical Decision Making</u>, 15: 231-239]		

COMPUTER-BASED DECISION SUPPORT SYSTEM FOR BREAST CANCER TREATMENT FLOWCHART (Stages I, IIA & B, IIIA)



APPENDIX C: Sample Screens - Utility Assessment Program



Chemotherapy



7



Resumen
¿Algún Cambio?



7



12



14




NO

SÍ



APPENDIX C: UTILITY ASSESSMENT ("Preference Ranking") PROGRAM FLOWCHART

The Health Ruler




APPENDIX D: Sample Screens - CDSS for Breast Cancer Program



Scene IV of the main story presented in the African-American, English, older woman path which links to Interactive Learning Module I



Educational frame presented in the Spanish version of Interactive Learning Module I for learning facts about cancer



Educational frame in Interactive Learning Module 2
for learning about the process of making a breast cancer diagnosis



Educational frame presented in the Spanish version of Interactive Learning
Module 3 for learning about her breast cancer treatment options

363 cast libraries found	44: Show/Hide List of Sprites (script)	1: 2500 Cue 1
1. Backgrounds.cst (31 members)	45: (script)	2: 4335 Cue 2
1: cafe (bitmap)	46: (script)	3: 5310 Cue 3
2: shop (bitmap)	47: (script)	41: Done (richText)
3: dresses (bitmap)	3. E1-3.cst (10 members)	42: DoneOver (richText)
4: kitchen (bitmap)	1: UTL01 (sound)	43: Stage I (richText)
5: park (bitmap)	2: UTL02 (sound)	44: Stage I Over (richText)
6: scissors (bitmap)	3: Entry E, L001 (sound)	46: Stage IIA (richText)
7: vanity (bitmap)	4: Entry E, L001A (sound)	47: Stage IIA Over (richText)
8: GrayShadow (shape)	1: 3428 Cue 1	49: Stage IIB (richText)
9: newJbox (bitmap)	2: 4681 Cue 2	50: Stage IIB Over (richText)
10: ScissorsMono (bitmap)	5: UTL03A (sound)	52: Stage IIIA (richText)
11: Parambg Palette (palette)	6: UTL01 (sound)	53: Stage IIIA Over (richText)
12: mirror wide (bitmap)	7: UTL02 (sound)	55: <1 (richText)
13: quilt1b (bitmap)	8: Entry S, L001 (sound)	56: <1 Over (richText)
14: quilt2b (bitmap)	9: Entry S, L001A (sound)	58: 1 - 2 (richText)
15: quilt3b (bitmap)	1: 4005 Cue 1	59: 1 - 2 Over (richText)
16: flipperBkg (bitmap)	2: 5129 Cue 2	61: >2 (richText)
17: HousesBkg.p (bitmap)	10: UTL03A (sound)	62: >2 Over (richText)
18: ochre bkg (bitmap)	4. E1AE.cst (4 members)	7. E5-11S.cst (62 members)
19: peach bkg (bitmap)	1: Entry E, L003 (sound)	1: UTL05 (sound)
20: green bkg (bitmap)	3: Entry E, L004 (sound)	2: IsThisCorrect (sound)
21: Title (field)	4: Entry E, L005 (sound)	1: 1959 Yes
22: TitleShadow (field)	1: 14954 Cue 1	2: 3081 No
23: SALON (bitmap)	5. E1AS.cst (4 members)	3: UTL07 (sound)
24: Party (bitmap)	2: ENTRY S, L003 (sound)	4: UTL08 (sound)
25: PartyB (bitmap)	3: ENTRY S, L004 (sound)	5: UTL09 (sound)
26: Credits (bitmap)	4: ENTRY S, L005 (sound)	6: UTL10 (sound)
27: (field)	1: 21044 Cue 1	7: UTL11a (sound)
28: (button)	6. E5-11E.cst (62 members)	8: UTL11b (sound)
29: insideJbox (bitmap)	1: UTL05 (sound)	9: UTL11c (sound)
30: compartments (bitmap)	2: IsThisCorrect (sound)	10: UTL11d (sound)
31: picshadow (shape)	1: 1450 Yes	11: UTL11e (sound)
2. CommonScripts.cst (47 members)	2: 2429 No	12: Correct (richText)
1: PlayAudioFile (script)	3: UTL07 (sound)	13: Yes (richText)
2: Wait Seconds (script)	4: UTL08 (sound)	14: YesOver (richText)
3: Wait for Cue Point (script)	5: UTL09 (sound)	15: No (richText)
4: Hold on Frame (script)	6: UTL10 (sound)	16: NoOver (richText)
5: Check User Response (script)	7: UTL11a (sound)	17: FirstName (richText)
6: PlayDone (script)	8: UTL11b (sound)	18: LastName (richText)
7: Start Timer (script)	9: UTL11c (sound)	19: MedicalRecordNumber (richText)
8: TileAudioEndScript (script)	10: UTL11d (sound)	20: Age (richText)
9: ShowContinueSprite (script)	11: UTL11e (sound)	21: Ethnicity (richText)
10: go the frame - DUP (script)	12: Correct (richText)	22: Stage (richText)
11: WaitForUserResponseOrTimeout (script)	13: Yes (richText)	23: TumorSize (richText)
12: Return to start (script)	14: YesOver (richText)	25: White (richText)
13: Wait Seconds Then Prompt (script)	15: No (richText)	26: WhiteOver (richText)
14: Check for End (script)	16: NoOver (richText)	27: Black (richText)
15: Wait for Cue Point and Branch (script)	17: FirstName (richText)	28: BlackOver (richText)
16: PlayVideoFile (script)	18: LastName (richText)	29: Hispanic (richText)
18: ProcessMPEvents (script)	19: MedicalRecordNumber (richText)	30: HispanicOver (richText)
19: GoLocation (script)	20: Age (richText)	31: Asian (richText)
20: Set Scene Titles for Scenes 2,4,6,8 (script)	21: Ethnicity (richText)	32: AsianOver (richText)
21: WaitForUserResponse (script)	22: Stage (richText)	33: MoreThanOne (richText)
22: misc (script)	23: TumorSize (richText)	34: MoreThanOneOver (richText)
23: PLayerVideoFilePattern (script)	25: White (richText)	35: HispanicShadow (bitmap)
24: Enable/Disable Sprites (script)	26: WhiteOver (richText)	37: ENTRY S, L011 (sound)
25: Hide video sprite (script)	27: Black (richText)	1: 5909 Cue 1
26: FlashSprite (script)	28: BlackOver (richText)	2: 7653 Cue 2
27: StopFlashing (script)	29: Hispanic (richText)	3: 10204 Cue 3
28: PromptUserLoop (script)	30: HispanicOver (richText)	4: 12833 Cue 4
29: VideoSpriteBehavior (script)	31: Asian (richText)	38: ENTRY S, L012 (sound)
30: Loop while Audio Playing (script)	32: AsianOver (richText)	1: 3007 Cue 1
31: Play Videosprite () (script)	33: MoreThanOne (richText)	2: 5242 Cue 2
32: General Button Behavior (script)	34: MoreThanOneOver (richText)	3: 7593 Cue 3
33: Flash sprite (script)	35: HispanicShadow (bitmap)	39: ENTRY S, L012Stgl (sound)
34: (script)	37: Entry E, L011 (sound)	1: 3004 Cue 3
35: hide animation or video (script)	1: 3985 Cue 1	2: 5240 Cue 2
36: stop videosprite (script)	2: 5923 Cue 2	3: 6249 Cue 1
37: Go no video (script)	3: 8271 Cue 3	41: Done (richText)
38: ReturnToPrompts (script)	4: 10598 Cue 4	42: DoneOver (richText)
39: WomanInMirror (script)	38: Entry E, L012 (sound)	43: Stage I (richText)
40: Start timer then Wait Seconds (script)	1: 2503 Cue 1	44: Stage I Over (richText)
41: ShowIssuesInJbox (script)	2: 4338 Cue 2	46: Stage IIA (richText)
42: Reset cast filenames if needed (script)	3: 6052 Cue 3	47: Stage IIA Over (richText)
43: check if chemo played (script)	39: Entry E, L012 i (sound)	49: Stage IIB (richText)

50: Stage IIB Over (richText)	21: M5 S, L003 (sound)	7: P009 (sound)
52: Stage IIIA (richText)	22: M5 S, L004 (sound)	8: P010 (sound)
53: Stage IIIA Over (richText)	23: M5 S, L005 (sound)	9: LOO3 (sound)
55: <1 (richText)	24: M5 S, L006 (sound)	10: LOO4 (sound)
56: <1 Over (richText)	25: Lumpectomy (field)	11: LOO5 (sound)
58: 1 - 2 (richText)	26: Radiation (field)	27. M1AE.cst (23 members)
59: 1 - 2 Over (richText)	27: Tamoxifen (field)	1: M1A E, P005 (sound)
61: >2 (richText)	28: Chemotherapy (field)	2: M1A E, P006 (sound)
62: >2 Over (richText)	29: Mastectomy (field)	3: M1A E, P007 (sound)
8. empty.cst (0 members)	30: Reconstruction (field)	4: M1A E, P008 (sound)
9. GenericWoman.cst (1 members)	12. JboxChemotherapyE.cst (2 members)	5: M1A E, P009 (sound)
1: GenericWomen (bitmap)	1: M3B E, P026 4A (sound)	6: M1A E, P010 (sound)
10. Jbox5E.cst (30 members)	2: M3B E, P026 4D (sound)	9: M1A E, LOO3 (sound)
1: M5A E, L005 MRM (sound)	13. JboxChemotherapyS.cst (2 members)	10: M1A E, LOO4 (sound)
2: M5A E, L005 (sound)	1: M3B S, P026 4A (sound)	11: M1A E, LOO5 (sound)
3: M5A E, L006 MRM (sound)	2: M3B S, P026 4D (sound)	1: 3198 Cue 1
4: M5A E, L006 (sound)	14. JboxE.cst (8 members)	12: M1B E, P011 (sound)
1: 4711 Cue 1	1: M3B E, P026 1B (sound)	13: M1B E, P012 (sound)
2: 5948 Cue 2	2: M3B E, P026 1C (sound)	14: M1B E, LOO6 (sound)
3: 6950 Cue 3	1: 2761 Cue 1	15: M1B E, LOO7 (sound)
4: 12547 Cue 4	2: 3731 Cue 2	1: 18140 Cue 1
5: 14019 Cue 5	3: M3B E, P026 1E (sound)	20: What is Cancer (richText)
6: 15109 Cue 6	4: Are you sure? (richText)	21: What is Cancer (richText)
5: M5A E, P052 (sound)	5: Yes (field)	22: Understanding Breast Cancer (richText)
6: P053 (sound)	6: No (field)	23: Understanding Breast Cancer Shadow
7: (richText)	7: Done (richText)	(richText)
10: M5A E, L007 (sound)	8: DoneShadow (richText)	28. M1AS.cst (23 members)
1: 4054 Cue 1	15. JboxLumpectomyE.cst (2 members)	1: M1A S H, P005 (sound)
11: M5A E, P054 (sound)	1: M3B E, P026 1A (sound)	2: M1A S H, P006 (sound)
12: M5A E, L008 (sound)	2: M3B E, P026 1D (sound)	3: M1A S H, P007 (sound)
13: M5A E, L009 (sound)	16. JboxLumpectomyS.cst (2 members)	4: M1A S H, P008 (sound)
1: 3817 Cue 1	1: M3B S, P026 1A (sound)	5: M1A S H, P009 (sound)
2: 5950 Cue 2	2: M3B S, P026 1D (sound)	6: M1A S H, P010 (sound)
3: 8284 Cue 3	17. JboxMastectomyE.cst (2 members)	7: M1A S, L001 (sound)
14: M5A E, L010 (sound)	1: M3B E, P026 5A (sound)	8: M1A S, L002 (sound)
1: 9319 Cue 1	2: M3B E, P026 5D (sound)	9: M1A S, L003 (sound)
15: P055 (sound)	18. JboxMastectomyS.cst (2 members)	10: M1A S, L004 (sound)
19: M5 E, L001 (sound)	1: M3B S, P026 5A (sound)	11: M1A S, L005 (sound)
20: M5 E, L002 (sound)	2: M3B S, P026 5D (sound)	1: 7367 Cue 1
21: M5 E, L003 (sound)	19. JboxRadiationE.cst (2 members)	12: M1B S H, P011 (sound)
22: M5 E, L004 (sound)	1: M3B E, P026 2A (sound)	13: M1B S H, P012 (sound)
23: M5 E, L005 (sound)	2: M3B E, P026 2D (sound)	14: M1B S, L006 (sound)
24: M5 E, L006 (sound)	20. JboxRadiationS.cst (2 members)	15: M1B S, L007 (sound)
25: Lumpectomy (field)	1: M3B S, P026 2A (sound)	1: 26400 Cue 1
26: Radiation (field)	2: M3B S, P026 2D (sound)	20: What is Cancer (richText)
27: Tamoxifen (field)	21. JboxReconstructionE.cst (2 members)	21: What is Cancer (richText)
28: Chemotherapy (field)	1: M3B E, P026 6A (sound)	22: Understanding Breast Cancer (richText)
29: Mastectomy (field)	2: M3B E, P026 6D (sound)	23: Understanding Breast Cancer Shadow
30: Reconstruction (field)	22. JboxReconstructionS.cst (2 members)	(richText)
11. Jbox5S.cst (30 members)	1: M3B S, P026 6A (sound)	29. m1cE.cst (13 members)
1: M5A S, L005 MRM (sound)	2: M3B S, P026 6D (sound)	2: M1C E, LOO8 (sound)
2: M5A S, L005 (sound)	23. JboxS.cst (9 members)	4: Title (richText)
3: M5A S, L006 MRM (sound)	1: M3B S, P026 1B (sound)	5: TitleShadow (richText)
4: M5A S, L006 (sound)	2: M3B S, P026 1C (sound)	6: Title (richText)
1: 4876 Cue 1	1: 3224 Cue 1	7: TitleShadow (richText)
2: 6088 Cue 2	2: 4322 Cue 2	9: Yes (bitmap)
3: 7333 Cue 3	3: M3B S, P026 1E (sound)	10: Yes (bitmap)
4: 14223 Cue 4	4: Are you sure? (richText)	12: No (bitmap)
5: 15945 Cue 5	5: Yes (field)	13: No (bitmap)
6: 17158 Cue 4	6: No (field)	30. m1cEAA.cst (82 members)
5: M5A S, P052 (sound)	7: Done (richText)	1: (field)
6: P053 (sound)	8: DoneShadow (richText)	80: M1C E AA, P013 (sound)
7: (richText)	9: Translate (field)	81: M1C E AA, P014 (sound)
10: M5A S, L007 (sound)	24. JboxTamoxifenE.cst (2 members)	82: M1C E AA, P015 (sound)
1: 4023 Cue 1	1: M3B E, P026 3A (sound)	31. m1cEAA1.cst (7 members)
11: M5A S, P054 (sound)	2: M3B E, P026 3D (sound)	1: Question (richText)
12: M5A S, L008 (sound)	25. JboxTamoxifenS.cst (2 members)	2: M1C E AA, LO10 (sound)
13: M5A S, L009 (sound)	1: M3B S, P026 3A (sound)	3: No Text (richText)
1: 3162 Cue 1	2: M3B S, P026 3D (sound)	4: M1C E AA, LO11 NO (sound)
2: 4391 Cue 2	26. M1A.cst (11 members)	5: Yes text (richText)
3: 5802 Cue 3	1: LOO1 (sound)	6: M1C E AA, LO11 YES (sound)
14: M5A S, L010 (sound)	2: LOO2 (sound)	7: M1C E AA, LO12 YES (sound)
1: 9719 Cue 1	3: P005 (sound)	32. m1cEAA2.cst (7 members)
15: P055 (sound)	4: P006 (sound)	1: (richText)
19: M5 S, L001 (sound)	5: P007 (sound)	2: M1C E AA, LO13 (sound)
20: M5 S, L002 (sound)	6: P008 (sound)	3: (richText)

- 4: MIC E AA, LO14 NO (sound)
5: (richText)
6: MIC E AA, LO14 YES (sound)
7: MIC E AA, LO15 YES (sound)
33. m1cEAA3.cst (82 members)
1: (richText)
2: MIC E AA, LO16 (sound)
3: (richText)
4: MIC E AA, LO17 NO (sound)
5: (richText)
6: MIC E AA, LO17 YES (sound)
7: MIC E AA, LO18 YES (sound)
80: M1C E AA, P013 (sound)
81: M1C E AA, P014 (sound)
82: M1C E AA, P015 (sound)
34. m1ceaa4.cst (82 members)
1: (richText)
2: MIC E AA, LO19 (sound)
3: (richText)
4: MIC E AA, LO20 NO (sound)
5: (richText)
6: MIC E AA, LO20 YES (sound)
7: MIC E AA, LO21 YES (sound)
80: M1C E AA, P013 (sound)
81: M1C E AA, P014 (sound)
82: M1C E AA, P015 (sound)
35. m1cEAA5.cst (82 members)
1: (richText)
2: MIC E AA, LO22 (sound)
3: (richText)
4: MIC E AA, LO23 NO (sound)
5: (richText)
6: MIC E AA, LO23 YES (sound)
7: MIC E AA, LO24 YES (sound)
80: M1C E AA, P013 (sound)
81: M1C E AA, P014 (sound)
82: M1C E AA, P015 (sound)
36. m1cECA.cst (82 members)
1: (field)
80: M1C E AA, P013 (sound)
81: M1C E AA, P014 (sound)
82: M1C E AA, P015 (sound)
37. m1cECA1.cst (7 members)
1: Question (richText)
2: M1C E AA, LO10 (sound)
3: No Text (richText)
4: M1C E AA, LO11 NO (sound)
5: Yes text (richText)
6: M1C E AA, LO11 YES (sound)
7: M1C E AA, LO12 YES (sound)
38. m1cECA2.cst (7 members)
1: (richText)
2: M1C E AA, LO13 (sound)
3: (richText)
4: MIC E AA, LO14 NO (sound)
5: (richText)
6: MIC E AA, LO14 YES (sound)
7: MIC E AA, LO15 YES (sound)
39. m1cECA3.cst (82 members)
1: (richText)
2: M1C E W, L016 (sound)
3: (richText)
4: M1C E W, L017 NO (sound)
5: (richText)
6: M1C E W, L017 YES (sound)
80: M1C E AA, P013 (sound)
81: M1C E AA, P014 (sound)
82: M1C E AA, P015 (sound)
40. m1cECA4.cst (82 members)
1: (richText)
2: MIC E AA, LO16 (sound)
3: (richText)
4: MIC E AA, LO17 NO (sound)
5: (richText)
6: MIC E AA, LO17 YES (sound)
7: MIC E AA, LO18 YES (sound)
80: M1C E AA, P013 (sound)
81: M1C E AA, P014 (sound)
82: M1C E AA, P015 (sound)
41. m1cECA5.cst (82 members)
1: (richText)
2: MIC E AA, LO22 (sound)
3: (richText)
4: MIC E AA, LO23 NO (sound)
5: (richText)
6: MIC E AA, LO23 YES (sound)
7: MIC E AA, LO24 YES (sound)
80: M1C E AA, P013 (sound)
81: M1C E AA, P014 (sound)
82: M1C E AA, P015 (sound)
42. m1cEHS.cst (82 members)
1: (field)
80: M1C E AA, P013 (sound)
81: M1C E AA, P014 (sound)
82: M1C E AA, P015 (sound)
43. m1cEHS1.cst (7 members)
1: Question (richText)
2: M1C E AA, LO10 (sound)
3: No Text (richText)
4: M1C E AA, LO11 NO (sound)
5: Yes text (richText)
6: M1C E AA, LO11 YES (sound)
7: M1C E AA, LO12 YES (sound)
44. m1cEHS2.cst (7 members)
1: (richText)
2: M1C E AA, LO13 (sound)
3: (richText)
4: MIC E AA, LO14 NO (sound)
5: (richText)
6: MIC E AA, LO14 YES (sound)
7: MIC E AA, LO15 YES (sound)
45. m1cEHS3.cst (82 members)
1: (richText)
2: M1C E H, L016 (sound)
3: (richText)
4: M1C E H, L017 NO (sound)
5: (richText)
6: M1C E H, L017 YES (sound)
7: M1C E H, L018 YES (sound)
80: M1C E AA, P013 (sound)
81: M1C E AA, P014 (sound)
82: M1C E AA, P015 (sound)
46. m1cEHS4.cst (82 members)
1: (richText)
2: M1C E H, L019 (sound)
3: (richText)
4: M1C E H, L020 NO (sound)
5: (richText)
6: M1C E H, L020 YES (sound)
7: M1C E H, L021 YES (sound)
80: M1C E AA, P013 (sound)
81: M1C E AA, P014 (sound)
82: M1C E AA, P015 (sound)
47. m1cEHS5.cst (82 members)
1: (richText)
2: MIC E AA, LO22 (sound)
3: (richText)
4: MIC E AA, LO23 NO (sound)
5: (richText)
6: MIC E AA, LO23 YES (sound)
7: MIC E AA, LO24 YES (sound)
80: M1C E AA, P013 (sound)
81: M1C E AA, P014 (sound)
82: M1C E AA, P015 (sound)
48. m1cS.cst (13 members)
2: M1C S H, L008 (sound)
4: Title (richText)
5: TitleShadow (richText)
6: Title (richText)
7: TitleShadow (richText)
9: (bitmap)
10: (bitmap)
12: No (bitmap)
13: No (bitmap)
49. m1cSHS.cst (82 members)
1: (field)
80: M1C E AA, P013 (sound)
81: M1C E AA, P014 (sound)
82: M1C E AA, P015 (sound)
50. m1cSHS1.cst (7 members)
1: Question (richText)
2: M1C S H, L010 (sound)
3: No Text (richText)
4: M1C S H, L011 NO (sound)
5: Yes text (richText)
6: M1C S H, L011 YES (sound)
7: M1C S H, L012 YES (sound)
51. m1cSHS2.cst (7 members)
1: (richText)
2: M1C S H, L013A (sound)
3: (richText)
4: M1C S H, L014A NO (sound)
5: (richText)
6: M1C S H, L014A YES (sound)
7: M1C S H, L015 YES (sound)
52. m1cSHS3.cst (82 members)
1: (richText)
2: M1C S H, L016 (sound)
3: (richText)
4: M1C S H, L017 NO (sound)
5: (richText)
6: M1C S H, L018 YES (sound)
7: M1C S H, L018 YES (sound)
80: M1C E AA, P013 (sound)
81: M1C E AA, P014 (sound)
82: M1C E AA, P015 (sound)
53. m1cSHS4.cst (82 members)
1: (richText)
2: M1C S H, L019 (sound)
3: (richText)
4: M1C S H, L020 NO (sound)
5: (richText)
6: M1C S H, L020 YES (sound)
7: M1C S H, L021 YES (sound)
80: M1C E AA, P013 (sound)
81: M1C E AA, P014 (sound)
82: M1C E AA, P015 (sound)
54. m1cSHS5.cst (82 members)
1: (richText)
2: M1C S H, L022 (sound)
3: (richText)
4: M1C S H, L023 NO (sound)
5: (richText)
6: M1C S H, L023 YES (sound)
80: M1C E AA, P013 (sound)
81: M1C E AA, P014 (sound)
82: M1C E AA, P015 (sound)
55. M2C11e.cst (4 members)
1: Learning (richText)
2: M2C E, L016 (sound)
3: M2C E, L017 (sound)
1: 8947 Cue 1
4: P008 (sound)
56. M2C11s.cst (4 members)
1: Learning (richText)
2: M2C S, L016 (sound)
3: M2C S, L017 (sound)
1: 11993 Cue 1
4: P008 (sound)
57. M2C12El.cst (4 members)
1: stage1 (richText)
2: M2C E, L018 I (sound)
1: 5257 Cue 1
2: 8219 Cue 2
3: <= 1 inch (richText)
4: Not Spread (richText)
58. M2C12EIIA.cst (5 members)
1: stage1 (richText)

2: M2C E, L018, II (sound)	30: Lymph (richText)	55: M2D E, L030, I (sound)
1: 9025 Cue 1	31: cell growth (richText)	1: 6973 Cue 1
2: 16604 Cue 2	32: Hormones (richText)	2: 15934 Cue 2
3: 25513 Cue 3	37: M5 E, L007 (sound)	58: M2D E, L031 STG I (sound)
3: <= 1 inch (richText)	40: M2C E, L019 ALT (sound)	1: 5809 Cue 1
4: May Spread (richText)	42: M2D E, L020 (sound)	2: 10303 Cue 2
5: Not Spread (richText)	43: M2D E, L021 ALT (sound)	59: M2D E, L032 STG I (sound)
59: M2C12EIIIB.cst (5 members)	45: M2D E, L022 (sound)	68: M2DEIIA.cst (59 members)
1: stage1 (richText)	46: M2D E, L023 (sound)	15: (richText)
2: M2C E, L018, II (sound)	47: M2D E, L024 (sound)	16: stage1 (richText)
1: 9025 Cue 1	48: M2D E, L025 (sound)	17: treatment (richText)
2: 16604 Cue 2	1: 3997 Cue 1	18: no treatment (richText)
3: 25513 Cue 3	2: 6307 Cue 2	21: SuccessTreatment (richText)
3: <= 1 inch (richText)	3: 9258 Cue 3	22: SuccessNoTreatment (richText)
4: May Spread (richText)	4: 15339 Cue 4	55: M2D E, L030, II (sound)
5: Not Spread (richText)	5: 23470 Cue 5	1: 7667 Cue 1
60: M2C12EIIIA.cst (4 members)	49: M2D E, L026 (sound)	2: 16673 Cue 2
1: stage1 (richText)	51: M2D E, L027 (sound)	58: M2D E, L031, II (sound)
2: M2C E, L018, III (sound)	1: 16312 Cue 1	1: 6298 Cue 1
1: 8021 Cue 1	2: 18401 Cue 2	2: 10828 Cue 2
2: 18888 Cue 2	3: 22728 Cue 3	59: M2D E, L032 STG I (sound)
3: <= 1 inch (richText)	4: 25463 Cue 4	69: M2DEIIB.cst (59 members)
4: Not Spread (richText)	52: M2D E, L028 (sound)	15: (richText)
61: M2C12SII.cst (4 members)	53: M2D E, L029 (sound)	16: stage1 (richText)
1: stage1 (richText)	66: M2C13S.cst (53 members)	17: treatment (richText)
2: M2C S, L018 STG I (sound)	10: Treatment Heading (richText)	18: no treatment (richText)
1: 6642 Cue 1	11: Biopsy (richText)	21: SuccessTreatment (richText)
2: 8431 Cue 2	12: (richText)	22: SuccessNoTreatment (richText)
3: <= 1 inch (richText)	13: (richText)	55: M2D E, L030, II (sound)
4: Not Spread (richText)	14: (richText)	1: 7667 Cue 1
62: M2C12SIIA.cst (5 members)	15: (richText)	2: 16673 Cue 2
1: stage1 (richText)	16: stage1 (richText)	58: M2D E, L031, II (sound)
2: M2C S, L018, II (sound)	17: treatment (richText)	1: 6298 Cue 1
1: 11888 Cue 1	18: no treatment (richText)	2: 10828 Cue 2
2: 20853 Cue 2	19: <= 1 inch (richText)	59: M2D E, L032 STG I (sound)
3: 30151 Cue 3	20: Not Spread (richText)	70: M2DEIIIA.cst (59 members)
3: <= 1 inch (richText)	21: (richText)	15: (richText)
4: May Spread (richText)	22: Recovery Heading (richText)	16: stage1 (richText)
5: Not Spread (richText)	23: Type and Stage (richText)	17: treatment (richText)
63: M2C12SIIIB.cst (5 members)	24: Growth of Cancer (richText)	18: no treatment (richText)
1: stage1 (richText)	25: Hormones (richText)	20: SuccessTreatment (richText)
2: M2C S, L018, II (sound)	26: Age (richText)	21: SuccessTreatment (richText)
1: 11888 Cue 1	27: Health State (richText)	22: SuccessNoTreatment (richText)
2: 20853 Cue 2	28: Returning Heading (richText)	35: (richText)
3: 30151 Cue 3	29: Size (richText)	36: (richText)
3: <= 1 inch (richText)	30: Lymph (richText)	55: M2D E, L030, III (sound)
4: May Spread (richText)	31: cell growth (richText)	1: 11380 Cue 1
5: Not Spread (richText)	32: Hormones (richText)	2: 24507 Cue 2
64: M2C12SIIIA.cst (4 members)	37: M5 S, L007 (sound)	3: 30513 Cue 3
1: stage1 (richText)	40: M2C S, L019 (sound)	4: 33865 Cue 4
2: M2C S, L018, III (sound)	42: M2D S, L020 (sound)	58: M2D E, L031, III (sound)
1: 10128 Cue 1	44: M2D S, L021 (sound)	1: 7030 Cue 1
2: 23743 Cue 2	45: M2D S, L022 (sound)	2: 11551 Cue 2
3: <= 1 inch (richText)	46: M2D S, L023 (sound)	59: M2D E, L032 STG I (sound)
4: Not Spread (richText)	47: M2D S, L024 (sound)	71: M2DSI.cst (59 members)
65: M2C13E.cst (53 members)	48: M2D S, L025 (sound)	15: (richText)
10: Treatment Heading (richText)	1: 3595 Cue 1	16: stage1 (richText)
11: Biopsy (richText)	2: 6374 Cue 2	17: treatment (richText)
12: (richText)	3: 9479 Cue 3	18: no treatment (richText)
13: (richText)	4: 18904 Cue 4	21: SuccessTreatment (richText)
14: (richText)	5: 28874 Cue 5	22: SuccessNoTreatment (richText)
15: (richText)	49: M2D S, L026 (sound)	55: M2D S, L030, I (sound)
16: stage1 (richText)	51: M2D S, L027 (sound)	1: 8504 Cue 1
17: treatment (richText)	1: 20379 Cue 1	2: 10167 Cue 2
18: no treatment (richText)	2: 23538 Cue 2	58: M2D S, L031 STG I (sound)
19: <= 1 inch (richText)	3: 31914 Cue 3	1: 7282 Cue 1
20: Not Spread (richText)	4: 36903 Cue 4	2: 12964 Cue 2
21: Choosing Heading (richText)	52: M2D S, L028 (sound)	59: M2D S, L032 STG I (sound)
22: Recovery Heading (richText)	53: M2D S, L029 (sound)	72: M2DSIIA.cst (59 members)
23: Type and Stage (richText)	67: M2DEI.cst (59 members)	15: (richText)
24: Growth of Cancer (richText)	15: (richText)	16: stage1 (richText)
25: Hormones (richText)	16: stage1 (richText)	17: treatment (richText)
26: Age (richText)	17: treatment (richText)	18: no treatment (richText)
27: Health State (richText)	18: no treatment (richText)	21: SuccessTreatment (richText)
28: Returning Heading (richText)	21: SuccessTreatment (richText)	22: SuccessNoTreatment (richText)
29: Size (richText)	22: SuccessNoTreatment (richText)	55: M2D S, L030, II (sound)

1: 8733 Cue 1	2: 7221 Cue 2	6: M2E S, L037 YES (sound)
2: 19709 Cue 2	3: 10759 Cue 3	7: M2E S, L038 YES (sound)
58: M2D S, L031, II (sound)	4: 16011 Cue 4	82. m2eS2.cst (7 members)
1: 7937 Cue 1	32: M2B E, L013 (sound)	1: Question (richText)
2: 13110 Cue 2	33: M2B E, L014 (sound)	2: M2E S, L039 (sound)
59: M2D S, L032 STG I (sound)	34: M2B E, L015 (sound)	1: 5730 Cue 1
73. M2DSIIB.cst (59 members)	1: 3521 Cue 1	2: 7055 Cue 2
15: (richText)	2: 5782 Cue 2	3: (richText)
16: stage1 (richText)	3: 7510 Cue 3	4: M2E S, L040 NO (sound)
17: treatment (richText)	35: P008 (sound)	5: (richText)
18: no treatment (richText)	76. m2eE.cst (23 members)	6: M2E S, L040 YES (sound)
21: SuccessTreatment (richText)	1: (field)	7: M2E S, L041 YES (sound)
22: SuccessNoTreatment (richText)	2: (bitmap)	83. m2eS3.cst (7 members)
55: M2D S, L030, II (sound)	3: (bitmap)	1: Question (richText)
1: 8733 Cue 1	7: M2E E, L034 (sound)	2: M2E S, L042 (sound)
2: 19709 Cue 2	8: M2E E, L035 (sound)	1: 4097 Cue 1
58: M2D S, L031, II (sound)	13: M1 E, P002 (sound)	2: 5683 Cue 2
1: 7937 Cue 1	1: 4842 Cue 1	3: (richText)
2: 13110 Cue 2	14: M1 E, P003 (sound)	4: M2E S, L043 NO (sound)
59: M2D S, L032 STG I (sound)	15: M1 E, P004 (sound)	5: (richText)
74. M2DSIIIA.cst (59 members)	20: (richText)	6: M2E S, L043 YES (sound)
15: (richText)	22: (field)	7: M2E S, L044 YES (sound)
16: stage1 (richText)	23: (field)	84. M2S.cst (35 members)
17: treatment (richText)	77. m2eE1.cst (7 members)	1: Understanding (richText)
18: no treatment (richText)	1: Question (richText)	2: UnderstandingOver (richText)
20: SuccessTreatment (richText)	2: M2E E, L036 (sound)	3: Diagnosis (richText)
21: SuccessTreatment (richText)	1: 4097 Cue 1	4: DiagnosisOver (richText)
22: SuccessNoTreatment (richText)	2: 5391 Cue 2	5: StagingHeading (richText)
35: (richText)	3: No Text (richText)	6: StagingHeadingOver (richText)
36: (richText)	4: M2E E, L037 NO (sound)	7: Biopsy Heading (richText)
55: M2D S, L030, III (sound)	5: Yes text (richText)	8: TypesHeading (richText)
1: 13553 Cue 1	6: M2E E, L037 YES (sound)	9: TypesHeadingOver (richText)
2: 29668 Cue 2	7: M2E E, L038 YES (sound)	10: Treatment Heading (richText)
3: 36528 Cue 3	78. m2eE2.cst (7 members)	11: Biopsy (richText)
4: 40412 Cue 4	1: (richText)	12: (richText)
58: M2D S, L031, III (sound)	2: M2E E, L039 (sound)	13: (richText)
1: 8321 Cue 1	1: 5091 Cue 1	14: (richText)
2: 13783 Cue 2	2: 6511 Cue 2	19: M2 S, L001 (sound)
59: M2D S, L032 STG I (sound)	3: (richText)	20: M2 S, L002 (sound)
75. M2E.cst (35 members)	4: M2E E, L040 NO (sound)	21: M2A S, L003 (sound)
1: Understanding (richText)	5: (richText)	22: M2A S, L004 (sound)
3: Diagnosis (richText)	6: M2E E, L040 YES (sound)	1: 13695 Cue 1
4: DiagnosisOver (richText)	7: M2E E, L041 YES (sound)	23: M2A S, L005 (sound)
5: StagingHeading (richText)	79. m2eE3.cst (82 members)	1: 5677 Cue 1
6: StagingHeadingOver (richText)	1: Question (richText)	2: 16493 Cue 2
7: Biopsy Heading (richText)	2: M2E E, L042 (sound)	24: M2A S, L006 (sound)
8: TypesHeading (richText)	1: 3724 Cue 1	25: M2A S, L007 (sound)
9: TypesHeadingOver (richText)	2: 5118 Cue 2	26: M2A S, L008 (sound)
10: Treatment Heading (richText)	3: (richText)	27: M2A S, L009 (sound)
11: Biopsy (richText)	4: M2E E, L043 NO (sound)	1: 1959 Cue 1
12: (richText)	5: (richText)	2: 7199 Cue 2
13: (richText)	6: M2E E, L043 YES (sound)	3: 11799 Cue 3
14: (richText)	7: M2E E, L044 YES (sound)	4: 19552 Cue 4
19: M2 E, L001 (sound)	80: M1C E AA, P013 (sound)	28: M2A S, P016 (sound)
20: M2 E, L002 (sound)	81: M1C E AA, P014 (sound)	29: M2B S, L010 (sound)
21: M2A E, L003 (sound)	82: M1C E AA, P015 (sound)	30: M2B S, L011 (sound)
22: M2A E, L004 (sound)	80. m2eS.cst (23 members)	31: M2B S, L012 (sound)
1: 9787 Cue 1	1: (field)	1: 4203 Cue 1
2: 12047 Cue 2	2: (bitmap)	2: 7962 Cue 2
23: M2A E, L005 (sound)	3: (bitmap)	3: 11641 Cue 3
1: 4960 Cue 1	7: M2E S, L034 (sound)	4: 18515 Cue 4
2: 16968 Cue 2	8: M2E S, L035 (sound)	32: M2B S, L013 (sound)
24: M2A E, L006 (sound)	13: M1 S H, P002 (sound)	33: M2B S, L014 (sound)
25: M2A E, L007 (sound)	14: M1 S H, P003 (sound)	34: M2B S, L015 (sound)
26: M2A E, L008 (sound)	15: M1 S H, P004 (sound)	35: P008 (sound)
27: M2A E, L009 (sound)	20: (richText)	85. m3aE.cst (45 members)
1: 1934 Cue 1	22: (field)	1: No (richText)
2: 7327 Cue 2	23: (field)	2: NOOver (richText)
3: 11716 Cue 3	81. m2eS1.cst (7 members)	4: YESOver (richText)
4: 17296 Cue 4	1: Question (richText)	5: YES (richText)
28: M2A E, P016 (sound)	2: M2E S, L036 (sound)	7: shadow (shape)
29: M2B E, L010 (sound)	1: 4584 Cue 1	8: (richText)
30: M2B E, L011 (sound)	2: 5968 Cue 2	9: (richText)
31: M2B E, L012 (sound)	3: (richText)	10: (richText)
1: 3793 Cue 1	4: M2E S, L037 NO (sound)	11: (richText)
	5: (richText)	12: (richText)

13: (richText)	2: 18807 Cue 2	16: stage1 (richText)
14: (richText)	3: 27699 Cue 3	17: treatment (richText)
15: (richText)	5: (richText)	18: no treatment (richText)
16: (richText)	6: (richText)	20: SuccessTreatment (richText)
17: (richText)	7: (richText)	21: SuccessTreatment (richText)
18: (richText)	8: BCSMRM (sound)	22: SuccessNoTreatment (richText)
19: (richText)	1: 4364 Cue 1	35: (richText)
20: (richText)	2: 15166 Cue 2	36: (richText)
21: (richText)	3: 23486 Cue 3	55: M3B E, L004, IIB (sound)
22: (richText)	9: Timeout (sound)	1: 5130 Cue 1
23: (richText)	10: MRMOnly (sound)	2: 6380 Cue 2
24: (richText)	1: 68 Cue 1	3: 9638 Cue 3
25: (richText)	2: 7687 Cue 2	4: 17312 Cue 4
26: (richText)	11: MRMTimeout (sound)	58: M3B E, L005, IIB (sound)
27: (richText)	19: M3BP020 (sound)	1: 13312 Cue 1
28: quesabouthhealth (richText)	21: BCSText (bitmap)	59: M3B E, L006, IIB (sound)
29: (richText)	22: MRMTText (bitmap)	60: M3B E, P022 NEW (sound)
30: (richText)	23: (richText)	94. M3b16BIIBS.cst (60 members)
34: (richText)	88. M3b12S.cst (23 members)	15: (richText)
36: (richText)	1: (richText)	16: stage1 (richText)
37: (richText)	2: (richText)	17: treatment (richText)
38: (richText)	3: M3B S, L038 (sound)	18: no treatment (richText)
39: (richText)	4: M3B S, L039 (sound)	20: SuccessTreatment (richText)
40: (richText)	1: 5478 Cue 1	21: SuccessTreatment (richText)
41: (richText)	2: 20817 Cue 2	22: SuccessNoTreatment (richText)
42: (richText)	3: 33384 Cue 3	35: (richText)
43: (richText)	5: (richText)	36: (richText)
44: Done1 (richText)	6: (richText)	55: M3B S, L004, IIB (sound)
45: DoneOver1 (richText)	7: (richText)	1: 5763 Cue 1
86. m3as.cst (45 members)	8: BCSMRM (sound)	2: 6627 Cue 2
1: NO (richText)	1: 5251 Cue 1	3: 9221 Cue 3
2: NOOver (richText)	2: 18823 Cue 2	4: 20943 Cue 4
4: YesOver (richText)	3: 29617 Cue 3	58: M3B S, L005, IIB (sound)
5: YES (richText)	9: Timeout (sound)	1: 14799 Cue 1
7: shadow (shape)	10: MRMONLY (sound)	59: M3B S, L006, IIB (sound)
8: (richText)	1: 47 Cue 1	60: M3B S, P022 (sound)
9: (richText)	2: 10569 Cue 2	95. M3b16BIIAE.cst (60 members)
10: (richText)	11: MRMTimeout (sound)	15: (richText)
11: (richText)	19: M3BP020 (sound)	16: stage1 (richText)
12: (richText)	21: (bitmap)	17: treatment (richText)
13: (richText)	22: (bitmap)	18: no treatment (richText)
14: (richText)	23: (richText)	20: SuccessTreatment (richText)
15: (richText)	89. m3b14E.cst (7 members)	21: SuccessTreatment (richText)
16: (richText)	1: M3A E, L041 (sound)	22: SuccessNoTreatment (richText)
17: (richText)	1: 8926 Cue 1	35: (richText)
18: (richText)	2: M3A E, L042 (sound)	36: (richText)
19: (richText)	3: M3A E, L043 (sound)	55: M3B E, L004, IIIA (sound)
20: (richText)	4: M3A E, L044 STG I BCS (sound)	1: 5186 Cue 1
21: (richText)	6: (richText)	2: 6505 Cue 2
22: (richText)	7: (richText)	3: 9598 Cue 3
23: (richText)	90. M3b14S.cst (7 members)	4: 17878 Cue 4
24: (richText)	1: M3B S, L041 (sound)	58: M3B E, L005, IIIA (sound)
25: (richText)	1: 11712 Cue 1	1: 12756 Cue 1
26: (richText)	2: M3B S, L042 (sound)	59: M3B E, L006, IIB (sound)
27: (richText)	3: M3B S, L043 (sound)	60: M3B E, P022 NEW (sound)
28: quesabouthhealth (richText)	4: M3B S, L044 STG I BCS (sound)	96. M3b16BIIIAS.cst (60 members)
29: (richText)	6: (richText)	15: (richText)
30: (richText)	7: (richText)	16: stage1 (richText)
33: SpanishContinue (bitmap)	91. m3b16AE.cst (5 members)	17: treatment (richText)
34: (richText)	1: Chemo (richText)	18: no treatment (richText)
36: (richText)	2: M3B E, L001, IIB (sound)	20: SuccessTreatment (richText)
37: (richText)	1: 9560 Cue 1	21: SuccessTreatment (richText)
38: (richText)	3: M3B E, L002, IIB (sound)	22: SuccessNoTreatment (richText)
39: (richText)	4: M3B E, L003, IIB (sound)	35: (richText)
40: (richText)	1: 13572 Cue 1	36: (richText)
41: (richText)	5: M3B E, P022 NEW (sound)	55: M3B S, L004, IIIA (sound)
42: (richText)	92. m3b16AS.cst (5 members)	1: 5796 Cue 1
43: (richText)	1: (richText)	2: 7090 Cue 2
44: Done1 (richText)	2: M3B S, L001, IIB (sound)	3: 11023 Cue 3
45: DoneOver1 (richText)	1: 11081 Cue 1	4: 22926 Cue 4
87. M3b12E.cst (23 members)	3: M3B S, L002, IIB (sound)	58: M3B S, L005, IIIA (sound)
1: (richText)	4: M3B S, L003, IIB (sound)	1: 15207 Cue 1
2: (richText)	1: 16781 Cue 1	59: M3B S, L006, IIB (sound)
3: M3A E, L038 (sound)	5: M3B S, P022 (sound)	60: M3B S, P022 (sound)
4: M3A E, L039 (sound)	93. M3b16BIIBE.cst (60 members)	97. m3b16EE.cst (5 members)
1: 4889 Cue 1	15: (richText)	1: Chemo (richText)

- 2: M3B E, L001, IIA (sound)
1: 9691 Cue 1
3: M3B E, L002, IIB (sound)
4: M3B E, L003, IIB (sound)
1: 13710 Cue 1
5: M3B E, P022 NEW (sound)
98. m3b16ES.cst (5 members)
1: (richText)
2: M3B S, L001, IIA (sound)
1: 11193 Cue 1
3: M3B S, L002, IIB (sound)
4: M3B S, L003, IIB (sound)
1: 16815 Cue 1
5: M3B S, P022 (sound)
99. m3b17AE.cst (5 members)
1: Chemo (richText)
2: M3B E, L043, II, BCS (sound)
1: 6535 Cue 1
4: M3B E, L044 I BCS (sound)
5: M3B E, P022 NEW (sound)
100. m3b17As.cst (5 members)
1: Chemo (richText)
2: M3B S, L043, II, BCS (sound)
1: 8226 Cue 1
4: M3B S, L044 STG I BCS (sound)
5: M3B S, P022 (sound)
101. m3b17BE.cst (5 members)
1: Chemo (richText)
2: M3B E, L043, II, BCS (sound)
1: 14562 Cue 1
4: M3B E, L148 I MRM (sound)
5: M3B E, P022 NEW (sound)
102. m3b17BS.cst (5 members)
1: Chemo (richText)
2: M3B S, L043, II, BCS (sound)
1: 16223 Cue 1
4: M3B S, L148 I MRM (sound)
5: M3B S, P022 (sound)
103. m3b17E.cst (3 members)
1: (richText)
2: M3B E, L044 I BCS (sound)
3: P022 (sound)
104. m3b17S.cst (3 members)
1: (richText)
2: M3B S, L044 STG I BCS (sound)
3: P022 (sound)
105. m3b19IE.cst (15 members)
1: (richText)
2: M3B E, L045 I BCS (sound)
3: M3B E, L046 I BCS (sound)
1: 13118 Cue 1
10: IssueList (field)
11: M3B E, L047 I BCS (sound)
12: M3B E, L048 I BCS (sound)
13: M3B E, L049 I BCS (sound)
1: 4370 Cue 1
2: 8657 Cue 2
14: M3B E, L050 I BCS (sound)
15: M3B E, L051 I BCS (sound)
106. m3b19IS.cst (15 members)
1: (richText)
2: M3B S, L045 STG I BCS (sound)
3: M3B S, L046 STG I BCS (sound)
1: 16263 Cue 1
10: IssueList (field)
11: M3B S, L047 STG I BCS (sound)
12: M3B S, L048 STG I BCS (sound)
13: M3B S, L049 STG I BCS (sound)
1: 4967 Cue 1
2: 10946 Cue 2
14: M3B S, L050 STG I BCS (sound)
15: M3B S, L051 STG I BCS (sound)
107. m3b20ale.cst (12 members)
1: (richText)
2: M3B E, L052 I BCS (sound)
10: IssueList (field)
11: M3B E, L053 I BCS (sound)
12: M3B E, L054 I BCS (sound)
108. m3b20aIS.cst (12 members)
1: (richText)
2: M3B S, L052 STG I BCS (sound)
10: IssueList (field)
11: M3B S, L053 STG I BCS (sound)
12: M3B S, L054 STG I BCS (sound)
109. m3b20bie.cst (12 members)
1: (richText)
10: IssueList (field)
11: M3B E, L055 I BCS (sound)
1: 5054 Cue 1
12: M3B E, L056 I BCS (sound)
110. m3b20biS.cst (12 members)
1: (richText)
10: IssueList (field)
11: M3B S, L055 STG I BCS (sound)
1: 5769 Cue 1
12: M3B S, L056 STG I BCS (sound)
111. m3b20IE.cst (10 members)
1: (richText)
2: M3B E, L052 I BCS (sound)
4: IssueList (field)
5: M3B E, L053 I BCS (sound)
6: M3B E, L054 I BCS (sound)
7: (richText)
8: (field)
9: M3B E, L055 I BCS (sound)
10: M3B E, L056 I BCS (sound)
112. m3b20IS.cst (10 members)
1: (richText)
2: M3B E, L052 I BCS (sound)
4: IssueList (field)
5: M3B E, L053 I BCS (sound)
6: M3B E, L054 I BCS (sound)
7: (richText)
8: (field)
9: M3B E, L055 I BCS (sound)
10: M3B E, L056 I BCS (sound)
113. m3b21IE.cst (14 members)
1: (richText)
2: M3B E, L057 I BCS (sound)
3: M3B P023 (sound)
10: IssueList (field)
11: M3B E, L058 I BCS (sound)
12: M3B E, L059 I BCS (sound)
13: M3B E, L060 I BCS (sound)
14: M3B E, L061 I BCS (sound)
114. m3b21IS.cst (14 members)
1: (richText)
2: M3B S, L057 STG I BCS (sound)
3: M3B S, P023 (sound)
10: IssueList (field)
11: M3B S, L058 STG I BCS (sound)
12: M3B S, L059 STG I BCS (sound)
13: M3B S, L060 STG I BCS (sound)
14: M3B S, L061 STG I BCS (sound)
115. m3b22IE.cst (13 members)
1: (richText)
2: M3B E, L062 I BCS (sound)
10: IssueList (field)
11: M3B E, L063 I BCS (sound)
12: M3B E, L064 I BCS (sound)
13: M3B E, L065 I BCS (sound)
116. m3b22IS.cst (13 members)
1: (richText)
2: M3B S, L062 STG I BCS (sound)
10: IssueList (field)
11: M3B S, L063 STG I BCS (sound)
12: M3B S, L064 STG I BCS (sound)
13: M3B S, L065 STG I BCS (sound)
117. m3b23AE.cst (3 members)
1: (richText)
2: M3B E, L067A, I, BCS (sound)
3: P022 (sound)
118. m3b23AS.cst (3 members)
1: (richText)
2: M3B S, L067A, I, BCS (sound)
3: P022 (sound)
119. m3b23IE.cst (10 members)
1: M3B E, L067 I BCS (sound)
3: M3B E, P025 (sound)
4: M3B E, P026 1A (sound)
5: M3B E, P026 1B (sound)
6: M3B E, P026 1C (sound)
7: M3B E, P026 1D (sound)
8: M3B E, P026 1E (sound)
9: M3B E, P027 (sound)
10: M3B E, P028 (sound)
120. m3b23IS.cst (10 members)
1: M3B S, L067 STG I BCS (sound)
3: M3B S, P025 (sound)
4: M3B S, P026 1A (sound)
5: M3B S, P026 1B (sound)
6: M3B S, P026 1C (sound)
7: M3B S, P026 1D (sound)
8: M3B S, P026 1E (sound)
9: M3B S, P027 (sound)
10: M3B S, P028 (sound)
121. m3b24IE.cst (16 members)
1: (richText)
2: M3B E, L068 I BCS (sound)
10: IssueList (field)
11: M3B E, L069 I BCS (sound)
12: M3B E, L070 I BCS (sound)
13: M3B E, L071 I BCS (sound)
14: M3B E, L072 I BCS (sound)
15: M3B E, L073 I BCS (sound)
16: M3B E, L074 I BCS (sound)
122. m3b24IS.cst (16 members)
1: (richText)
2: M3B S, L068 STG I BCS (sound)
10: IssueList (field)
11: M3B S, L069 STG I BCS (sound)
12: M3B S, L070 STG I BCS (sound)
13: M3B S, L071 STG I BCS (sound)
14: M3B S, L072 STG I BCS (sound)
15: M3B S, L073 STG I BCS (sound)
16: M3B S, L074 STG I BCS (sound)
123. m3b25AE.cst (19 members)
1: M3B E, L084A, IIA, BCS (sound)
1: 7597 Cue 2
2: M3B E, L085A, IIA, BCS (sound)
1: 3524 Cue 1
2: 4648 Cue 2
3: M3B E, L086A, IIA, BCS (sound)
1: 2509 Cue 1
2: 3649 Cue 2
4: M3B E, P022 NEW (sound)
5: Title (richText)
6: SubTitle (richText)
7: QuestionOne (richText)
8: QuestionTwo (richText)
18: Yes (richText)
19: No (richText)
124. m3b25aIE.cst (14 members)
1: (richText)
2: M3B E, L075 I BCS (sound)
10: IssueList (field)
11: M3B E, L076 I BCS (sound)
12: M3B E, L077 I BCS (sound)
13: M3B E, L078 I BCS (sound)
14: M3B E, L078A, I, BCS (sound)
125. m3b25aIS.cst (14 members)
1: (richText)
2: M3B S, L075 STG I BCS (sound)
10: IssueList (field)
11: M3B S, L076 STG I BCS (sound)
12: M3B S, L077 STG I BCS (sound)
13: M3B S, L078 STG I BCS (sound)
14: M3B S, L078A, I, BCS (sound)

126. M3b25AS.cst (19 members)
 1: M3B S, L084A, IIA, BCS (sound)
 1: 7751 Cue 1
 2: M3B S, L085A, IIA, BCS (sound)
 1: 3593 Cue 1
 2: 4595 Cue 2
 3: M3B S, L086A, IIA, BCS (sound)
 1: 2639 Cue 1
 2: 3684 Cue 2
 4: M3B S, P022 (sound)
 5: Title (richText)
 6: SubTitle (richText)
 7: QuestionOne (richText)
 8: QuestionTwo (richText)
 18: Yes (richText)
 19: No (richText)
127. M3b25BE.cst (8 members)
 1: M3B E, L084B, IIA, BCS (sound)
 2: M3B E, L085B, IIA, BCS (sound)
 3: M3B E, L086B, IIA, BCS (sound)
 1: 3330 Cue 1
 2: 13323 Cue 2
 3: 13928 Cue 3
 4: 20633 Cue 4
 4: M3B E, P022 NEW (sound)
 5: Title (richText)
 7: Positive Nodes (richText)
 8: Negative Nodes (richText)
128. m3b25bIE.cst (13 members)
 1: (richText)
 2: M3B E, L080 I BCS (sound)
 10: IssueList (field)
 11: M3B E, L081 I BCS (sound)
 12: M3B E, L082 I BCS (sound)
 13: M3B E, L083 I BCS (sound)
129. m3b25bIS.cst (13 members)
 1: (richText)
 2: M3B S, L080 STG I BCS (sound)
 10: IssueList (field)
 11: M3B S, L081 STG I BCS (sound)
 12: M3B S, L082 STG I BCS (sound)
 13: M3B S, L083 STG I BCS (sound)
130. M3b25BS.cst (8 members)
 1: M3B S, L084B, IIA, BCS (sound)
 2: M3B S, L085B, IIA, BCS (sound)
 3: M3B S, L086B, IIA, BCS (sound)
 1: 3936 Cue 1
 2: 15747 Cue 2
 3: 16146 Cue 3
 4: 23272 Cue 4
 4: M3B S, P022 (sound)
 5: Title (richText)
 7: Positive Nodes (richText)
 8: Negative Nodes (richText)
131. M3b25LIIAPostE.cst (29 members)
 1: Title (richText)
 2: Chemo (richText)
 4: MenopausalStatus (richText)
 5: Pos (richText)
 17: M3B E, P031 (sound)
 28: M3B E L084C III BCS (sound)
 1: 4131 Cue 1
 2: 11450 Cue 2
 29: M3B E, L085M, III, POST (sound)
 1: 5045 Cue 1
132. M3b25LIIAPostS.cst (29 members)
 1: Title (richText)
 2: Chemo (richText)
 4: Menopausal Status (richText)
 5: pos (richText)
 17: M3B S, P031 (sound)
 28: M3B S, L084C, III, BCS (sound)
 1: 3693 Cue 1
 2: 13690 Cue 2
 29: M3B S, L085M, III, POST (sound)
 1: 7397 Cue 1
133. M3b25LIIAPreE.cst (35 members)
 1: Title (richText)
 12: M3B E L084C III BCS (sound)
 1: 4061 Cue 1
 2: 11310 Cue 2
 14: M3B E, L085M, III, PRE (sound)
 1: 8475 Cue 1
 15: M3B E, L086M, III, PRE (sound)
 1: 0 Cue 1
 2: 3601 Cue 2
 3: 6082 Cue 3
 4: 11897 Cue 4
 5: 12938 Cue 5
 17: M3B E, P031 (sound)
 29: MenopausalStatus (richText)
 30: Chemo (richText)
 31: EstrogenRT (richText)
 32: Pos (richText)
 33: Tamoxifen (richText)
 34: Neg (richText)
 35: NoTreatment (richText)
134. M3b25LIIAPreS.cst (35 members)
 1: Title (richText)
 12: M3B S, L084C, III, BCS (sound)
 1: 3693 Cue 1
 2: 13690 Cue 2
 14: M3B S, L085M, III, PRE (sound)
 1: 10955 Cue 1
 15: M3B S, L086M, III, PRE (sound)
 1: 0 Cue 5
 2: 3257 Cue 1
 3: 5950 Cue 2
 4: 14495 Cue 3
 5: 17055 Cue 4
 17: M3B S, P031 (sound)
 29: MenopausalStatus (richText)
 30: Chemo (richText)
 31: EstrogenRT (richText)
 32: Pos (richText)
 33: Tamoxifen (richText)
 34: Neg (richText)
 35: NoTreatment (richText)
135. M3b25LPostE.cst (17 members)
 1: Title (richText)
 2: MenopausalStatus (richText)
 4: Nodal Status (richText)
 5: Pos (richText)
 6: ChemoTamoxifen (richText)
 7: Neg (richText)
 8: Tamoxifen (richText)
 13: M3B E L084C III BCS (sound)
 1: 11695 Cue 1
 14: M3B E, L085M, II, POST (sound)
 1: 5042 Cue 1
 15: M3B E, L086M, II, POST (sound)
 1: 2031 Cue 1
 2: 8745 Cue 2
 3: 15327 Cue 3
 4: 21466 Cue 4
 17: M3B E, P031 (sound)
136. M3b25LPostS.cst (17 members)
 1: Title (richText)
 2: MenopausalStatus (richText)
 4: Nodal Status (richText)
 5: Pos (richText)
 6: ChemoTamoxifen (richText)
 7: Neg (richText)
 8: Tamoxifen (richText)
 13: M3B S, L084B, II, BCS (sound)
 1: 3554 Cue 1
 14: M3B S, L085L, II, POST (sound)
 1: 7193 Cue 1
 15: M3B S, L086L, II, POST (sound)
 1: 3798 Cue 1
 2: 12257 Cue 2
 3: 20199 Cue 3
- 4: 28025 Cue 4
 17: M3B S, P031 (sound)
137. M3b25LPreE.cst (17 members)
 1: Title (richText)
 2: MenopausalStatus (richText)
 3: Chemo (richText)
 4: EstrogenRT (richText)
 5: Pos (richText)
 6: Neg (richText)
 7: Tamoxifen (richText)
 8: NoTreatment (richText)
 13: M3B E, L084B, II, BCS (sound)
 1: 3425 Cue 1
 14: M3B E, L085M, II, PRE (sound)
 1: 5915 Cue 1
 15: M3B E, L086M, II, PRE (sound)
 1: 342 Cue 1
 2: 9880 Cue 2
 3: 10711 Cue 3
 4: 19614 Cue 4
 5: 25434 Cue 5
 17: M3B E, P031 (sound)
138. M3b25LPreS.cst (17 members)
 1: Title (richText)
 2: MenopausalStatus (richText)
 3: Chemo (richText)
 4: EstrogenRT (richText)
 5: Pos (richText)
 6: Neg (richText)
 7: Tamoxifen (richText)
 8: NoTreatment (richText)
 13: M3B S, L084B, II, BCS (sound)
 1: 3277 Cue 1
 14: M3B S, L085L, II, PRE (sound)
 1: 7712 Cue 1
 15: M3B S, L086L, II, PRE (sound)
 1: 321 Cue 1
 2: 4549 Cue 2
 3: 5513 Cue 3
 4: 19804 Cue 4
 5: 28314 Cue 5
 17: M3B S, P031 (sound)
139. M3b25MIIAPostE.cst (29 members)
 1: Title (richText)
 2: Chemo (richText)
 4: MenopausalStatus (richText)
 5: Pos (richText)
 17: M3B E, P031 (sound)
 28: M3B E, L084C, III, MRM (sound)
 1: 3915 Cue 1
 2: 11603 Cue 2
 29: M3B E, L085M, III, POST (sound)
 1: 5045 Cue 1
140. M3b25MIIAPostS.cst (29 members)
 1: Title (richText)
 2: Chemo (richText)
 4: Menopausal Status (richText)
 5: pos (richText)
 17: M3B S, P031 (sound)
 28: M3B S, L084C, III, MRM (sound)
 1: 4243 Cue 1
 2: 11813 Cue 2
 29: M3B S, L085M, III, POST (sound)
 1: 7397 Cue 1
141. M3b25MIIAPreE.cst (35 members)
 1: Title (richText)
 12: M3B E, L084C, III, MRM (sound)
 1: 3986 Cue 1
 2: 11817 Cue 2
 14: M3B E, L085M, III, PRE (sound)
 1: 8475 Cue 1
 15: M3B E, L086M, III, PRE (sound)
 1: 0 Cue 1
 2: 3601 Cue 2
 3: 6082 Cue 3
 4: 11897 Cue 4

- 5: 12938 Cue 5
 17: M3B E, P031 (sound)
 29: MenopausalStatus (richText)
 30: Chemo (richText)
 31: EstrogenRT (richText)
 32: Pos (richText)
 33: Tamoxifen (richText)
 34: Neg (richText)
 35: NoTreatment (richText)
 142. M3b25MIIPreS.cst (35 members)
 1: Title (richText)
 12: M3B S, L084C, III, MRM (sound)
 1: 4320 Cue 1
 2: 11966 Cue 2
 14: M3B S, L085M, III, PRE (sound)
 1: 10955 Cue 1
 15: M3B S, L086M, III, PRE (sound)
 1: 0 Cue 5
 2: 3257 Cue 1
 3: 5950 Cue 2
 4: 14495 Cue 3
 5: 17055 Cue 4
 17: M3B S, P031 (sound)
 29: MenopausalStatus (richText)
 30: Chemo (richText)
 31: EstrogenRT (richText)
 32: Pos (richText)
 33: Tamoxifen (richText)
 34: Neg (richText)
 35: NoTreatment (richText)
 143. M3b25MPostE.cst (17 members)
 1: Title (richText)
 2: MenopausalStatus (richText)
 4: Nodal Status (richText)
 5: Pos (richText)
 6: ChemoTamoxifen (richText)
 7: Neg (richText)
 8: Tamoxifen (richText)
 13: M3B E, L084B, II, MRM (sound)
 1: 3010 Cue 1
 14: M3B E, L085M, II, POST (sound)
 1: 5042 Cue 1
 15: M3B E, L086M, II, POST (sound)
 1: 2031 Cue 1
 2: 8745 Cue 2
 3: 15327 Cue 3
 4: 21466 Cue 4
 17: M3B E, P031 (sound)
 144. M3b25MPostS.cst (17 members)
 1: Title (richText)
 2: MenopausalStatus (richText)
 4: Nodal Status (richText)
 5: Pos (richText)
 6: ChemoTamoxifen (richText)
 7: Neg (richText)
 8: Tamoxifen (richText)
 13: M3B S, L084B, II, MRM (sound)
 1: 3891 Cue 1
 14: M3B S, L085M, II, POST (sound)
 1: 7374 Cue 1
 15: M3B S, L086M, II, POST (sound)
 1: 3755 Cue 1
 2: 10930 Cue 2
 3: 19954 Cue 3
 4: 26904 Cue 4
 17: M3B S, P031 (sound)
 145. M3b25MPreE.cst (17 members)
 1: Title (richText)
 2: MenopausalStatus (richText)
 3: Chemo (richText)
 4: EstrogenRT (richText)
 5: Pos (richText)
 6: Neg (richText)
 7: Tamoxifen (richText)
 8: NoTreatment (richText)
 13: M3B E, L084B, II, MRM (sound)
 1: 3010 Cue 1
 14: M3B E, L085M, II, PRE (sound)
 1: 5915 Cue 1
 15: M3B E, L086M, II, PRE (sound)
 1: 342 Cue 1
 2: 9880 Cue 2
 3: 10711 Cue 3
 4: 19614 Cue 4
 5: 25434 Cue 5
 17: M3B E, P031 (sound)
 146. M3b25MPreS.cst (17 members)
 1: Title (richText)
 2: MenopausalStatus (richText)
 3: Chemo (richText)
 4: EstrogenRT (richText)
 5: Pos (richText)
 6: Neg (richText)
 7: Tamoxifen (richText)
 8: NoTreatment (richText)
 13: M3B S, L084B, II, MRM (sound)
 1: 4004 Cue 1
 14: M3B S, L085M, II, PRE (sound)
 1: 8065 Cue 1
 15: M3B S, L086M, II, PRE (sound)
 1: 294 Cue 1
 2: 8876 Cue 2
 3: 9676 Cue 3
 4: 16743 Cue 4
 5: 21329 Cue 5
 17: M3B S, P031 (sound)
 147. m3b26le.cst (5 members)
 1: (richText)
 2: M3B E, L084 I BCS (sound)
 3: P022 (sound)
 4: (richText)
 5: M3B E, L085 I BCS (sound)
 148. m3b26IS.cst (5 members)
 1: (richText)
 2: M3B S, L084 STG I BCS (sound)
 3: P022 (sound)
 4: (richText)
 5: M3B S, L085 STG I BCS (sound)
 149. m3b26LIE.cst (9 members)
 1: (richText)
 2: (richText)
 3: (richText)
 6: M3B E, L085L, I, BCS (sound)
 7: M3B E, L096R, I, BCS (sound)
 8: M3B E, L084 I BCS (sound)
 9: M3B E, P022 NEW (sound)
 150. m3b26LIS.cst (9 members)
 1: (richText)
 2: (richText)
 3: (richText)
 6: M3B S, L085L, I, BCS (sound)
 7: M3B S, L096R, I, BCS (sound)
 8: M3B S, L084 STG I BCS (sound)
 9: M3B S, P022 (sound)
 151. m3b26mlE.cst (8 members)
 1: (richText)
 2: (richText)
 3: (richText)
 4: M3B E, P022 NEW (sound)
 6: M3B E, L085M, I, MRM (sound)
 7: M3B E, L096R, I, BCS (sound)
 8: M3B E, L084 I BCS (sound)
 152. m3b26mlS.cst (8 members)
 1: (richText)
 2: (richText)
 3: (richText)
 4: M3B S, P022 (sound)
 6: M3B S, L085M, I, MRM (sound)
 7: M3B S, L096R, I, BCS (sound)
 8: M3B S, L084 STG I BCS (sound)
 153. M3B28IE.cst (15 members)
 1: M3B E, L087 I BCS (sound)
 2: M3B E, L088, I, BCS (sound)
 1: 4656 Cue 1
 2: 7885 Cue 2
 3: 11527 Cue 3
 4: 15658 Cue 4
 3: M3B E, L089 I BCS (sound)
 4: M3B E, L090 I BCS (sound)
 5: M3B E, L091, I, BCS (sound)
 1: 4524 Cue 1
 2: 7284 Cue 2
 3: 10926 Cue 3
 4: 15259 Cue 4
 6: M3B E, L092 I BCS (sound)
 1: 367 Cue 1
 7: LowRiskList (field)
 8: HighRiskList (field)
 9: HighRiskList (field)
 10: M3B E, L093 I BCS (sound)
 1: 3653 Cue 1
 2: 4496 Cue 2
 11: HighRiskList (field)
 12: M3B E, L094 I BCS (sound)
 1: 2708 Cue 1
 2: 8338 Cue 2
 13: HighRiskList (field)
 15: M3B E, L089 I MRM Only (sound)
 154. M3B28IIAE.cst (20 members)
 1: M3B E, L087 I BCS (sound)
 2: M3B E L088 II BCS (sound)
 1: 5322 Cue 1
 2: 8524 Cue 2
 3: 13182 Cue 3
 4: 18006 Cue 4
 3: M3B E, L089, IIA, MRM (sound)
 4: M3B E, L090 I BCS (sound)
 5: M3B E L091 II BCS (sound)
 1: 4090 Cue 1
 2: 7185 Cue 2
 3: 10686 Cue 3
 4: 14849 Cue 4
 6: M3B E, L092, IIA, MRM (sound)
 7: LowRiskList (field)
 8: HighRiskList (field)
 9: HighRiskList (field)
 10: M3B E, L092A, IIA, MRM (sound)
 11: HighRiskList (field)
 12: M3B E, L092B, IIA, MRM (sound)
 13: HighRiskList (field)
 14: M3B E, L092A, IIA, MRM (sound)
 17: M3B E, P027 (sound)
 19: M3B E, L067A, I, BCS (sound)
 20: M3B E, P022 NEW (sound)
 155. M3B28IIAS.cst (20 members)
 1: M3B S, L087 STG I BCS (sound)
 2: M3B S, L088 II BCS (sound)
 1: 5723 Cue 1
 2: 8585 Cue 2
 3: 13471 Cue 3
 4: 18490 Cue 4
 3: M3B S, L089, IIA, MRM (sound)
 4: M3B S, L090 STG I BCS (sound)
 5: M3B S, L091 II BCS (sound)
 1: 5243 Cue 1
 2: 8514 Cue 2
 3: 12995 Cue 3
 4: 18597 Cue 4
 6: M3B S, L092, IIA, MRM (sound)
 7: LowRiskList (field)
 8: HighRiskList (field)
 9: HighRiskList (field)
 10: M3B S, L092A, IIA, MRM (sound)
 11: HighRiskList (field)
 12: M3B S, L092B, IIA, MRM (sound)
 13: HighRiskList (field)
 17: M3B S, P027 (sound)
 19: M3B S, L067A, I, BCS (sound)

- 20: M3B S, P022 (sound)
 156. M3B28IS.cst (15 members)
 1: M3B S, L087 STG I BCS (sound)
 2: M3B S, L088, I, BCS (sound)
 1: 6977 Cue 1
 2: 10318 Cue 2
 3: 15477 Cue 3
 4: 20882 Cue 4
 3: M3B S, L089 STG I BCS (sound)
 4: M3B S, L090 STG I BCS (sound)
 5: M3B S, L091, I, BCS (sound)
 1: 5800 Cue 1
 2: 9407 Cue 2
 3: 14135 Cue 3
 4: 20227 Cue 4
 6: M3B S, L092 STG I BCS (sound)
 1: 171 Cue 1
 7: LowRiskList (field)
 8: HighRiskList (field)
 9: HighRiskList (field)
 10: M3B S, L093 STG I BCS (sound)
 1: 3260 Cue 1
 2: 6840 Cue 2
 11: HighRiskList (field)
 12: M3B S, L094 STG I BCS (sound)
 1: 2895 Cue 1
 2: 8313 Cue 2
 13: HighRiskList (field)
 15: M3B S, L089 I MRM ONLY (sound)
 157. M3B31AE.cst (16 members)
 1: M3B E, L145B, IIA, BCS (sound)
 2: M3B E, P032 (sound)
 3: M3B E, L146 I BCS (sound)
 4: M3B E, L096B, IIA, BCS (sound)
 1: 5783 Cue 1
 2: 7012 Cue 2
 5: M3B E, L097, I, BCS (sound)
 1: 25624 Cue 1
 6: M3B E, L092 I BCS (sound)
 1: 367 Cue 1
 7: NegList (field)
 8: PosList (field)
 9: HighRiskList (field)
 10: M3B E, L093 I BCS (sound)
 1: 3653 Cue 1
 2: 4496 Cue 2
 11: HighRiskList (field)
 12: M3B E, L094 I BCS (sound)
 1: 2708 Cue 1
 2: 8338 Cue 2
 13: HighRiskList (field)
 14: M3B E, P031 (sound)
 15: M3B E, P027 (sound)
 16: M3B E, P022 NEW (sound)
 158. M3B31AS.cst (16 members)
 1: M3B S, L145 STG I BCS (sound)
 1: 8394 Cue 1
 2: M3B S, P032 (sound)
 3: M3B S, L146, I, BCS (sound)
 4: M3B S, L096B, IIA, BCS (sound)
 1: 6708 Cue 1
 2: 7804 Cue 2
 5: M3B S, L097, I, BCS, NEW (sound)
 1: 35198 Cue 1
 6: M3B S, L092 STG I BCS (sound)
 1: 171 Cue 1
 7: NegList (field)
 8: PosList (field)
 9: HighRiskList (field)
 10: M3B S, L093 STG I BCS (sound)
 1: 3260 Cue 1
 2: 6840 Cue 2
 11: HighRiskList (field)
 12: M3B S, L094 STG I BCS (sound)
 1: 2895 Cue 1
 2: 8313 Cue 2
 13: HighRiskList (field)
 14: M3B S, P031 (sound)
 15: M3B S, P027 (sound)
 162. M3B31IS.cst (15 members)
 13: HighRiskList (field)
 14: M3B S, P031 (sound)
 15: M3B S, P027 (sound)
 16: M3B S, P022 (sound)
 159. M3B31IE.cst (15 members)
 1: M3B E, L145 I BCS (sound)
 1: 6221 Cue 1
 2: M3B E, P032 (sound)
 3: M3B E, L146 I BCS (sound)
 4: M3B E, L096 I BCS (sound)
 1: 6099 Cue 1
 2: 11651 Cue 2
 5: M3B E, L097, I, BCS (sound)
 1: 25624 Cue 1
 6: M3B E, L092 I BCS (sound)
 1: 367 Cue 1
 7: NegList (field)
 8: PosList (field)
 9: HighRiskList (field)
 10: M3B E, L093 I BCS (sound)
 1: 3653 Cue 1
 2: 4496 Cue 2
 11: HighRiskList (field)
 12: M3B E, L094 I BCS (sound)
 1: 2708 Cue 1
 2: 8338 Cue 2
 13: HighRiskList (field)
 14: M3B E, P031 (sound)
 15: M3B E, P027 (sound)
 160. M3B31IAE.cst (15 members)
 1: M3B E, L145 I BCS (sound)
 1: 6221 Cue 1
 2: M3B E, P032 (sound)
 3: M3B E, L146 I BCS (sound)
 4: M3B E, L096, II, BCS (sound)
 5: M3B E, L097, I, BCS (sound)
 1: 25624 Cue 1
 6: M3B E, L092 I BCS (sound)
 1: 367 Cue 1
 7: NegList (field)
 8: PosList (field)
 9: HighRiskList (field)
 10: M3B E, L093 I BCS (sound)
 1: 3653 Cue 1
 2: 4496 Cue 2
 11: HighRiskList (field)
 12: M3B E, L094 I BCS (sound)
 1: 2708 Cue 1
 2: 8338 Cue 2
 13: HighRiskList (field)
 14: M3B E, P031 (sound)
 15: M3B E, P027 (sound)
 161. M3B31IIAS.cst (15 members)
 1: M3B S, L145 STG I BCS (sound)
 1: 8394 Cue 1
 2: M3B S, P032 (sound)
 3: M3B S, L146, I, BCS (sound)
 4: M3B S, L096A, IIA, BCS (sound)
 5: M3B S, L097, I, BCS, NEW (sound)
 1: 35198 Cue 1
 6: M3B S, L092 STG I BCS (sound)
 1: 171 Cue 1
 7: NegList (field)
 8: PosList (field)
 9: HighRiskList (field)
 10: M3B S, L093 STG I BCS (sound)
 1: 3260 Cue 1
 2: 6840 Cue 2
 11: HighRiskList (field)
 12: M3B S, L094 STG I BCS (sound)
 1: 2895 Cue 1
 2: 8313 Cue 2
 13: HighRiskList (field)
 14: M3B S, P031 (sound)
 15: M3B S, P027 (sound)
 162. M3B31IS.cst (15 members)
 1: M3B S, L145 STG I BCS (sound)
 1: 8394 Cue 1
 2: M3B S, P032 (sound)
 3: M3B S, L146, I, BCS (sound)
 4: M3B S, L096 STG I BCS (sound)
 1: 8555 Cue 1
 2: 14788 Cue 2
 5: M3B S, L097, I, BCS, NEW (sound)
 1: 35198 Cue 1
 6: M3B S, L092 STG I BCS (sound)
 1: 171 Cue 1
 7: NegList (field)
 8: PosList (field)
 9: HighRiskList (field)
 10: M3B S, L093 STG I BCS (sound)
 1: 3260 Cue 1
 2: 6840 Cue 2
 11: HighRiskList (field)
 12: M3B S, L094 STG I BCS (sound)
 1: 2895 Cue 1
 2: 8313 Cue 2
 13: HighRiskList (field)
 14: M3B S, P031 (sound)
 15: M3B S, P027 (sound)
 163. M3B32CE.cst (17 members)
 1: M3B E, L145A, IIA, BCS (sound)
 1: 4362 Cue 1
 2: NoTreatment (richText)
 3: M3B E, P027 (sound)
 17: Receptor Test Negative (richText)
 164. M3B32CS.cst (17 members)
 1: M3B S, L145A, IIA, BCS (sound)
 1: 6087 Cue 1
 2: NoTreatment (richText)
 3: M3B S, P027 (sound)
 17: Receptor Test Negative (richText)
 165. M3B32DE.cst (4 members)
 1: M3B E, L145B, IIA, BCS (sound)
 1: 4958 Cue 1
 2: 8992 Cue 2
 2: Tamoxifen (richText)
 3: M3B E, P027 (sound)
 4: M3B E, P022 NEW (sound)
 166. M3B32DS.cst (4 members)
 1: M3B S, L145B, IIA, BCS (sound)
 1: 6500 Cue 1
 2: 12291 Cue 2
 2: Tamoxifen (richText)
 3: M3B S, P027 (sound)
 4: M3B S, P022 (sound)
 167. m3b33aE.cst (2 members)
 1: M3B E, L226 I NSO (sound)
 2: M3B E, P022 NEW (sound)
 168. m3b33aIAE.cst (3 members)
 1: M3B E, L097, IIA, BCS (sound)
 1: 20930 Cue 1
 2: M3B E, P022 NEW (sound)
 3: M3B E, P027 (sound)
 169. m3b33aIIAS.cst (3 members)
 1: M3B S, L097, IIA, BCS (sound)
 1: 13731 Cue 1
 2: M3B S, P022 (sound)
 3: M3B S, P027 (sound)
 170. m3b33aS.cst (2 members)
 1: M3B S, L226 I NSO (sound)
 2: M3B S, P022 (sound)
 171. m3b33bE.cst (3 members)
 1: M3B E, L227 I NSO (sound)
 2: M3B E, P022 NEW (sound)
 3: Title (richText)
 172. M3b33bS.cst (3 members)
 1: M3B S, L227 I NSO (sound)
 2: M3B S, P022 (sound)
 3: Title (richText)
 173. m3b34IE.cst (13 members)
 1: (richText)

- 2: M3B E, L098 I BCS (sound)
 10: IssueList (field)
 11: M3B E, L099 I BCS (sound)
 12: M3B E, L099A, I, BCS (sound)
 13: M3B E, L100 I BCS (sound)
 174. M3b34IS.cst (13 members)
 1: (richText)
 2: M3B S, L098 STG I BCS (sound)
 10: IssueList (field)
 11: M3B S, L099 STG I BCS (sound)
 12: M3B S, L099A, I, BCS (sound)
 13: M3B S, L100 STG I BCS (sound)
 175. m3b35IE.cst (20 members)
 1: (richText)
 2: M3B E, L102 I BCS (sound)
 4: M3B E, L103 I BCS (sound)
 10: IssueList (field)
 11: M3B E, L104 I BCS (sound)
 12: M3B E, L105 I BCS (sound)
 13: M3B E, L106 I BCS (sound)
 14: M3B E, L107 I BCS (sound)
 15: M3B E, L108 I BCS (sound)
 16: M3B E, L109 I BCS (sound)
 17: M3B E, L110 I BCS (sound)
 18: M3B E, L111 I BCS (sound)
 19: M3B E, L111A, I, BCS (sound)
 20: M3B E, L112 I BCS (sound)
 176. m3b35IS.cst (20 members)
 1: (richText)
 2: M3B S, L102 STG I BCS (sound)
 4: M3B S, L103 STG I BCS (sound)
 10: IssueList (field)
 11: M3B S, L104 STG I BCS (sound)
 12: M3B S, L105 STG I BCS (sound)
 13: M3B S, L106 STG I BCS (sound)
 14: M3B S, L107 STG I BCS (sound)
 15: M3B S, L108 STG I BCS (sound)
 16: M3B S, L109 STG I BCS (sound)
 17: M3B S, L110 STG I BCS (sound)
 18: M3B S, L111 STG I BCS (sound)
 19: M3B S, L111A, I, BCS (sound)
 20: M3B S, L112 STG I BCS (sound)
 177. m3b36AE.cst (6 members)
 1: (richText)
 2: M3B E, L112A (sound)
 3: P022 (sound)
 4: P031 (sound)
 5: M3B E, L146 I BCS (sound)
 6: M3B E, P027 (sound)
 178. M3b36AS.cst (6 members)
 1: (richText)
 2: M3B S, L112A (sound)
 3: P022 (sound)
 4: P031 (sound)
 5: M3B S, L146, I, BCS (sound)
 6: M3B S, P027 (sound)
 179. m3b36BE.cst (6 members)
 1: (richText)
 2: M3B E, L112A (sound)
 3: P022 (sound)
 4: P031 (sound)
 5: M3B E, L146 I BCS (sound)
 6: M3B E, P027 (sound)
 180. M3b36BS.cst (5 members)
 1: (richText)
 2: M3B S, L112A (sound)
 3: P022 (sound)
 4: P031 (sound)
 5: M3B S, L146, I, BCS (sound)
 181. m3b36IE.cst (15 members)
 1: (richText)
 2: M3B E, L113 I BCS (sound)
 4: M3B E, L114 I BCS (sound)
 10: IssueList (field)
 11: M3B E, L115 I BCS (sound)
 12: M3B E, L116 I BCS (sound)
 13: M3B E, L117 I BCS (sound)
 14: M3B E, L118 I BCS (sound)
 15: M3B E, L119 I BCS (sound)
 182. M3b36IS.cst (15 members)
 1: (richText)
 2: M3B S, L113 STG I BCS (sound)
 4: M3B S, L114 STG I BCS (sound)
 10: IssueList (field)
 11: M3B S, L115 STG I BCS (sound)
 12: M3B S, L116 STG I BCS (sound)
 13: M3B S, L117 STG I BCS (sound)
 14: M3B S, L118 STG I BCS (sound)
 15: M3B S, L119 STG I BCS (sound)
 183. m3b37aIE.cst (16 members)
 1: (richText)
 2: M3B E, L128 I BCS (sound)
 10: IssueList (field)
 11: M3B E, L129 I BCS (sound)
 12: M3B E, L130 I BCS (sound)
 13: M3B E, L131 I BCS (sound)
 14: M3B E, L132 I BCS (sound)
 15: M3B E, L133 I BCS (sound)
 16: M3B E, L134 I BCS (sound)
 184. M3b37aIS.cst (16 members)
 1: (richText)
 2: M3B S, L128 STG I BCS (sound)
 10: IssueList (field)
 11: M3B S, L129 STG I BCS (sound)
 12: M3B S, L130 STG I BCS (sound)
 13: M3B S, L131 STG I BCS (sound)
 14: M3B S, L132 STG I BCS (sound)
 15: M3B S, L133 STG I BCS (sound)
 16: M3B S, L134 STG I BCS (sound)
 185. m3b37bIE.cst (11 members)
 1: (richText)
 10: IssueList (field)
 11: M3B E, L135 I BCS (sound)
 186. M3b37bIS.cst (11 members)
 1: (richText)
 10: IssueList (field)
 11: M3B S, L135 STG I BCS (sound)
 187. m3b37cIE.cst (15 members)
 1: (richText)
 10: IssueList (field)
 11: M3B E, L136 I BCS (sound)
 12: M3B E, L137 I BCS (sound)
 13: M3B E, L138 I BCS (sound)
 14: M3B E, L139 I BCS (sound)
 15: M3B E, L140 I BCS (sound)
 188. m3b37cIS.cst (15 members)
 1: (richText)
 10: IssueList (field)
 11: M3B S, L136 STG I BCS (sound)
 12: M3B S, L137 STG I BCS (sound)
 13: M3B S, L138 STG I BCS (sound)
 14: M3B S, L139 STG I BCS (sound)
 15: M3B S, L140 STG I BCS (sound)
 189. m3b37IE.cst (15 members)
 1: (richText)
 2: M3B E, L120 I BCS (sound)
 3: M3B E, L121 I BCS (sound)
 4: M3B E, L122 I BCS (sound)
 10: IssueList (field)
 11: M3B E, L123 I BCS (sound)
 12: M3B E, L124 I BCS (sound)
 13: M3B E, L125 I BCS (sound)
 14: M3B E, L126 I BCS (sound)
 15: M3B E, L127 I BCS (sound)
 190. M3b37IS.cst (15 members)
 1: (richText)
 2: M3B S, L120 STG I BCS (sound)
 3: M3B S, L121 STG I BCS (sound)
 4: M3B S, L122 STG I BCS (sound)
 10: IssueList (field)
 11: M3B S, L123 STG I BCS (sound)
 12: M3B S, L124 STG I BCS (sound)
 13: M3B S, L125 STG I BCS (sound)
 14: M3B S, L126 STG I BCS (sound)
 15: M3B S, L127 STG I BCS (sound)
 191. M3b38AE.cst (9 members)
 1: Title (richText)
 2: M3B E, L092, IIA, BCS (sound)
 1: 8003 Cue 1
 2: 12622 Cue 2
 3: P022 (sound)
 4: Estrogen (richText)
 5: Progesterone (richText)
 6: Estrogen Receptor POS (richText)
 7: Estrogen Receptor NEG (richText)
 8: M3B E, L093 I BCS (sound)
 1: 3653 Cue 1
 2: 4518 Cue 2
 9: M3B E, L094 I BCS (sound)
 1: 2921 Cue 1
 2: 5185 Cue 2
 3: 8725 Cue 3
 192. M3b38AS.cst (9 members)
 1: (richText)
 2: M3B S, L092, IIA, BCS (sound)
 1: 5381 Cue 1
 2: 12070 Cue 2
 3: P022 (sound)
 4: Estrogen (richText)
 5: Progesterone (richText)
 6: Estrogen Receptor POS (richText)
 7: Estrogen Receptor NEG (richText)
 8: M3B S, L093 STG I BCS (sound)
 1: 3522 Cue 1
 2: 4355 Cue 2
 9: M3B S, L094 STG I BCS (sound)
 1: 4264 Cue 1
 2: 5359 Cue 2
 3: 9702 Cue 3
 193. m3b38IE.cst (13 members)
 1: (richText)
 2: M3B E, L141 I BCS (sound)
 10: IssueList (field)
 11: M3B E, L142 I BCS (sound)
 12: M3B E, L143 I BCS (sound)
 13: M3B E, L144 I BCS (sound)
 194. M3b38IS.cst (13 members)
 1: (richText)
 2: M3B S, L141 STG I BCS (sound)
 10: IssueList (field)
 11: M3B S, L142 STG I BCS (sound)
 12: M3B S, L143 STG I BCS (sound)
 13: M3B S, L144 STG I BCS (sound)
 195. M3B40IE.cst (3 members)
 1: M3B E, L147 I BCS (sound)
 2: M3B E, L147A, I, MRM (sound)
 3: M3B E, P021 (sound)
 196. m3b40IEmrm.cst (17 members)
 1: (richText)
 2: (richText)
 3: (richText)
 4: (richText)
 5: (richText)
 6: (richText)
 7: (richText)
 8: (richText)
 9: BCSText (bitmap)
 10: MRMTText (bitmap)
 17: (richText)
 197. M3B40IS.cst (24 members)
 1: M3B S, L147 STG I BCS (sound)
 2: M3B S, L147A, I, MRM (sound)
 3: M3B S, P021 (sound)
 23: M3B E, L147 I BCS (sound)
 24: M3B E, L147A, I, MRM (sound)
 198. m3b40ISmrm.cst (17 members)
 3: (richText)
 4: (richText)

- 5: (richText)
6: (richText)
7: (richText)
8: (richText)
9: BCMText (bitmap)
10: MRMTText (bitmap)
17: (richText)
199. m3b41E.cst (4 members)
1: (richText)
2: M3B E, L149 I BCS (sound)
3: P022 (sound)
4: M3B E, L148 I MRM (sound)
200. m3b41S.cst (4 members)
1: (richText)
2: M3B S, L149 STG I MRM (sound)
3: P022 (sound)
4: M3B S, L148 I MRM (sound)
201. m3b42IE.cst (17 members)
1: (richText)
2: M3B E, L149 I BCS (sound)
10: IssueList (field)
11: M3B E, L150 I BCS (sound)
12: M3B E, L151 I BCS (sound)
13: M3B E, L152 I BCS (sound)
14: M3B E, L153 I BCS (sound)
15: M3B E, L154 I BCS (sound)
16: M3B E, L155 I BCS (sound)
17: M3B E, L156 I BCS (sound)
202. m3b42IS.cst (17 members)
1: (richText)
2: M3B S, L149 STG I MRM (sound)
10: IssueList (field)
11: M3B S, L150 STG I BCS (sound)
12: M3B S, L151 I MRM (sound)
13: M3B S, L152 I MRM (sound)
14: M3B S, L153 I MRM (sound)
15: M3B S, L154 I MRM (sound)
16: M3B S, L155 I MRM (sound)
17: M3B S, L156 I MRM (sound)
203. m3b43aIE.cst (13 members)
1: (richText)
10: IssueList (field)
11: M3B E, L161A I BCS (sound)
12: M3B E, L162 I BCS (sound)
13: M3B E, L163 I BCS (sound)
204. m3b43aIS.cst (13 members)
1: (richText)
10: IssueList (field)
11: M3B S, L161A I MRM (sound)
12: M3B S, L162 I MRM (sound)
13: M3B S, L163 I MRM (sound)
205. m3b43bIE.cst (11 members)
1: (richText)
10: IssueList (field)
11: M3B E, L164 I BCS (sound)
206. M3b43bIS.cst (11 members)
1: (richText)
10: IssueList (field)
11: M3B S, L164 I MRM (sound)
207. m3b43IE.cst (13 members)
1: (richText)
2: M3B E, L157 I BCS (sound)
10: IssueList (field)
11: M3B E, L159 I BCS (sound)
12: M3B E, L160 I BCS (sound)
13: M3B E, L161 I BCS (sound)
208. M3b43IS.cst (13 members)
1: (richText)
2: M3B S, L157 I MRM (sound)
4: M3B S, L158 I MRM (sound)
10: IssueList (field)
11: M3B S, L159 I MRM (sound)
12: M3B S, L160 I MRM (sound)
13: M3B S, L161 I MRM (sound)
209. m3b44IE.cst (14 members)
1: (richText)
2: M3B E, L165 I BCS (sound)
10: IssueList (field)
11: M3B E, L166 I BCS (sound)
12: M3B E, L167 I BCS (sound)
13: M3B E, L168 I BCS (sound)
14: M3B E, L169 I BCS (sound)
210. m3b44IS.cst (14 members)
1: (richText)
2: M3B S, L165 I MRM (sound)
10: IssueList (field)
11: M3B S, L166 I MRM (sound)
12: M3B S, L167 I MRM (sound)
13: M3B S, L168 I MRM (sound)
14: M3B S, L169 I MRM (sound)
211. M3b45aIE.cst (3 members)
1: M3B E, L172 I BCS (sound)
2: M3B E, P022 NEW (sound)
3: (richText)
212. m3b45aIS.cst (3 members)
1: M3B S, L172 I BCS (sound)
2: M3B S, P022 (sound)
3: (richText)
213. m3b45bIE.cst (20 members)
1: M3B E, L173 I BCS (sound)
2: M3B E, L174 I BCS (sound)
3: M3B E, L175 I BCS (sound)
4: M3B E, L176 I BCS (sound)
5: M3B E, L177 I BCS (sound)
6: M3B E, L178 I BCS (sound)
7: M3B E, L179 I BCS (sound)
8: After BCS Text (richText)
9: After MRM Text (richText)
10: saves most (richText)
11: radio treatment (richText)
12: entire removed (richText)
13: make new breast (richText)
14: risk of returning (richText)
15: Length of life (richText)
16: M3B E, P025 (sound)
17: M3B E, P027 (sound)
18: M3B E, P028 (sound)
19: M3B E, L171 I BCS (sound)
20: M3B E, L180 I BCS (sound)
214. m3b45bIS.cst (20 members)
1: M3B S, L173 I BCS (sound)
2: M3B S, L174 I BCS (sound)
3: M3B S, L175 I BCS (sound)
4: M3B S, L176 I BCS (sound)
5: M3B S, L177 I BCS (sound)
6: M3B S, L178 I BCS (sound)
7: M3B S, L179 I BCS (sound)
8: After BCS Text (richText)
9: After MRM Text (richText)
10: saves most (richText)
11: radio treatment (richText)
12: entire removed (richText)
13: make new breast (richText)
14: risk of returning (richText)
15: Length of life (richText)
16: M3B S, P025 (sound)
17: M3B S, P027 (sound)
18: M3B S, P028 (sound)
19: M3B S, L171 I MRM (sound)
20: M3B S, L180 I BCS (sound)
215. m3b45cIE.cst (3 members)
1: (richText)
2: M3B E, P033 (sound)
3: P022 (sound)
216. m3b45cIS.cst (3 members)
1: (richText)
2: M3B S, P033 (sound)
3: P022 (sound)
217. M3B46IE.cst (14 members)
1: prosthesis (richText)
2: M3B E, L182 I MRM (sound)
3: Breast reconstruction (richText)
4: M3B E, L189 I MRM (sound)
5: M3B E, L181 I MRM (sound)
1: 3095 Cue 1
2: 4672 Cue 2
3: 5374 Cue 3
4: 6467 Cue 4
10: prosthesis r (richText)
12: Breast reconstruction r (richText)
14: M3B E, P028 (sound)
218. M3B46IS.cst (12 members)
1: prosthesis (richText)
2: M3B S, L182 I MRM (sound)
3: Breast reconstruction (richText)
4: M3B S, L189 I MRM (sound)
5: M3B S, L181 I MRM (sound)
1: 3872 Cue 1
2: 6294 Cue 2
3: 7227 Cue 3
10: prosthesis r (richText)
12: Breast reconstruction r (field)
219. m3b47IE.cst (15 members)
1: (richText)
2: M3B E, L182 I MRM (sound)
10: IssueList (field)
11: M3B E, L183 I MRM (sound)
12: M3B E, L184 I MRM (sound)
13: M3B E, L185 I MRM (sound)
14: M3B E, L186 I MRM (sound)
15: M3B E, L187 I MRM (sound)
220. m3b47IS.cst (15 members)
1: (richText)
2: M3B S, L182 I MRM (sound)
10: IssueList (field)
11: M3B S, L183 I MRM (sound)
12: M3B S, L184 I MRM (sound)
13: M3B S, L185 I MRM (sound)
14: M3B S, L186 I MRM (sound)
15: M3B S, L187 I MRM (sound)
221. m3b48IE.cst (15 members)
1: (richText)
2: M3B E, L189 I MRM (sound)
10: IssueList (field)
11: M3B E, L190 I MRM (sound)
12: M3B E, L191 I MRM (sound)
13: M3B E, L192 I MRM (sound)
14: M3B E, L193 I MRM (sound)
15: M3B E, L194 I MRM (sound)
222. m3b48IS.cst (15 members)
1: (richText)
2: M3B S, L189 I MRM (sound)
10: IssueList (field)
11: M3B S, L190 I MRM (sound)
12: M3B S, L191 I MRM (sound)
13: M3B S, L192 I MRM (sound)
14: M3B S, L193 I MRM (sound)
15: M3B S, L194 I MRM (sound)
223. m3b49IE.cst (14 members)
1: (richText)
2: M3B E, L195 I MRM (sound)
4: M3B E, L196 I MRM (sound)
10: IssueList (field)
11: M3B E, L197 I MRM (sound)
12: M3B E, L198 I MRM (sound)
13: M3B E, L199 I MRM (sound)
14: M3B E, L199A I MRM (sound)
224. M3b49IS.cst (14 members)
1: (richText)
2: M3B S, L195 I MRM (sound)
4: M3B S, L196 I MRM (sound)
10: IssueList (field)
11: M3B S, L197 I MRM (sound)
12: M3B S, L198 I MRM (sound)
13: M3B S, L199 I MRM (sound)
14: M3B S, L199A I MRM (sound)
225. m3b50IE.cst (19 members)
1: (richText)

- 2: M3B E, L200A I MRM (sound)
 10: IssueList (field)
 11: M3B E, L201 I MRM (sound)
 12: M3B E, L202 I MRM (sound)
 13: M3B E, L203 I MRM (sound)
 14: M3B E, L205 I MRM (sound)
 15: M3B E, L206 I MRM (sound)
 16: M3B E, L207 I MRM (sound)
 17: M3B E, L208 I MRM (sound)
 18: M3B E, L209 I MRM (sound)
 19: M3B E, L210 I MRM (sound)
 226. m3b50IS.cst (19 members)
 1: (richText)
 2: M3B S, L200A I MRM (sound)
 10: IssueList (field)
 11: M3B S, L201 I MRM (sound)
 12: M3B S, L202 I MRM (sound)
 13: M3B S, L203 I MRM (sound)
 14: M3B S, L205 I MRM (sound)
 15: M3B S, L206 I MRM (sound)
 16: M3B S, L207 I MRM (sound)
 17: M3B S, L208 I MRM (sound)
 18: M3B S, L209 I MRM (sound)
 19: M3B S, L210 I MRM (sound)
 227. m3b51IE.cst (12 members)
 1: (richText)
 2: M3B E, L210A I MRM (sound)
 10: IssueList (field)
 11: M3B E, L211 I MRM (sound)
 12: M3B E, L212 I MRM (sound)
 228. M3b51IS.cst (12 members)
 1: (richText)
 2: M3B S, L210A I MRM (sound)
 10: IssueList (field)
 11: M3B S, L211 I MRM (sound)
 12: M3B S, L212 I MRM (sound)
 229. m3b52IE.cst (17 members)
 1: (richText)
 2: (richText)
 3: (richText)
 4: (richText)
 5: (richText)
 6: (richText)
 7: (richText)
 8: (richText)
 9: BCSText (bitmap)
 10: MRMTText (bitmap)
 11: M3B E, L213 I MRM (sound)
 12: m3bEP034 NOT (sound)
 13: M3A E, L040 STG I BCS (sound)
 14: M3B E, P034 (sound)
 15: NewHouse (bitmap)
 17: (richText)
 230. m3b52IS.cst (17 members)
 1: (richText)
 2: (richText)
 3: (richText)
 4: (richText)
 5: (richText)
 6: (richText)
 7: (richText)
 8: (richText)
 9: BCMTText (bitmap)
 10: MRMTText (bitmap)
 11: M3B S, L213 (sound)
 12: M3BSP034 NOT (sound)
 13: M3B S, L040 STG I BCS (sound)
 14: M3B S, P034 (sound)
 15: NewHouse (bitmap)
 17: (richText)
 231. m3b53IE.cst (18 members)
 1: (richText)
 2: M3B E, L213A I NTX (sound)
 3: P022 (sound)
 4: (richText)
 5: M3B E, L213B I NTX (sound)
 9: M3B E, L214 I NTX (sound)
 10: M3B E, L215 I NTX (sound)
 11: M3B E, L216 I NTX (sound)
 12: M3B E, L217 I NTX (sound)
 13: M3B E, L218 I NTX (sound)
 16: M3B E, P025 (sound)
 17: M3B E, P027 (sound)
 18: M3B E, P035 (sound)
 232. m3b53IS.cst (18 members)
 1: (richText)
 2: M3B S, L213A I MRM (sound)
 3: P022 (sound)
 4: (richText)
 5: M3B S, L213B I MRM (sound)
 9: M3B S, L214 I NTX (sound)
 10: M3B S, L215 I NTX (sound)
 11: M3B S, L216 I NTX (sound)
 12: M3B S, L217 I NTX (sound)
 13: M3B S, L218 I NTX (sound)
 16: M3B S, P025 (sound)
 17: M3B S, P027 (sound)
 18: M3B S, P035 (sound)
 233. m3b54aIE.cst (17 members)
 1: (richText)
 2: (richText)
 3: (richText)
 4: (richText)
 5: (richText)
 6: (richText)
 7: (richText)
 8: (richText)
 9: BCSText (bitmap)
 10: MRMTText (bitmap)
 11: M3B E, L228 I NSO (sound)
 13: (richText)
 17: (richText)
 234. m3b54aIS.cst (17 members)
 1: (richText)
 2: (richText)
 3: (richText)
 4: (richText)
 5: (richText)
 6: (richText)
 7: (richText)
 8: (richText)
 9: BCSText (bitmap)
 10: MRMTText (bitmap)
 11: M3B S, L228 I NSO (sound)
 13: (richText)
 17: (richText)
 235. m3b54IE.cst (17 members)
 1: (richText)
 2: (richText)
 3: (richText)
 4: (richText)
 5: (richText)
 6: (richText)
 7: (richText)
 8: (richText)
 9: BCSText (bitmap)
 10: MRMTText (bitmap)
 11: M3B E, L219 I (sound)
 15: NewHouse (bitmap)
 17: (richText)
 236. m3b54IS.cst (17 members)
 1: (richText)
 2: (richText)
 3: (richText)
 4: (richText)
 5: (richText)
 6: (richText)
 7: (richText)
 8: (richText)
 9: BCMTText (bitmap)
 10: MRMTText (bitmap)
 11: M3B S, L219 I (sound)
 15: NewHouse (bitmap)
 17: (richText)
 237. m3b55IE.cst (14 members)
 1: (richText)
 2: M3B E, L219A I NSO (sound)
 3: P022 (sound)
 4: (richText)
 5: M3B E, L219B I NSO (sound)
 6: (richText)
 7: M3B E, L219C I NSO (sound)
 9: M3B E, L220 I NSO (sound)
 10: M3B E, L221 I NSO (sound)
 11: M3B E, L222 I NSO (sound)
 12: M3B E, L223 I NSO (sound)
 13: M3B E, L224 I NSO (sound)
 14: M3B E, L225 I NSO (sound)
 238. m3b55IS.cst (14 members)
 1: (richText)
 2: M3B S, L219A I (sound)
 3: P022 (sound)
 4: (richText)
 5: M3B S, L219B I (sound)
 6: (richText)
 7: M3B S, L219C I (sound)
 9: M3B S, L220 I NSO (sound)
 10: M3B S, L221 I NSO (sound)
 11: M3B S, L222 I NSO (sound)
 12: M3B S, L223 I NSO (sound)
 13: M3B S, L224 I NSO (sound)
 14: M3B S, L225 I NSO (sound)
 239. m3bPromptE.cst (19 members)
 1: M3B E, P022 (sound)
 2: M3B P023 (sound)
 3: M3B E, P024 (sound)
 4: M3B E, P025 (sound)
 5: M3B E, P026 (sound)
 6: M3B E, P026 1A (sound)
 7: M3B E, P026 1B (sound)
 8: M3B E, P026 1C (sound)
 9: M3B E, P026 1D (sound)
 10: M3B E, P026 1E (sound)
 11: M3B E, P026 2A (sound)
 12: M3B E, P026 2D (sound)
 13: M3B E, P027 (sound)
 14: M3B E, P028 (sound)
 15: M3B E, L067 I BCS (sound)
 16: M3B P023 (sound)
 18: M3B E, L171 I BCS (sound)
 19: M5 E, L007 (sound)
 240. m3bPromptS.cst (19 members)
 1: M3B S, P022 (sound)
 2: M3B P023 (sound)
 3: M3B S, P024 (sound)
 4: M3B S, P025 (sound)
 5: M3B S, P026 (sound)
 6: M3B S, P026 1A (sound)
 7: M3B S, P026 1B (sound)
 8: M3B S, P026 1C (sound)
 9: M3B S, P026 1D (sound)
 10: M3B S, P026 1E (sound)
 11: M3B S, P026 2A (sound)
 12: M3B S, P026 2D (sound)
 13: M3B S, P027 (sound)
 14: M3B S, P028 (sound)
 15: M3B S, L067 STG I BCS (sound)
 16: M3B P023 (sound)
 18: M3B S, L171 I MRM (sound)
 19: M5 S, L007 (sound)
 241. m3E.cst (39 members)
 1: M3A E, L001 (sound)
 2: M3A E, L002 (sound)
 3: M3A E, L003 (sound)
 1: 5401 Cue 1
 2: 7827 Cue 2
 4: M3A E, L004 (sound)
 5: M3A E, L005 (sound)

6: M3A E, L006 (sound)
 7: M3A E, L007 (sound)
 8: M3A E, L008 (sound)
 9: M3A E, L009 (sound)
 10: M3A E, L010 (sound)
 11: M3A E, L011 (sound)
 12: M3A E, L012 (sound)
 1: 7282 Cue 1
 2: 8311 Cue 2
 13: M3A E, L013 (sound)
 14: M3A E, L014 (sound)
 15: M3A E, L015 (sound)
 16: M3A E, L016 (sound)
 17: M3A E, L017 (sound)
 18: M3A E, L018 (sound)
 19: M3A E, L019 (sound)
 1: 3054 Cue 1
 2: 4182 Cue 2
 20: M3A E, L020 (sound)
 1: 4436 Cue 1
 2: 5472 Cue 2
 21: M3A E, L021 (sound)
 1: 3705 Cue 1
 2: 4676 Cue 2
 22: M3A E, L022 (sound)
 1: 6140 Cue 1
 2: 7064 Cue 2
 23: M3A E, L023 (sound)
 24: M3A E, L024 (sound)
 25: M3A E, L025 (sound)
 26: M3A E, L026 (sound)
 1: 1644 Cue 1
 2: 2910 Cue 2
 27: M3A E, L027 (sound)
 1: 5716 Cue 1
 2: 7333 Cue 2
 3: 9226 Cue 3
 4: 10961 Cue 4
 5: 12696 Cue 5
 6: 14353 Cue 6
 7: 16048 Cue 7
 8: 17980 Cue 8
 9: 19794 Cue 9
 10: 21294 Cue 10
 28: M3A E, L028 (sound)
 29: M3A E, L029 (sound)
 30: M3A E, L030 (sound)
 1: 3634 Cue 1
 2: 4775 Cue 2
 31: M3A E, L031 (sound)
 32: M3A E, L032 ALT (sound)
 1: 5260 Cue 1
 2: 6670 Cue 2
 33: M3A E, L032 (sound)
 34: M3A E, L033 (sound)
 35: M3A E, L034 (sound)
 36: M3A E, L035 ALT (sound)
 1: 8462 Cue 1
 2: 14302 Cue 2
 3: 18657
 37: M3A E, L035 (sound)
 39: M3A E, L037 (sound)
 242: M3ES.cst (23 members)
 1: (field)
 2: (bitmap)
 7: M2E S, L034 (sound)
 8: M2E S, L035 (sound)
 13: M1 S H, P002 (sound)
 14: M1 S H, P003 (sound)
 15: M1 S H, P004 (sound)
 20: (field)
 21: (field)
 22: (field)
 23: (field)
 243: m3S.cst (39 members)
 1: M3A S, L001-01-00 (sound)

2: M3A S, L002 (sound)
 3: M3A S, L003 (sound)
 1: 7613 Cue 1
 2: 8981 Cue 2
 4: M3A S, L004 (sound)
 5: M3A S, L005 (sound)
 6: M3A S, L006 (sound)
 7: M3A S, L007 (sound)
 8: M3A S, L008 (sound)
 9: M3A S, L009 (sound)
 10: M3A S, L010 (sound)
 11: M3A S, L011 (sound)
 12: M3A S, L012 (sound)
 13: M3A S, L013 (sound)
 14: M3A S, L014 (sound)
 15: M3A S, L015 (sound)
 16: M3A S, L016 (sound)
 17: M3A S, L017 (sound)
 18: M3A S, L018 (sound)
 19: M3A S, L019 (sound)
 1: 2779 Cue 1
 2: 3803 Cue 2
 20: M3A S, L020 (sound)
 1: 3248 Cue 1
 2: 4214 Cue 2
 21: M3A S, L021 (sound)
 1: 2951 Cue 1
 2: 3962 Cue 2
 22: M3A S, L022 (sound)
 1: 7626 Cue 1
 2: 8669 Cue 2
 23: M3A S, L023 (sound)
 24: M3A S, L024 (sound)
 25: M3A S, L025 (sound)
 26: M3A S, L026 (sound)
 1: 2219 Cue 1
 2: 3182 Cue 2
 27: M3A S, L027 (sound)
 1: 7476 Cue 1
 2: 9142 Cue 2
 3: 10979 Cue 3
 4: 12773 Cue 4
 5: 14610 Cue 5
 6: 16362 Cue 6
 7: 18369 Cue 7
 8: 20292 Cue 8
 9: 21958 Cue 9
 28: M3A S, L028 (sound)
 29: M3A S, L029 (sound)
 30: M3A S, L030 (sound)
 1: 2906 Cue 1
 2: 3985 Cue 2
 31: M3A S, L031 (sound)
 32: M3A S, L032 (sound)
 1: 7371 Cue 1
 2: 8145 Cue 2
 34: M3A S, L033 (sound)
 35: M3A S, L034 (sound)
 1: 3363 Cue 1
 2: 4132 Cue 2
 36: M3A S, L035 (sound)
 1: 10261 Cue 1
 2: 17762 Cue 2
 3: 23271 Cue 3
 38: M3A S, L036 (sound)
 39: M3A S, L037 (sound)
 244: M4AE.cst (33 members)
 1: M4A E, P041 (sound)
 2: P042 (sound)
 3: M4A E, L001 (sound)
 4: M4A E, L002 (sound)
 5: M4A E, L003 (sound)
 1: 11530 Cue 1
 6: M4A E, L004 (sound)
 7: Life After (richText)
 8: Life After Shadow (richText)

9: (bitmap)
 10: (bitmap)
 11: (bitmap)
 12: (bitmap)
 13: (bitmap)
 30: TitleShadow (richText)
 31: Title (richText)
 32: QuestionCount (field)
 33: TitleCenter (richText)
 245: M4AEq1.cst (8 members)
 1: (richText)
 2: M4A E, L005 (sound)
 3: (richText)
 4: (field)
 5: M4A E, L006 (sound)
 6: M4A E, L007 (sound)
 7: M4A E, L008 (sound)
 8: M4A E, L009 (sound)
 246: M4AEq2.cst (9 members)
 1: (richText)
 2: M4A E, L010 (sound)
 3: (richText)
 4: (field)
 5: M4A E, L011 (sound)
 6: M4A E, L012 (sound)
 7: M4A E, L013 (sound)
 8: M4A E, L014 (sound)
 9: M4A E, L015 (sound)
 247: m4AEq3.cst (8 members)
 1: (richText)
 2: M4A E, L016 (sound)
 3: (richText)
 4: (field)
 5: M4A E, L017 (sound)
 6: M4A E, L018 (sound)
 7: M4A E, L019 (sound)
 8: M4A E, L020 (sound)
 248: m4AEq4.cst (6 members)
 1: (richText)
 2: M4A E, L021 (sound)
 3: (richText)
 4: (field)
 5: M4A E, L022 (sound)
 6: M4A E, L023 (sound)
 249: M4AEq5.cst (5 members)
 1: (richText)
 2: M4A E, L024 (sound)
 3: (richText)
 4: (field)
 5: M4A E, L025 (sound)
 250: M4AEq6.cst (5 members)
 1: (richText)
 2: M4A E, L026 (sound)
 3: HealthInsurance (bitmap)
 4: (field)
 5: M4A E, L027 (sound)
 251: M4AS.cst (33 members)
 1: M4A S, P041 (sound)
 2: P042 (sound)
 3: M4A S, L001A (sound)
 4: M4A S, L002 (sound)
 5: M4A S, L003 (sound)
 1: 13546 Cue 1
 2: 18776 Cue 2
 6: M4A S, L004 (sound)
 7: Life After (richText)
 8: Life After (richText)
 9: (bitmap)
 10: (bitmap)
 30: TitleShadow (richText)
 31: Title (richText)
 32: QuestionCount (field)
 33: TitleCenter (richText)
 252: M4ASq1.cst (8 members)
 1: (richText)
 2: M4A S, L005 (sound)

3: (richText)	2: M4B S, L001A (sound)	8: (richText)
4: (field)	3: (richText)	9: BCSText (bitmap)
5: M4A S, L006 (sound)	4: (field)	10: MRMTText (bitmap)
6: M4A S, L007 (sound)	5: M4B S, L001 (sound)	11: M5A E, L001 (sound)
7: M4A S, L008 (sound)	6: M4B S, L002 (sound)	12: M5A E, L002 (sound)
8: M4A S, L009 (sound)	7: M4B S, L003 (sound)	1: 6222 Cue 1
253. M4ASq2.cst (9 members)	263. m4bSq2.cst (5 members)	2: 9383 Cue 2
1: (richText)	1: (richText)	3: 14414 Cue 3
2: M4A S, L010 (sound)	2: M4B S, L003A (sound)	13: M5A E, L002A (sound)
3: (richText)	3: (richText)	14: M5A E, L003 (sound)
4: (field)	4: (field)	15: M5A E, L004 (sound)
5: M4A S, L011 (sound)	5: M4B S, L004 (sound)	16: M5A S, P050 (sound)
6: M4A S, L012 (sound)	264. M4cE.cst (9 members)	17: (richText)
7: M4A S, L013 (sound)	1: M4A E, P041 (sound)	19: M5A E, L001 MRM (sound)
8: M4A S, L014 (sound)	2: (richText)	20: M5A E, L002 MRM (sound)
9: M4A S, L015 (sound)	3: M4B E, L005 (sound)	273. M5a2E.cst (11 members)
254. M4ASq3.cst (8 members)	4: questioncount (field)	1: M5A E, L002A MRM (sound)
1: (richText)	9: (richText)	2: M5A E, L003 (sound)
2: M4A S, L016 (sound)	265. M4cEq1.cst (6 members)	1: 1840 Cue 1
3: (richText)	1: (richText)	2: 10168 Cue 1
4: (field)	2: M4B E, L006 (sound)	3: M5A E, L004 (sound)
5: M4A S, L017 (sound)	3: (richText)	1: 2120 Cue 1
6: M4A S, L018 (sound)	4: (field)	4: M5A E, P050 (sound)
7: M4A S, L019 (sound)	5: M4B E, L007 (sound)	5: P051 (sound)
8: M4A S, L020 (sound)	6: M4B E, L008 (sound)	7: (richText)
255. M4ASq4.cst (6 members)	266. M4cEq2.cst (7 members)	8: (richText)
1: (richText)	1: (richText)	9: (richText)
2: M4A S, L021 (sound)	2: M4B E, L009 (sound)	10: (richText)
3: (richText)	3: (richText)	11: M5A E, L003 MRM (sound)
4: (field)	4: (field)	1: 1469 Cue 1
5: M4A S, L022 (sound)	5: M4B E, L010 (sound)	274. m5a2s.cst (11 members)
6: M4A S, L023 (sound)	6: M4B E, L011 (sound)	1: M5A S L002A (sound)
256. m4ASq5.cst (5 members)	7: M4B E, L012 (sound)	2: M5A S, L003 (sound)
1: (richText)	267. M4cEq3.cst (6 members)	1: 3080 Cue 1
2: M4A S, L024 (sound)	1: (richText)	2: 11153 Cue 2
3: (richText)	2: M4B E, L013 (sound)	3: M5A S, L004 (sound)
4: (field)	3: (richText)	1: 2742 Cue 1
5: M4A S, L025 (sound)	4: (field)	4: M5A S, P050 (sound)
257. m4ASq6.cst (5 members)	5: M4B E, L014 (sound)	5: P051 (sound)
1: (richText)	6: M4B E, L015 (sound)	7: (richText)
2: M4A S L026 (sound)	268. M4cS.cst (9 members)	8: (richText)
3: HealthInsurance (bitmap)	1: M4A S, P041 (sound)	9: (richText)
4: (field)	2: (richText)	10: (richText)
5: M4A S, L027 (sound)	3: M4B S, L005 (sound)	11: M5A S, L003 MRM (sound)
258. M4BE.cst (32 members)	4: QuestionCount (field)	1: 2325 Cue 1
1: M4A E, P041 (sound)	9: (richText)	275. M5BE.cst (33 members)
2: P042 (sound)	269. M4cSq1.cst (6 members)	1: Title (richText)
30: TitleShadow (richText)	1: (richText)	2: Title Shadow (richText)
31: Title (richText)	2: M4B S, L006 (sound)	3: M5B E, L001 (sound)
32: QuestionCount (field)	3: (richText)	4: M5B E, L002 (sound)
259. M4bEq1.cst (7 members)	4: (field)	1: 5467 Cue 1
1: (richText)	5: M4B S, L007 (sound)	2: 7937 Cue 2
2: M4B E, L001A (sound)	6: M4B S, L008 (sound)	5: M5B E, L003 (sound)
3: (richText)	270. M4cSq2.cst (7 members)	6: M5B E, L004 (sound)
4: (field)	1: (richText)	7: M5B E, L005 (sound)
5: M4B E, L001 (sound)	2: M4B S, L009 (sound)	8: Timeout (sound)
6: M4B E, L002 (sound)	3: (richText)	10: MRMOnly (sound)
7: M4B E, L003 NEW (sound)	4: (field)	1: 68 Cue 1
1: 4552 Cue 1	5: M4B S, L010 (sound)	2: 7687 Cue 2
2: 13426 Cue 2	6: M4B S, L011 (sound)	11: MRMTTimeout (sound)
3: 21220 Cue 3	7: M4B S, L012 (sound)	12: M5B E, L006 (sound)
4: 31945 Cue 4	271. m4cSq3.cst (6 members)	13: M5B E, L007 (sound)
260. M4BEq2.cst (5 members)	1: (richText)	14: M5B E, L008 (sound)
1: (richText)	2: M4B S, L013 (sound)	15: M5B E, L009 (sound)
2: M4B E, L003A (sound)	3: (richText)	16: M5B E, L010 (sound)
3: (richText)	4: (field)	17: M5B E, L011 (sound)
4: (field)	5: M4B S, L014 (sound)	18: M5B E, L012 (sound)
5: M4B E, L004 (sound)	6: M4B S, L015 (sound)	19: M5B E, L013 (sound)
261. M4BS.cst (32 members)	272. m54IE.cst (20 members)	20: M5B E, L014 (sound)
1: M4A S, P041 (sound)	1: (richText)	25: Lumpectomy Text (bitmap)
2: P042 (sound)	2: (richText)	26: Mastectomy Text (bitmap)
30: TitleShadow (richText)	3: (richText)	27: VerifyBCS (richText)
31: Title (richText)	4: (richText)	28: VerifyMRM (richText)
32: QuestionCount (field)	5: (richText)	29: Yes (field)
262. M4BSq1.cst (7 members)	6: (richText)	30: Reconstruction (richText)
1: (richText)	7: (richText)	31: Initial Surgery (field)

32: Later On (field)	15: M5A S, L004 (sound)	4: IMG0098 (bitmap)
33: ChoiceVerifyText (field)	16: M5A S, P050 (sound)	5: IMG0036 (bitmap)
276. M5BS.cst (33 members)	17: (richText)	6: IMG0037 (bitmap)
1: Title (richText)	19: M5A S, L001 MRM (sound)	7: IMG0104 (bitmap)
2: Title Shadow (richText)	20: M5A S, L002 MRM (sound)	8: IMG0101 (bitmap)
3: M5B S, L001 (sound)	279. music.cst (3 members)	9: IMG0099 (bitmap)
4: M5B S, L002 (sound)	1: njj15cu (sound)	10: IMG0107 (bitmap)
1: 6091 Cue 1	2: njj24cu (sound)	11: IMG0035 (bitmap)
2: 8971 Cue 2	3: njj16cu (sound)	12: IMG0039 (bitmap)
5: M5B S, L003 (sound)	280. S1Et.cst (2 members)	290. S2Et.cst (2 members)
6: M5B S, L004 (sound)	1: SceneTitle (richText)	1: SceneTitle (richText)
7: M5B S, L005 (sound)	2: SceneTitleShadow (richText)	2: SceneTitleShadow (richText)
8: Timeout (sound)	281. S1St.cst (2 members)	291. S2SHSOa.cst (1 members)
10: MRMonly (sound)	1: SceneTitle (richText)	1: Scene2 (sound)
1: 0 Cue 1	2: SceneTitleShadow (richText)	1: 21969 Cue 1
2: 10761 Cue 2	282. S2EAAOa.cst (1 members)	2: 42391 Cue 2
11: MRMTimeout (sound)	1: Scene2 (sound)	3: 54329 Cue 3
12: M5B S, L006 (sound)	1: 17423 Cue 1	4: 70806 Cue 4
13: M5B S, L007 (sound)	2: 31716 Cue 2	5: 77788 Cue 5
14: M5B S, L008 (sound)	3: 46386 Cue 3	292. S2SHSOi.cst (11 members)
15: M5B S, L009 (sound)	4: 56724 Cue 4	1: IMG0085 (bitmap)
16: M5B S, L010 (sound)	5: 60500 Cue 5	2: IMG0086 (bitmap)
17: M5B S, L011 (sound)	283. S2EAAOi.cst (8 members)	3: IMG0002 (bitmap)
18: M5B S, L012 (sound)	1: IMG0017 (bitmap)	4: IMG0003 (bitmap)
19: M5B S, L013 (sound)	2: IMG0019 (bitmap)	5: IMG0005 (bitmap)
20: M5B S, L014 (sound)	3: IMG0024 (bitmap)	6: IMG0049 (bitmap)
25: (bitmap)	4: IMG0060 (bitmap)	7: IMG0050 (bitmap)
26: (bitmap)	5: IMG0061 (bitmap)	8: IMG0051 (bitmap)
27: VerifyBCS (richText)	6: IMG0062 (bitmap)	9: IMG0052 (bitmap)
28: VerifyMRM (richText)	7: IMG0063 (bitmap)	10: IMG0053 (bitmap)
29: Yes (field)	8: IMG0025 (bitmap)	11: IMG0054 (bitmap)
30: Reconstruction (richText)	284. S2EAAYa.cst (1 members)	293. S2SHSYa.cst (1 members)
31: Initial Surgery (field)	1: Scene2 (sound)	1: Scene2 (sound)
32: Later On (field)	1: 21282 Cue 1	1: 20863 Cue 1
33: ChoiceVerifyText (field)	2: 38068 Cue 2	2: 41082 Cue 2
277. m5IE.cst (20 members)	3: 47715 Cue 3	3: 51612 Cue 3
1: (richText)	4: 57745 Cue 4	4: 68816 Cue 4
2: (richText)	5: 66937 Cue 5	5: 76901 Cue 5
3: (richText)	285. S2EAAyi.cst (10 members)	294. S2SHSYi.cst (14 members)
4: (richText)	1: IMG0042 (bitmap)	1: IMG0013 (bitmap)
5: (richText)	2: IMG0047 (bitmap)	2: IMG0014 (bitmap)
6: (richText)	3: IMG0048 (bitmap)	3: IMG0089 (bitmap)
7: (richText)	4: IMG0057 (bitmap)	4: IMG0090 (bitmap)
8: (richText)	5: IMG0116 (bitmap)	5: IMG0091 (bitmap)
9: BCSText (bitmap)	6: IMG0006 (bitmap)	6: IMG0092 (bitmap)
10: MRMText (bitmap)	7: IMG0012 (bitmap)	7: IMG0094 (bitmap)
11: M5A E, L001 (sound)	8: IMG0043 (bitmap)	8: IMG0095 (bitmap)
12: M5A E, L002 (sound)	9: IMG0044 (bitmap)	9: IMG0096 (bitmap)
1: 6222 Cue 1	10: IMG0046 (bitmap)	10: IMG0097 (bitmap)
2: 9383 Cue 2	286. S2ECAOa.cst (1 members)	11: IMG0015 (bitmap)
3: 14414 Cue 3	1: Scene2 (sound)	12: IMG0016 (bitmap)
13: M5A E, L002A (sound)	1: 15903 Cue 1	13: IMG0087 (bitmap)
14: M5A E, L003 (sound)	2: 30407 Cue 2	14: IMG0088 (bitmap)
15: M5A E, L004 (sound)	3: 38900 Cue 3	295. S2St.cst (2 members)
16: M5A E, P050 (sound)	4: 48099 Cue 4	1: SceneTitle (richText)
17: (richText)	5: 54388 Cue 5	2: SceneTitleShadow (richText)
19: M5A E, L001 MRM (sound)	287. S2ECAOi.cst (8 members)	296. S3Et.cst (2 members)
20: M5A E, L002 MRM (sound)	1: IMG0026 (bitmap)	1: SceneTitle (richText)
278. m5IS.cst (20 members)	2: IMG0027 (bitmap)	2: SceneTitleShadow (richText)
1: (richText)	3: IMG0021 (bitmap)	297. S4EAAOa.cst (1 members)
2: (richText)	4: IMG0022 (bitmap)	1: Scene4 (sound)
3: (richText)	5: IMG0029 (bitmap)	1: 14269 Cue 1
4: (richText)	6: IMG0020 (bitmap)	2: 15754 Cue 2
5: (richText)	7: IMG0032 (bitmap)	298. S4EAAOi.cst (5 members)
6: (richText)	8: IMG0033 (bitmap)	1: IMG0087 (bitmap)
7: (richText)	288. S2ECAYa.cst (1 members)	2: IMG0088 (bitmap)
8: (richText)	1: Scene2 (sound)	3: IMG0089 (bitmap)
9: BCStext (bitmap)	1: 14662 Cue 1	4: IMG0091 (bitmap)
10: MRMtext (bitmap)	2: 31404 Cue 2	5: IMG0093 (bitmap)
11: M5A S, L001 (sound)	3: 37161 Cue 3	299. S4EAAYa.cst (1 members)
12: M5A S, L002 (sound)	4: 44949 Cue 4	1: Scene4 (sound)
1: 7753 Cue 1	5: 50429 Cue 5	1: 5660 Cue 3
2: 10969 Cue 2	289. S2ECAYi.cst (12 members)	2: 14166 Cue 1
3: 17023 Cue 3	1: IMG0058 (bitmap)	3: 20183 Cue 2
13: M5A S, L002A (sound)	2: IMG0103 (bitmap)	4: 24625 Cue 4
14: M5A S, L003 (sound)	3: IMG0102 (bitmap)	5: 27652 Cue 5

300. S4EAYi.cst (6 members)
 1: IMG0118 (bitmap)
 2: IMG0085 (bitmap)
 3: IMG0086 (bitmap)
 4: IMG0069 (bitmap)
 5: IMG0068 (bitmap)
 6: IMG0084 (bitmap)
301. S4ECAOa.cst (1 members)
 1: Scene4 (sound)
 1: 16952 Cue 1
 2: 18814 Cue 2
302. S4ECAOi.cst (7 members)
 1: IMG0061 (bitmap)
 2: IMG0062 (bitmap)
 3: IMG0063 (bitmap)
 4: IMG0065 (bitmap)
 5: IMG0066 (bitmap)
 6: IMG0079 (bitmap)
 7: IMG0064 (bitmap)
303. S4ECAYa.cst (1 members)
 1: Scene4 (sound)
 1: 12027 Cue 1
 2: 15658 Cue 2
304. S4ECAYi.cst (5 members)
 1: IMG0074 (bitmap)
 2: IMG0075 (bitmap)
 3: IMG0082 (bitmap)
 4: IMG0083 (bitmap)
 5: IMG0080 (bitmap)
305. S4Et.cst (2 members)
 1: SceneTitle (richText)
 2: SceneTitleShadow (richText)
306. S4SHSOa.cst (1 members)
 1: Scene4 (sound)
 1: 23492 Cue 1
 2: 27597 Cue 2
307. S4SHSOi.cst (5 members)
 1: IMG0055 (bitmap)
 2: IMG0056 (bitmap)
 3: IMG0057 (bitmap)
 4: IMG0058 (bitmap)
 5: IMG0059 (bitmap)
308. S4SHSYa.cst (1 members)
 1: Scene4 (sound)
 1: 23097 Cue 1
 2: 25018 Cue 2
309. S4SHSYi.cst (5 members)
 1: IMG0070 (bitmap)
 2: IMG0071 (bitmap)
 3: IMG0072 (bitmap)
 4: IMG0076 (bitmap)
 5: IMG0077 (bitmap)
310. S4St.cst (2 members)
 1: SceneTitle (richText)
 2: SceneTitleShadow (richText)
311. S5Et.cst (2 members)
 1: SceneTitle (richText)
 2: SceneTitleShadow (richText)
312. S5St.cst (2 members)
 1: SceneTitle (richText)
 2: SceneTitleShadow (richText)
313. S6EAAOa.cst (1 members)
 1: Scene6 (sound)
 1: 4266 Cue 1
 2: 8876 Cue 2
 3: 12676 Cue 3
 4: 13751 Cue 4
 5: 16008 Cue 5
 6: 20584 Cue 6
 7: 26897 Cue 7
 8: 29232 Cue 8
 9: 34508 Cue 9
 10: 37255 Cue 10
 11: 39611 Cue 11
314. S6EAAOi.cst (9 members)
 1: IMG0073 (bitmap)
- 2: IMG0074 (bitmap)
 3: IMG0075 (bitmap)
 4: IMG0081 (bitmap)
 5: IMG0054 (bitmap)
 6: IMG0082 (bitmap)
 7: IMG0083 (bitmap)
 8: IMG0057 (bitmap)
 9: IMG0058 (bitmap)
315. S6EAYa.cst (1 members)
 1: Scene6 (sound)
 1: 5020 Cue 1
 2: 8209 Cue 2
 3: 11053 Cue 14
 4: 12007 Cue 3
 5: 12921 Cue 4
 6: 17239 Cue 5
 7: 25254 Cue 9
 8: 27141 Cue 10
 9: 31202 Cue 11
 10: 32702 Cue 12
 11: 36327 Cue 13
316. S6EAYi.cst (9 members)
 1: IMG0020 (bitmap)
 2: IMG0025 (bitmap)
 3: IMG0019 (bitmap)
 4: IMG0023 (bitmap)
 5: IMG0024 (bitmap)
 6: IMG0026 (bitmap)
 7: IMG0028 (bitmap)
 8: IMG0029 (bitmap)
 9: IMG0030 (bitmap)
317. S6ECAOa.cst (1 members)
 1: Scene6 (sound)
 1: 4074 Cue 1
 2: 6251 Cue 2
 3: 9259 Cue 3
 4: 11105 Cue 4
 5: 17097 Cue 5
 6: 22826 Cue 6
 7: 25092 Cue 7
 8: 31676 Cue 10
 9: 33264 Cue 11
 10: 35061 Cue 9
318. S6ECAOi.cst (10 members)
 1: IMG0071 (bitmap)
 2: IMG0072 (bitmap)
 3: IMG0032 (bitmap)
 4: IMG0033 (bitmap)
 5: IMG0039 (bitmap)
 6: IMG0038 (bitmap)
 7: IMG0034 (bitmap)
 8: IMG0035 (bitmap)
 9: IMG0036 (bitmap)
 10: IMG0037 (bitmap)
319. S6ECAYa.cst (1 members)
 1: Scene6 (sound)
 1: 3576 Cue 1
 2: 8559 Cue 2
 3: 10770 Cue 3
 4: 12614 Cue 4
 5: 13131 Cue 5
 6: 20306 Cue 6
 7: 26310 Cue 7
 8: 28237 Cue 8
 9: 37298 Cue 11
 10: 40843 Cue 12
 11: 41838 Cue 10
320. S6ECAYi.cst (11 members)
 1: IMG0001 (bitmap)
 2: IMG0002 (bitmap)
 3: IMG0003 (bitmap)
 4: IMG0004 (bitmap)
 5: IMG0005 (bitmap)
 6: IMG0006 (bitmap)
 7: IMG0008 (bitmap)
 8: IMG0009 (bitmap)
- 9: IMG0042 (bitmap)
 10: IMG0044 (bitmap)
 11: IMG0045 (bitmap)
321. S6Et.cst (2 members)
 1: SceneTitle (richText)
 2: SceneTitleShadow (richText)
322. S6SHSOa.cst (1 members)
 1: Scene6 (sound)
 1: 5587 Cue 1
 2: 13550 Cue 2
 3: 19799 Cue 3
 4: 20893 Cue 4
 5: 21743 Cue 5
 6: 29639 Cue 6
 7: 41483 Cue 7
 8: 45794 Cue 8
 9: 54307 Cue 9
323. S6SHSOi.cst (6 members)
 1: IMG0061 (bitmap)
 2: IMG0062 (bitmap)
 3: IMG0066 (bitmap)
 4: IMG0067 (bitmap)
 5: IMG0068 (bitmap)
 6: IMG0069 (bitmap)
324. S6SHSYa.cst (1 members)
 1: Scene6 (sound)
 1: 5312 Cue 1
 2: 11237 Cue 2
 3: 15426 Cue 3
 4: 16448 Cue 4
 5: 17163 Cue 5
 6: 24825 Cue 6
 7: 35781 Cue 7
 8: 39631 Cue 8
 9: 46790 Cue 9
325. S6SHSYi.cst (11 members)
 1: IMG0012 (bitmap)
 2: IMG0013 (bitmap)
 3: IMG0014 (bitmap)
 4: IMG0015 (bitmap)
 5: IMG0016 (bitmap)
 6: IMG0017 (bitmap)
 7: IMG0018 (bitmap)
 8: IMG0047 (bitmap)
 9: IMG0049 (bitmap)
 10: IMG0050 (bitmap)
 11: IMG0051 (bitmap)
326. S6St.cst (2 members)
 1: SceneTitle (richText)
 2: SceneTitleShadow (richText)
327. S7Et.cst (2 members)
 1: SceneTitle (richText)
 2: SceneTitleShadow (richText)
328. S7St.cst (2 members)
 1: SceneTitle (richText)
 2: SceneTitleShadow (richText)
329. S8EAAOa.cst (1 members)
 1: Scene8 (sound)
 1: 6185 Cue 1
 2: 19508 Cue 2
 3: 20746 Cue 3
 4: 36851 Cue 4
 5: 40026 Cue 5
 6: 45039 Cue 6
330. S8EAAOi.cst (8 members)
 1: IMG0025 (bitmap)
 2: IMG0026 (bitmap)
 3: IMG0027 (bitmap)
 4: IMG0029 (bitmap)
 5: IMG0070 (bitmap)
 6: IMG0071 (bitmap)
 7: IMG0072 (bitmap)
 8: IMG0115 (bitmap)
331. S8EAYa.cst (2 members)
 2: Scene8 (sound)
 1: 6099 Cue 1

- 2: 11104 Cue 2
 3: 19659 Cue 3
 4: 20962 Cue 4
 5: 34019 Cue 5
 6: 36570 Cue 6
 7: 41297 Cue 7
 8: 42738 Cue 8
 9: 44149 Cue 9
 332. S8EAAyi.cst (11 members)
 1: IMG0073 (bitmap)
 2: IMG0074 (bitmap)
 3: IMG0075 (bitmap)
 4: IMG0076 (bitmap)
 5: IMG0078 (bitmap)
 6: IMG0081 (bitmap)
 7: IMG0077 (bitmap)
 8: IMG0080 (bitmap)
 9: IMG0082 (bitmap)
 10: IMG0083 (bitmap)
 11: IMG0084 (bitmap)
 333. S8ECAOa.cst (1 members)
 1: Scene8 (sound)
 1: 5417 Cue 1
 2: 18395 Cue 2
 3: 19659 Cue 6
 4: 33376 Cue 3
 5: 35350 Cue 4
 6: 38893 Cue 5
 334. S8ECAOi.cst (10 members)
 1: IMG0038 (bitmap)
 2: IMG0017 (bitmap)
 3: IMG0018 (bitmap)
 4: IMG0019 (bitmap)
 5: IMG0020 (bitmap)
 6: IMG0067 (bitmap)
 7: IMG0068 (bitmap)
 8: IMG0021 (bitmap)
 9: IMG0022 (bitmap)
 10: IMG0023 (bitmap)
 335. S8ECAYa.cst (1 members)
 1: Scene8 (sound)
 1: 4274 Cue 1
 2: 12367 Cue 2
 3: 14444 Cue 3
 4: 25735 Cue 4
 5: 28721 Cue 6
 6: 28721 Cue 5
 7: 35557 Cue 8
 8: 35557 Cue 7
 336. S8ECAYi.cst (9 members)
 1: IMG0030 (bitmap)
 2: IMG0031 (bitmap)
 3: IMG0032 (bitmap)
 4: IMG0033 (bitmap)
 5: IMG0034 (bitmap)
 6: IMG0035 (bitmap)
 7: IMG0036 (bitmap)
 8: IMG0037 (bitmap)
 9: IMG0065 (bitmap)
 337. S8Et.cst (2 members)
 1: SceneTitle (richText)
 2: SceneTitleShadow (richText)
 338. S8NSOAAO.cst (5 members)
 1: M3B E, L229A I NSO (sound)
 2: IMG0025 (bitmap)
 3: IMG0070 (bitmap)
 4: IMG0071 (bitmap)
 5: IMG0072 (bitmap)
 339. S8NSOAAy.cst (6 members)
 1: M3B E, L229 I NSO (sound)
 2: IMG0073 (bitmap)
 3: IMG0074 (bitmap)
 4: IMG0082 (bitmap)
 5: IMG0083 (bitmap)
 6: IMG0084 (bitmap)
 340. S8NSOCAO.cst (5 members)
 1: M3B E, L229C I NSO (sound)
 2: IMG0038 (bitmap)
 3: IMG0069 (bitmap)
 4: IMG0022 (bitmap)
 5: IMG0023 (bitmap)
 341. S8NSOCAY.cst (5 members)
 1: M3B E, L229B I NSO (sound)
 2: IMG0030 (bitmap)
 3: IMG0035 (bitmap)
 4: IMG0036 (bitmap)
 5: IMG0037 (bitmap)
 342. S8NSOHSO.cst (8 members)
 1: M3B S, L229A I NSO (sound)
 2: IMG0012 (bitmap)
 3: IMG0013 (bitmap)
 4: IMG0007 (bitmap)
 5: IMG0008 (bitmap)
 6: IMG0009 (bitmap)
 7: IMG0010 (bitmap)
 8: IMG0011 (bitmap)
 343. S8NSOHSY.cst (4 members)
 1: M3B S, L229 I NSO (sound)
 2: IMG0040 (bitmap)
 3: IMG0053 (bitmap)
 4: IMG0054 (richText)
 344. S8SHSOa.cst (1 members)
 1: Scene8 (sound)
 1: 3911 Cue 1
 2: 16596 Cue 2
 3: 18996 Cue 3
 4: 41352 Cue 4
 5: 47157 Cue 5
 6: 52632 Cue 6
 345. S8SHSOi.cst (13 members)
 1: IMG0002 (bitmap)
 2: IMG0003 (bitmap)
 3: IMG0006 (bitmap)
 4: IMG0007 (bitmap)
 5: IMG0008 (bitmap)
 6: IMG0009 (bitmap)
 7: IMG0010 (bitmap)
 8: IMG0011 (bitmap)
 9: IMG0014 (bitmap)
 10: IMG0015 (bitmap)
 11: IMG0016 (bitmap)
 12: IMG0012 (bitmap)
 13: IMG0013 (bitmap)
 346. S8SHSYa.cst (1 members)
 1: Scene8 (sound)
 1: 4153 Cue 1
 2: 18752 Cue 2
 3: 21239 Cue 3
 4: 37672 Cue 4
 5: 40667 Cue 5
 347. S8SHSYi.cst (7 members)
 1: IMG0040 (bitmap)
 2: IMG0041 (bitmap)
 3: IMG0042 (bitmap)
 4: IMG0043 (bitmap)
 5: IMG0050 (bitmap)
 6: IMG0053 (bitmap)
 7: IMG0054 (richText)
 348. S8St.cst (2 members)
 1: SceneTitle (richText)
 2: SceneTitleShadow (richText)
 349. S9Et.cst (2 members)
 1: SceneTitle (richText)
 2: SceneTitleShadow (richText)
 350. S9St.cst (2 members)
 1: SceneTitle (richText)
 2: SceneTitleShadow (richText)
 351. SceneTitlesE.cst (1 members)
 1: Scene Titles English (field)
 352. SceneTitles.cst (1 members)
 1: Scene Titles Spanish (field)
 353. Sfx.cst (28 members)
 2: Buzzer 01 (sound)
 3: Click 1 (sound)
 4: Click 2 (sound)
 5: Click 3 (sound)
 6: Click 4 (sound)
 7: Click 5 (sound)
 8: Click 6 (sound)
 9: Click 7 (sound)
 10: Click 8 (sound)
 11: Correct (sound)
 12: Ding 01 (sound)
 20: Xylophone 01 (sound)
 21: Xylophone 02 (sound)
 22: Xylophone 03 (sound)
 23: Xylophone 04 (sound)
 24: Xylophone 05 (sound)
 25: Xylophone 06 (sound)
 26: Xylophone 07 (sound)
 27: Xylophone 08 (sound)
 28: Yes (sound)
 354. TitleE.cst (9 members)
 1: titleText.p (bitmap)
 2: NewTitleEnglish.p (bitmap)
 3: DevelopedBy (richText)
 4: Disclaimer (richText)
 9: DevelopedBy (richText)
 355. TitleS.cst (9 members)
 1: titleTextSpa (bitmap)
 2: NewTitleSpanish.p (bitmap)
 3: DevelopedBy (richText)
 4: Disclaimer (richText)
 9: DevelopedBy (richText)
 356. TVAudio31E.cst (14 members)
 1: M3B E, L086 I BCS (sound)
 1: 3070 Cue 1
 2: 4112 Cue 2
 2: M3B E, P029 (sound)
 3: M3B E, P030 (sound)
 4: What if you were (richText)
 5: Negative (richText)
 6: Positive (richText)
 7: Low Button text (richText)
 8: High Button Text (richText)
 9: M3B E, L095 I BCS (sound)
 1: 14506 Cue 2
 2: 16092 Cue 1
 3: 16782 Cue 3
 10: M3B E, L095, IIA, BCS (sound)
 1: 14068 Cue 1
 2: 16060 Cue 2
 3: 16996 Cue 3
 11: Nodal Status (richText)
 12: M3B E, P028 (sound)
 13: Negative (richText)
 14: Positive (richText)
 357. TVAudio31S.cst (14 members)
 1: M3B S, L086 STG I BCS (sound)
 1: 3759 Cue 1
 2: 5149 Cue 2
 2: M3B S, P029 (sound)
 3: M3B S, P030 (sound)
 4: What if you were (richText)
 5: Negative (richText)
 6: Positive (richText)
 7: Low Button text (richText)
 8: High Button Text (richText)
 9: M3B S, L095 STG I BCS (sound)
 1: 16980 Cue 1
 2: 18200 Cue 2
 10: M3B S, L095, IIA, BCS (sound)
 1: 15862 Cue 1
 2: 16954 Cue 2
 3: 18013 Cue 3
 11: What if you were (richText)
 12: M3B S, P028 (sound)
 13: Negative (richText)

- 14: Positive (richText)
- 358. TVAudioE.cst (8 members)
 - 1: M3B E, L086 I BCS (sound)
 - 1: 3070 Cue 1
 - 2: 4112 Cue 2
- 2: M3B E, P029 (sound)
- 3: M3B E, P030 (sound)
- 4: What if you were (richText)
- 5: High Risk (richText)
- 6: Low Risk (richText)
- 7: Low Button text (richText)
- 8: High Button Text (richText)
- 359. TVAudioS.cst (8 members)
 - 1: M3B S, L086 STG I BCS (sound)
 - 1: 3565 Cue 1
 - 2: 4988 Cue 2
- 2: M3B S, P029 (sound)
- 3: M3B S, P030 (sound)
- 4: What if you were (richText)
- 5: High Risk (richText)
- 6: Low Risk (richText)
- 7: Low Button text (richText)
- 8: High Button Text (richText)
- 360. Vanity.cst (68 members)
 - 1: new jbox wide (bitmap)
 - 2: vase (bitmap)
 - 3: vase hilite (bitmap)
 - 4: big painting (bitmap)
 - 5: small painting (bitmap)
 - 6: tv (bitmap)
 - 7: tv hilite (bitmap)
 - 8: flowers (bitmap)
 - 9: flowers hilite (bitmap)
 - 10: (richText)
 - 11: Lump1.p (bitmap)
 - 12: Closeup Mirror BG (bitmap)
 - 13: Painting close up (bitmap)
 - 14: FlashJbox (script)
 - 15: JboxBottom (bitmap)
 - 16: JboxBottom hilite (bitmap)
 - 17: JboxTopClosed (bitmap)
 - 18: JboxTopOpen1 (bitmap)
 - 19: JboxTopOpen2 (bitmap)
 - 20: JboxTopOpen3 (bitmap)
 - 21: WHY IS THIS SCRIPT IN VANITY CAST?
- (script)
 - 22: Lump1.p (bitmap)
 - 23: insideJbox (bitmap)
 - 24: Perfume (bitmap)
 - 25: Perfume hilite (bitmap)
 - 26: Scissors (bitmap)
 - 27: ScissorsMono (bitmap)
 - 28: reflection (bitmap)
 - 29: tv close up (bitmap)
 - 30: green button (bitmap)
 - 31: yellow button (bitmap)
 - 32: green button hilite (bitmap)
 - 33: yellow button hilite (bitmap)
 - 36: Vanity Object Behavior (script)
 - 37: Hold on Frame (script)
 - 39: JboxTopClosed (bitmap)
 - 40: JboxTopOpen1 (bitmap)
 - 41: JboxTopOpen2 (bitmap)
 - 42: JboxTopOpen3 (bitmap)
 - 43: (bitmap)
 - 44: (bitmap)
 - 45: (bitmap)
 - 46: (bitmap)
 - 47: (bitmap)
 - 48: Vanity Object Behavior NEW (script)
 - 49: Save Clicked Issue (script)
 - 50: Jbox Object Behavior (script)
 - 51: FlashVanityObject (script)
 - 57: JboxFlash1 (bitmap)
 - 58: JboxFlash2 (bitmap)
 - 60: Jbox Object Behavior NEW (script)
- 61: Ding 01 (sound)
- 65: JboxTopClosed (bitmap)
- 66: JboxTopOpen1 (bitmap)
- 67: JboxTopOpen2 (bitmap)
- 68: JboxTopOpen3 (bitmap)
- 361. VButtons.cst (74 members)
 - 1: FlashVButton (script)
 - 2: FlashStory (script)
 - 3: FlashContinue (script)
 - 4: ButtonTimeout (script)
 - 5: WaitForAudioThenResetTimer (script)
 - 6: WaitForResponseOrTimeout (script)
 - 7: StartTimeoutTimer (script)
 - 8: ERepeat (bitmap)
 - 9: ERepeatOver (bitmap)
 - 10: ERepeatDown (bitmap)
 - 11: SRepeat (bitmap)
 - 12: SRepeatOver (bitmap)
 - 13: SRepeatDown (bitmap)
 - 14: EContinue (bitmap)
 - 15: EContinueOver (bitmap)
 - 16: EContinueDown (bitmap)
 - 17: SContinue (bitmap)
 - 18: SContinueOver (bitmap)
 - 19: SContinueDown (bitmap)
 - 20: StoryShadow (shape)
 - 21: StoryOverBlend (shape)
 - 22: AAY (bitmap)
 - 23: AAO (bitmap)
 - 24: CAY (bitmap)
 - 25: CAO (bitmap)
 - 26: HSY (bitmap)
 - 27: HSO (bitmap)
 - 28: Set English, Young, Caucaian for testing
- (script)
 - 29: ClickDown (sound)
 - 30: ClickUp (sound)
 - 31: EP002 (sound)
 - 1: 4859 Cue 1
 - 32: EP003 (sound)
 - 33: EP004 (sound)
 - 34: SP002 (sound)
 - 1: 4437 Cue 1
 - 35: SP003 (sound)
 - 36: SP004 (sound)
 - 37: FlashContinueNoTimer (script)
 - 38: FlashStoryNoTimer (script)
 - 39: GoTimeoutLoop (script)
 - 40: SetECAY - Shouldn't be in VBUTTONS cast
- (script)
 - 41: FlashRepeatNoTimer (script)
 - 42: Stop Sounds (script)
 - 43: Hide Repeat and Continue (script)
 - 44: Hide Repeat and Story (script)
 - 45: EP011 (sound)
 - 46: EP012 (sound)
 - 47: EP016 (sound)
 - 48: E1AL001 (sound)
 - 49: E1AL002 (sound)
 - 50: S1AL001 (sound)
 - 51: S1AL002 (sound)
 - 52: Hide Continue (script)
 - 53: Hide Story (script)
 - 54: FlashRepeat (script)
 - 55: ShowContinue (script)
 - 56: E3AL036 (sound)
 - 57: S3AL036 (sound)
 - 58: EM5AP056 (sound)
 - 59: SM5AP056 (sound)
 - 60: EM4AP042 (sound)
 - 61: SM4AP042 (sound)
 - 62: SM4AP042 (sound)
 - 63: SP011 (sound)
 - 64: SP012 (sound)
 - 65: SP016 (sound)
 - 66: (script)
- 67: (script)
- 68: (shape)
- 69: ShowContinueAndRepeatSprites (script)
- 71: SM1CL009 (sound)
 - 1: 8400 Cue 1
- 72: EM1CL009 (sound)
 - 1: 6682 Cue 1
- 73: EP070 (sound)
- 74: SP070 (sound)
- 362. video.cst (1 members)
 - 1: Video (ActiveX)
- 363. videobox.cst (1 members)
 - 1: Videobox (bitmap)

APPENDIX F

CDSS CLINICAL PROCEDURES DURING TRIALS

INCLUSION CRITERIA

Women:

1. With Diagnosis of breast cancer in stages I, IIA, IIB, or IIIA:.
2. Who are candidates for surgery.
3. Speak English or Spanish.
4. Who have other serious medical illnesses (Heart disease, hypertension, diabetes, chronic lung disease), but are not affected SEVERELLY. They must have someone to help them with everyday activities.
5. Who are pregnant between 7-9 months. [So they may be eligible for radiation therapy after lumpectomy]
6. Indicate willingness to participate in the study (by signing Informed Consent Form).

EXCLUSION CRITERIA

Women:

1. With diagnosis of breast cancer in stages 0, IIIB, or IV.
2. With recurrent breast cancer or inflammatory breast carcinoma.
3. Who have cancer in several areas of the breast. [not eligible for lumpectomy]
4. Who have had x-ray treatment in the chest area before. [not eligible for lumpectomy with radiation]
5. Who have lupus or scleroderma. [not eligible for lumpectomy with radiation]
6. Who have serious medical illness, in addition to breast cancer in stages I, IIA, IIB, IIIA, who are affected SEVERELLY: Heart disease, hypertension, diabetes, chronic lung disease
7. Who are pregnant for 1-6 months. [not eligible for lumpectomy with radiation]
8. Who don't speak English or Spanish.
6. Who refuse to sign the Informed Consent Form.

RECRUITMENT OF PATIENTS ¹

- Look for possible recruits in:
 1. X-Ray Department (Appointment Book).
 2. Breast Pathology Clinic (Black Notebook, on Wednesdays).
 3. Surgery schedule.
- Physicians' referrals.
- Look for biopsy results in computer (Pathology report).
- Look up patient appointments (positive results) in the computer. Case Manager will go to all Surgery Clinics (BPC, green, red, and/or blue surgery clinics) where potential recruits are present.

¹ *As of April 15, 2002, participants will also be recruited from the Lyndon B. Johnson Hospital Breast Pathology Clinic. Similar clinical procedures will be followed in recruiting these participants.*

DAY ONE ACTIVITIES (SCHEDULED CLINIC VISIT)

- On the day of the scheduled Clinic visit, the Case Manager will review the Patient's chart. If the Patient meets the Inclusion Criteria, the Patient's chart will be tagged (to let the Physician know that the Patient is eligible for the study).
- After the Physician has informed the eligible Patient of the results of her biopsy and referred her to the Case Manager, the Case Manager will inform the Patient about the study and ask whether she is willing to participate in it. If the Patient is willing to participate, she will be asked to read carefully (and ask any clarifications she may need) and sign the Informed Consent form. The Patient will also complete the required paperwork for reimbursement (i.e., cash receipt documentation).
- Randomization will occur at this point with Patients being assigned to either the Intervention Group or the Control Group. Randomization will be accomplished through use of permuted blocks to ensure equal numbers of intervention and control subjects. Four blocks will be used to determine the allocation sequence. The sequence in each block is given in the following table.

"I" is the CDSS intervention arm, and "C" is the control arm. Blocks will be drawn at random (using a table of random numbers), and subject assignment will be based on the block sequence. For example, if Block 3 is drawn, the first eligible patient will be assigned to the control group, the second patient assigned to the control group, and the third and fourth patients assigned to the CDSS intervention group. After a block is completed, another random drawing will be done and the process continued until the cells of the design are full (a block may be drawn more than once).

Allocation Sequence Using Permuted Blocks	
Block Number	Sequence
1	I, C, I, C
2	I, I, C, C
3	C, C, I, I
4	C, I, C, I

- Activities for each study group are as follows:

Intervention Group:

- Patient completes the CDSS program (indicating initial treatment decision at the end of the program) and receives the Patient Reminder Printout.
- Patient completes the BC Knowledge Test and the CDSS Evaluation Questionnaire. If Patient has difficulty reading, the questionnaires will be read for her.
- Patient receives \$ 10 and a receipt for 1st raffle entry (out of 4 possible) to participate in the (Fiesta) Gift Certificates Drawing [4 Gift Certificates will be raffled off at the end of the study-December 2001].

4. Patient is asked to arrive 45 minutes earlier to her pre-op screening Clinic appointment (her next visit).
5. Case Manager puts Provider Log in Patient's chart.
6. Case Manager contacts Patient by phone prior to the pre-op screening Clinic appointment, to remind her to arrive 45 minutes earlier.

Control Group:

1. Patient receives BC Printed Material.
2. Patient completes the BC Knowledge Test.
3. Patient indicates initial treatment decision.
4. Patient receives \$ 10 and a receipt for 1st raffle entry (out of 4) to participate in the (Fiesta) Gift Certificates Drawing [4 Gift Certificates will be raffled off at the end of the study-December 2001].
5. Patient is asked to arrive 45 minutes earlier to her pre-op screening Clinic appointment (her next visit).
6. Case Manager contacts Patient by phone prior to the pre-op screening Clinic appointment, to remind her to arrive 45 minutes earlier.

DAY TWO ACTIVITIES (PRE-OPERATION SCREENING VISIT)**Intervention and Control Groups:**

1. Patient to arrive 45 minutes prior to the scheduled pre-op screening Clinic appointment.
2. Patient completes the Satisfaction with Decision Instrument and the Breast Cancer Knowledge Questionnaire.
3. Patient completes the Utility Assessment Computerized Program.
4. Patient receives \$10 and a receipt for 2nd raffle entry (out of 4 possible) to participate in the (Fiesta) Gift Certificates Drawing.

6-MONTH FOLLOW-UP

1. Case Manager telephones patients (Intervention and Control Groups) and administers both the Breast Cancer Knowledge Questionnaire and the Satisfaction with Decision Instrument.
2. Patient is advised about her 3rd entry into the raffle.

1-YEAR FOLLOW-UP

1. Case Manager telephones patients (Intervention and Control Groups) and administers both the Breast Cancer Knowledge Questionnaire and the Satisfaction with Decision Instrument.
2. Patient is advised about her 4th entry into the raffle.

APPENDIX G

Date _____

Patient's MR# _____

Satisfaction with Decision Scale (Pre-U)

You have been considering treatment options for your breast cancer.

Please answer the following questions about your decision.

- | | Yes | No | ?
Unsure |
|---|-----|----|--------------------|
| 1. Are you satisfied with the information you received to make your decision for breast cancer treatment? | | | |
| 2. Was your treatment decision the best decision possible for you? | | | |
| 3. Are you satisfied that your treatment decision was consistent with how you feel? | | | |
| 4. Do you expect to stick to the treatment decision you made? | | | |
| 5. Are you satisfied because you were the one making the treatment decision? | | | |
| 6. Are you satisfied with your treatment decision? | | | |

Adapted from:

Holmes-Rovner M, Kroll J, Schmitt N, Rovner DR, Breer L, Rother ML, Faan GP, Talarczyk G (1996). Patient satisfaction with health care decisions: The Satisfaction with Decision Scale. *Medical Decision Making* 16: 58-64.

APPENDIX G

Date _____

Patient's MR # _____

Satisfaction with Decision Scale (Pre-U)-Spanish

Usted ha podido refleccionar sobre los tratamientos para tratar su cáncer del seno.

Por favor responda a las siguientes preguntas:

- | | | | |
|---|----|----|-------------------|
| 1. ¿Esta usted satisfecha con la información que recibió para tomar su decisión de tratamiento para el cancer del seno? | Si | No | ?
No sé |
| 2. ¿Fué esa la mejor decision de tratamiento para usted? | Si | No | No sé |
| 3. ¿Cree que su decisión de tratamiento refleja come se siente usted? | Si | No | No sé |
| 4. ¿Va usted a mantener la decisión de tratamiento que ha tomado? | Si | No | No sé |
| 5. ¿Se siente satisfecha porque fué usted la que eligió su tratamiento? | Si | No | No sé |
| 6. ¿Se siente satisfecha con su decisión de tratamiento? | Si | No | No sé |

Adapted and translated from:

Holmes-Rovner M, Kroll J, Schmitt N, Rovner DR, Breer L, Rother ML, Faan GP, Talarczyk G (1996).
Patient satisfaction with health care decisions: The Satisfaction with Decision Scale. *Medical Decision Making* 16: 58-64.

APPENDIX G: CDSS PROGRAM RATING FORM (T1-Post-I)

Patient's MR _____

Date: _____

Please tell us how you feel about the program you just watched:

1. Was the program easy to understand?
☐ Yes ☐ No ☐ Unsure
2. Was the amount of information given in the program less than you needed?
☐ Yes ☐ No ☐ Unsure
3. Was the program too long?
☐ Yes ☐ No ☐ Unsure
4. Did the amount of information given in the program make it hard to remember it?
☐ Yes ☐ No ☐ Unsure
5. Was the sound good?
☐ Yes ☐ No ☐ Unsure
6. Were the pictures and videos clear?
☐ Yes ☐ No ☐ Unsure
7. Did you enjoy using the program?
☐ Yes ☐ No ☐ Unsure
8. Did the program make you think about your health?
☐ Yes ☐ No ☐ Unsure
9. Did the program teach you things about the health of your breasts?
☐ Yes ☐ No ☐ Unsure
10. Would you use the program again?
☐ Yes ☐ No ☐ Unsure
11. Would you recommend that other women watch this program?
☐ Yes ☐ No ☐ Unsure
12. Did viewing the CDSS program increase or decrease your worries about treatment?
☐ Increase ☐ Decrease ☐ Same

APPENDIX G: EVALUACIÓN DEL PROGRAMA CDSS (T1-Post-I)

Patient's MR _____

Fecha: _____

Por favor díganos que le pareció el program que acaba de ver:

1. ¿Fué el programa fácil de entender?

☐ Sí

☐ No

☐ No sé

2. ¿Fué la cantidad de información en el programa menos de la que necesitaba?

☐ Sí

☐ No

☐ No sé

3. ¿Fué el programa muy largo?

☐ Sí

☐ No

☐ No sé

4. ¿Fué difícil acordarse de la cantidad de información que dió el programa?

☐ Sí

☐ No

☐ No sé

5. ¿Estuvo bien el sonido?

☐ Sí

☐ No

☐ No sé

6. ¿Estuvieron los dibujos y videos claros?

☐ Sí

☐ No

☐ No sé

7. ¿Le gustó usar el programa?

☐ Sí

☐ No

☐ No sé

8. ¿Le hizo pensar el programa sobre su salud?

☐ Sí

☐ No

☐ No sé

9. ¿Le hizo pensar el programa sobre la salud de sus senos?

☐ Sí

☐ No

☐ No sé

10. ¿Volvería a ver este programa?

☐ Sí

☐ No

☐ No sé

11. ¿Recomendaría Ud. este programa a otras mujeres?

☐ Sí

☐ No

☐ No sé

12. ¿Le ayudó el programa en la computadora a aumentar o bajar sus preocupaciones sobre el tratamiento?

☐ Bajar o Disminuir

☐ Subir

☐ Igual

CDSS DATA FORM I (DAY ONE)**DATE:** _____**GROUP:** **I** **C****NAME:** _____
Last First M.I.**AGE:** ____**MEDICAL RECORD No.:** _____ **LANGUAGE:** English: ____ Spanish: ____**ETHNICITY:** White: ____ Black: ____ Hispanic: ____ Asian: ____ More than One Race: ____**BREAST CANCER STAGE:** STG I ____ STG IIA ____ STG IIB ____ STGIIIA ____**SIZE OF TUMOR:** Less than 1 inch: ____ 1 to 2 inches: ____ Larger than 2 inches: ____**PREFERENCE:**

Given what you know now about your breast cancer, do you have a preference for any treatment? Yes ____ No ____

If you answered Yes to the previous question, which treatment do you prefer? BCS ____ MRM ____ NO TX ____

How sure are you that this is the treatment you want to have? Very Sure ____ Somewhat Sure ____ Not Sure ____

MENOPAUSAL STATUS (check one):

Are you still having regular menstrual periods? Yes ____ No ____

If you answered NO to the previous question, have you had a hysterectomy? Yes ____ No ____

OTHER SERIOUS MEDICAL CONDITIONS (check all that applies):

Heart disease ____ Hypertension ____ Diabetes ____ Chronic lung disease ____ Arthritis ____ Low back pain ____

How much do these diseases affect your life?(check one): Not at all ____ A little ____ Some ____ A lot ____

Are you able to use a telephone by yourself?(check one): Yes ____ No ____

Are you able to leave your house without the assistance from another person? Yes ____ No ____

Are you able to take your own medications by yourself? Yes ____ No ____

Do you have someone to help you with everyday activities like bathing,
getting out of bed, and shopping?

Yes ___

No ___

Are you pregnant?

Yes ___

No ___

If you answered YES to the previous question, how long have you been pregnant? (circle one)

1 2 3 4 5 6 7 8 9 months

Do you have cancer in several areas of your breast?

Yes ___

No ___

Have you had X-Ray treatment or Radiotherapy to your chest area before?

Yes ___

No ___

Do you have Lupus or Scleroderma?

Yes ___

No ___

WHEN HANDING PATIENT REMINDER PRINTOUT (Decision Assurance Q2):

How sure are you that this is the treatment you want to have? Very Sure ___ Somewhat Sure ___ Not Sure ___

REMARKS:

GROUP: I C

TIME: _____

MEDICAL RECORD No.: _____

DECISIONAL PROCESS:

How did you come to your treatment decision?

This image shows a single sheet of white paper with horizontal blue or grey ruling lines. The lines are evenly spaced and run across the width of the page. There are approximately 20 lines visible. The paper appears to be a standard notebook page or a sheet of stationery. There is no handwriting or other markings on the page.

REMARKS:

CDSS SUMMARY LOG

Page 1 of 3

CDSS SUMMARY LOG

Page 2 of 3

CDSS SUMMARY LOG

Page 3 of 3